

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 14/705, C12N 5/10, 15/09, 15/11, 15/12, 15/62, G01N 33/566	A1	(11) International Publication Number: WO 99/40114 (43) International Publication Date: 12 August 1999 (12.08.99)
(21) International Application Number: PCT/US99/02361 (22) International Filing Date: 3 February 1999 (03.02.99) (30) Priority Data: 60/073,767 5 February 1998 (05.02.98) US (71) Applicants (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO [US/US]; 7703 Floyd Curl Drive, San Antonio, TX 78284 (US). NATIONAL INSTITUTES OF HEALTH [US/US]; 36 Convent Drive, Bethesda, MD 20892-4094 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LIU, Quingyun [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). McDONALD, Terrence [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). BONNERT, Timothy, P. [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). NG, Gordon, Yiu, Kon [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). KOLAKOWSKI, Lee, F., Jr. [US/US]; 7703 Floyd	(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: NOVEL GABA _B RECEPTOR DNA SEQUENCES		
(57) Abstract <p>DNA encoding a novel human GABA_B receptor subunit, HG20, as well as the protein encoded by the DNA, is provided. Also provided is DNA encoding a novel murine GABA_B receptor subunit, GABA_BR1a, as well as the protein encoded by the DNA. Heterodimers of HG20 protein and GABA_BR1a protein that form a functional GABA_B receptor are disclosed. Methods of identifying agonists and antagonists of the GABA_B receptor are also provided.</p>		

Applicants: Kenneth A. Jones, et al.

U.S. Serial No. : 09/211,755

Filed: December 15, 1998

Exhibit 2

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE OF THE INVENTION
NOVEL GABA_B RECEPTOR DNA SEQUENCES

CROSS-REFERENCE TO RELATED APPLICATIONS

5 Not applicable.

STATEMENT REGARDING FEDERALLY-SPONSORED R&D

Not applicable.

10 REFERENCE TO MICROFICHE APPENDIX

Not applicable.

FIELD OF THE INVENTION

15 The present invention is directed to a novel human DNA sequence encoding HG20, a subunit of the GABA_B receptor, the protein encoded by the DNA, and uses thereof. The present invention also is directed to the murine GABA_BR1a subunit of the GABA_B receptor as well as to methods of combining an HG20 subunit with a GABA_BR1a subunit to form a GABA_B receptor having functional activity.

20

BACKGROUND OF THE INVENTION

Amino acids such as glutamic acid, γ -amino-butyric acid (GABA), and glycine are neurotransmitters that bind to specific receptors in the vertebrate nervous system and mediate synaptic transmission. Of these amino acids, GABA is the most widely distributed amino acid inhibitory neurotransmitter in the vertebrate central nervous system. The biological activities of GABA are mediated by three types of GABA receptors: ionotropic GABA_A receptors, metabotropic GABA_B receptors, and ionotropic GABA_C receptors. Each type of receptor has its own characteristic molecular structure, pattern of gene expression, agonist and antagonist mediated pharmacological effects, and spectrum of physiological activities.

30 GABA_A receptors mediate fast synaptic inhibition. They are heterooligomeric proteins (most likely pentamers) containing α , β , γ , and perhaps δ , subunits that function as ligand-gated Cl⁻ channels and have binding sites for benzodiazepines, barbiturates, and neuroactive steroids. Bicuculline is a widely used antagonist of GABA_A receptors.

35

Bicuculline is selective for GABA_A receptors in that it has no effect on GABA_B or GABA_C receptors. The expression of GABA_A receptors has been observed in a variety of brain structures (see. *e.g.*, McKernan & Whiting, 1996, Trends Neurosci. 16:139-143; Sequier et al., 1988, Proc. Natl. Acad. Sci. USA 85:7815-7819).

GABA_C receptors are ligand-gated Cl⁻ channels found in the vertebrate retina. They can be distinguished from GABA_A and GABA_B receptors in that they are insensitive to the GABA_A receptor antagonist bicuculline and the GABA_B receptor agonist (-)baclofen but are selectively activated by *cis*-4-aminocrotonic acid. GABA_C receptors are composed of homooligomers of a category of GABA receptor subunits known as "ρ" subunits, the best-studied of which are ρ1 and ρ2. ρ1 and ρ2 share 74% amino acid sequence identity but are only about 30-38% identical in amino acid sequence when compared to GABA_A receptor subunits. For a review of GABA_C receptors, see Bormann & Feigenspan, 1995, Trends Neurosci. 18:515-518.

GABA_B receptors play a role in the mediation of late inhibitory postsynaptic potentials (IPSPs). GABA_B receptors belong to the superfamily of seven transmembrane-spanning G-protein coupled receptors that are coupled through G-proteins to neuronal K⁺ or Ca⁺⁺ channels. GABA_B receptors are coupled through G-proteins to neuronal K⁺ or Ca⁺⁺ channels, and receptor activation increases K⁺ or decreases Ca⁺⁺ conductance and also inhibits or potentiates stimulated adenylyl cyclase activity. The expression of GABA_B receptors is widely distributed in the mammalian brain (*e.g.*, frontal cortex, cerebellar molecular layer, interpeduncular nucleus) and has been observed in many peripheral organs as well.

A large number of pharmacological activities have been attributed to GABA_B receptor activation, *e.g.*, analgesia; hypothermia; catatonia; hypotension; reduction of memory consolidation and retention; and stimulation of insulin, growth hormone, and glucagon release (see Bowery, 1989, Trends Pharmacol. Sci. 10:401-407, for a review.) It is well accepted that GABA_B receptor agonists and antagonists are pharmacologically useful. For example, the GABA_B receptor agonist (-)baclofen, a structural analog of GABA, is a clinically effective muscle relaxant (Bowery & Pratt, 1992, Arzneim.-Forsch./Drug

Res. 42:215-223). (-)baclofen, as part of a racemic mixture with (+)baclofen, has been sold in the United States as a muscle relaxant under the name LIORESAL® since 1972.

GABAB receptors represent a large family of related proteins, new family members of which are still being discovered. For example, Kaupmann et al., 1997, Nature 386:239-246 (Kaupmann) reported the cloning and expression of two members of the rat GABAB receptor family, GABABR1a and GABABR1b. A variety of experiments using known agonists and antagonists of GABAB receptors seemed to indicate that GABABR1a and GABABR1b represented rat GABAB receptors. This conclusion was based primarily on the ability of GABABR1a and GABABR1b to bind agonists and antagonist of GABAB receptors with the expected rank order, based upon studies of rat cerebral cortex GABAB receptors. However, there were data that did not fit the theory that Kaupmann had cloned the pharmacologically and functionally active GABAB receptor. For example, Kaupmann noted that agonists had significantly lower binding affinity to recombinant GABABR1a and GABABR1b as opposed to native GABAB receptors. Also, Couve et al., 1998, J. Biol. Chem. 273:26361-26367 showed that recombinantly expressed GABABR1a and GABABR1b failed to target correctly to the plasma membrane and failed to give rise to functional GABAB receptors when expressed in a variety of cell types.

Examination of the amino acid and gene sequence of GABABR1a led Kaupmann to propose a structure for GABABR1a similar to that of the metabotropic glutamate receptor gene family. The metabotropic glutamate receptor family comprises eight glutamate binding receptors and five calcium sensing receptors which exhibit a signal peptide sequence followed by a large N-terminal domain believed to represent the ligand binding pocket that precedes seven transmembrane spanning domains. The hallmark seven transmembrane spanning domains are typical of G-protein coupled receptors (GPCRs), although metabotropic glutamate receptors and GABABR1a are considerably larger than most GPCRs and contain a signal peptide sequence. No significant amino acid sequence similarities were found between GABABR1a and GABA_A receptors, GABA_C receptors, or other typical GPCRs.

Despite work such as that of Kaupmann, pharmacological and physiological evidence indicates that a large number of amino acid binding GABA_B receptors remain to be cloned and expressed in recombinant systems where agonists and antagonists can be efficiently identified. In particular, it would be extremely valuable to be able to recombinantly express GABA_B receptors in such a manner that not only pharmacologically relevant ligand binding properties would be exhibited by the recombinant receptors, but also such that the recombinant receptors would show proper functional activity.

10

SUMMARY OF THE INVENTION

The present invention is directed to a novel human DNA that encodes a GABA_B receptor subunit, HG20. The DNA encoding HG20 is substantially free from other nucleic acids and has the nucleotide sequence shown in SEQ.ID.NO.:1. Also provided is an HG20 protein encoded by the novel DNA sequence. The HG20 protein is substantially free from other proteins and has the amino acid sequence shown in SEQ.ID.NO.:2. Methods of expressing HG20 in recombinant systems and of identifying agonists and antagonists of HG20 are provided.

20

The present invention is also directed to a novel murine DNA that encodes a GABA_B receptor subunit, GABA_BR1a. The DNA encoding GABA_BR1a is substantially free from other nucleic acids and has the nucleotide sequence shown in SEQ.ID.NO.:19. Also provided is a GABA_BR1a protein encoded by the novel DNA sequence. The GABA_BR1a protein is substantially free from other proteins and has the amino acid sequence shown in SEQ.ID.NO.:20. Methods of expressing GABA_BR1a in recombinant systems and of identifying agonists and antagonists of HG20 are provided.

25

Also provided by the present invention are methods of co-expressing HG20 and GABA_BR1a in the same cells. Such co-expression results in the production of a GABA_B receptor that exhibits expected functional properties of GABA_B receptors as well as expected ligand binding properties. Recombinant cells co-expressing HG20 and GABA_BR1a are provided as well as methods of utilizing such recombinant cells to identify agonists and antagonists of GABA_B receptors.

30

35

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A-B shows the complete cDNA sequence of HG20 (SEQ.ID.NO.:1).

5 Figure 2 shows the complete amino acid sequence of HG20 (SEQ.ID.NO.:2).

Figure 3A-B shows predicted signal peptide cleavage sites of HG20. All sequences shown are portions of SEQ.ID.NO.:2.

10 Figure 4 shows *in situ* analysis of the expression of HG20 RNA in squirrel monkey brain.

Figure 5A shows *in vitro* coupled transcription/translation of a chimeric FLAG epitope-HG20 (amino acids 52-941) protein.

15 Figure 5B shows the expression in COS-7 cells and melanophores of a chimeric FLAG epitope-HG20 (amino acids 52-941) protein.

Figure 6 shows a comparison of the amino acid sequences of a portion of the N-terminus of HG20 protein and the ligand binding domain of the *Pseudomonas aeruginosa* amino acid binding protein LIVAT-BP (Swiss Protein database accession number P21175). The upper sequence shown is from HG20 and corresponds to amino acids 63-259 of SEQ.ID.NO.:2. The lower sequence shown is from *Pseudomonas aeruginosa* LIVAT-BP and is SEQ.ID.NO.:16.

Figure 7 shows expression in mammalian cells of a chimeric HG20 protein.

25 Figure 8 shows a comparison of the amino acid sequences of HG20 and GABABR1b. The HG20 sequence is SEQ.ID.NO.:2. The GABABR1b sequence is SEQ.ID.NO.:17.

Figure 9 shows the expression of recombinant GABABR1a and HG20 in COS-7 cells. Lanes 1 and 2 show [¹²⁵I]CGP71872 photolabeling of recombinant murine GABABR1a monomer and dimer in the presence (+) and absence (-) of 1 μM unlabeled CGP71872. Lanes 3 and 4 show that GABABR1a antibodies 1713.1-1713.2 confirmed (+) expression of recombinantly expressed murine GABABR1a (referred to as mgb1a here) and absence (-) in pcDNA3.1 mock transfected cells. 30 Lanes 5 and 6 show [¹²⁵I]CGP71872 photolabeling of human FLAG-HG20 in the presence (+) and absence (-) of 1 μM unlabeled CGP71872. 35 Lanes 7 and 8 show that an anti-FLAG antibody confirmed (+) the

expression of FLAG-HG20 (referred to as FLAG-gb2 here) and its absence (-) in pcDNA3.1 mock transfected cells. Experimental details were as in Examples 7-9 and 20 except that COS-7 rather than COS-1 cells were used.

- 5 Figure 10 shows co-localization of mRNA for HG20 and GABA_BR1a by *in situ* hybridization histochemistry in rat parietal cortex. Adjacent coronal sections of rat brain showing parietal cortex hybridized with radiolabelled GABA_BR1a (A) and HG20 (B) probes. Rat GABA_BR1a and HG20 probes were labelled using ³⁵S-UTP (A, B, and
10 D), and autoradiograms were developed after 4 weeks. For co-localization studies, the rat GABA_BR1a probe was digoxigenin labelled and developed using anti-digoxigenin HRP, the TSA amplification method and biotinyl tyramide followed by streptavidin-conjugated CY3 (C). (D) shows autoradiography of the same field as in (C), denoting
15 hybridization to HG20 mRNA. (E) is an overlay of images (C) and (D). Arrows denote some of the double-labelled cells. Scale bar = 0.5 mm in (A) and (B); scale bar = 50 μ m in (C-E).

- Figure 11 shows functional complementation following co-expression of GABA_BR1a and HG20 in *Xenopus* melanophores. GABA
20 mediated a dose-dependent aggregation response in melanophores co-expressing murine GABA_BR1a and FLAG-HG20 (■) that could be blocked with 100 nM (▼) and 1 μ M CGP71872 (▲). The response of GABA on mock-transfected cells is shown (●) as well as a control cannabinoid receptor subtype 2 response to HU210 ligand (inset). This experiment is
25 representative of n=4.

- Figure 12 shows GABA_B receptor modulation of forskolin-stimulated cAMP synthesis in HEK293 cells. HEK293 cells stably expressing HG20 (hgb2-42) or GABA_BR1a (rgb1a-50) were transiently transfected with GABA_BR1a and HG20 expression plasmids to examine
30 the effect of receptor co-expression on modulation of cAMP synthesis. All transfected cells were tested with 300 μ M baclofen or GABA (with 100 μ M AOAA and 100 μ M nipecotic acid) in the absence of forskolin and 30 μ M baclofen or GABA in the presence of 10 μ M forskolin. Wild-type HEK293 cells were tested with 250 μ M baclofen or 250 μ M GABA in the
35 presence of 10 μ M forskolin. Data are presented as the percent of total cAMP synthesized in the presence of forskolin only. The data presented are from single representative experiments that have been replicated

twice. Fsk, forskolin; B, baclofen; G, GABA with AOAA and nipecotic acid. The two right-most set of bar graphs (labeled "B + Fsk" and "G + Fsk") show that in cells expressing both GABA_BR1a and HG20 (rgb1a-50/hgb2 cells (□) and hgb2-42/rgb1a cells (■)), baclofen and GABA were able to mediate significant reductions in cAMP levels.

Figure 13 shows that co-expression of GABA_BR1a and HG20 permits inwardly rectifying potassium channel (GIRK or Kir) activation in *Xenopus* oocytes. (A) Representative current families of Kir 3.1/3.2. Currents were evoked by 500 msec voltage commands from a holding potential of -10 mV, delivered in 20 mV increments from -140 to 60 mV. (B) In a protocol designed to measure the effects of various receptors on Kir currents, oocytes were held at -80 mV (a potential where significant inward current is measured). Expression of GABA_BR1a or HG20 alone (with or without G α 1) resulted in no modulation of current after GABA treatment. Co-expression of GABA_BR1a and FLAG-HG20 receptors followed by treatment with 100 μ M GABA resulted in stimulation of Kir 3.1/3.2. Shown are representative traces from at least three independent experiments under each condition.

Figure 14 shows immunoblotting of murine GABA_BR1a and FLAG-HG20 transiently expressed in COS-7 cells. Digitonin-solubilized and anti-FLAG antibody immunoprecipitated membrane proteins were immunoblotted following SDS-PAGE with GABA_BR1a antibodies 1713.1-1713.2. The conditions are as follows: mock pcDNA3.1 vector transfected cells (lane 1), FLAG-HG20 expressing cells (lane 2), murine GABA_BR1a expressing cells (lane 3), and cells coexpressing murine GABA_BR1a and FLAG-HG20 (lane 4). The immunoreactive band corresponding to the GABA_BR1a /HG20 heterodimer as well as a band corresponding to the predicted GABA_BR1a monomer are denoted by arrows.

Figure 15 shows the complete cDNA sequence of murine GABA_BR1a (SEQ.ID.NO.:19). The sequence shown has been deposited in GenBank (accession number AF114168).

Figure 16 shows the complete amino acid sequence of murine GABA_BR1a (SEQ.ID.NO.:20). The sequence shown has been deposited in GenBank (accession number AF114168).

Figure 17A-B shows the results of experiments with N- and C-terminal fragments of murine GABABR1a. Figure 17A shows the results of coupled *in vitro* transcription/translation reactions; lane 1 = blank; lane 2 = full-length GABABR1a; lane 3 = N-terminal fragment of GABABR1a; lane 4 = C-terminal fragment of GABABR1a. Figure 17B shows the results of [¹²⁵I]CGP71872 photoaffinity labeling; lane 1 = N-terminal fragment of GABABR1a; lane 2 = N-terminal fragment of GABABR1a in the presence of GABA; lane 3 = C-terminal fragment of GABABR1a; lane 4 = C-terminal fragment of GABABR1a in the presence of GABA.

Figure 18A-B shows the amino acid sequence (Figure 18A) (SEQ.ID.NO.:21) and nucleotide sequence (Figure 18B) (SEQ.ID.NO.:22) (GenBank accession number AJ012185) of a human GABABR1a.

Figure 19A-B shows the nucleotide sequence (SEQ.ID.NO.:23) (GenBank accession number Y11044) of a human GABABR1a.

Figure 20 shows a framework map of chromosome 9. The locations of the HG20 gene (referred to as "GPR 51"), markers, and the HSN-1 locus are indicated.

Figure 21 shows a hydropathy plot for murine GABABR1a.

Figure 22 shows a family tree of genes related to HG20. Abbreviations are as follows: hGB1a = human GABABR1a; mGB1a = mouse GABABR1a; rGB1a = rat GABABR1a; hGB1b = human GABABR1b; rGB1b = rat GABABR1b; ceGB1b = a *C. elegans* gene related to mammalian GABABR1a and GABABR1b; hGB2 = human HG20; ceGB2 = a *C. elegans* gene related to human HG20; MGRDROME = a metabotropic glutamate receptor from *Drosophila melanogaster*; MGR2 HUMAN = human metabotropic glutamate receptor 2; MGR3 HUMAN = human metabotropic glutamate receptor 3; MGR6 HUMAN = human metabotropic glutamate receptor 6; MGR4 HUMAN = human metabotropic glutamate receptor 4; MGR7 HUMAN = human metabotropic glutamate receptor 7; MGR8 HUMAN = human metabotropic glutamate receptor 8; MGR1 HUMAN = human metabotropic glutamate receptor 1; MGR5 HUMAN = human metabotropic glutamate receptor 5.

Figure 23 shows the coiled-coil domains in the C-termini of human GABABR1a and HG20. The upper sequence is from human

GABAR1a and is positions 886-949 of SEQ.ID.NO.:21. The lower sequence is from HG20 and is positions 756-829 of SEQ.ID.NO.:2.

Figure 24 shows a comparison of the amino acid sequences of human GABAR1a (referred to as "Human GABA-B1aR,"

5 SEQ.ID.NO.:21); the proteins encoded by two genes from *C. elegans* (*C. elegans* GABA-B1 = SEQ.ID.NO.:42 and *C. elegans* GABA-B2 = SEQ.ID.NO.:43); and HG20) (referred to as "Human GABA-B2," (SEQ.ID.NO.:2). The *C. elegans* genes have been predicted from
10 *C. elegans* DNA sequence alone. ZK180 accession number: U58748 is predicted to be GABA-B2 and Y41G9. Contig99 and Y76F7. Contig73 were obtained from the Sanger *C. elegans* genomic sequence database and are predicted to be GABA-B1.

Figure 25A-D shows co-immunoprecipitation of the murine GABAR1a and FLAG-HG20 receptor subunits and immunoblotting
15 using reciprocal receptor subunit antibodies. Murine GABAR1a and FLAG-HG20 receptors were expressed individually or co-expressed in COS-7 cells. Figure 25A shows the results of immunoblotting using an anti-murine GABAR1a antibody. Immunoblot of the solubilized membranes using murine GABAR1a antibodies 1713.1-1713.2 shows
20 selective expression of murine GABAR1a in murine GABAR1a alone expressing cells (lane 3) and murine GABAR1a /FLAG-HG20 co-expressing cells (lane 4), but not in mock transfected and FLAG-HG20 alone expressing cells (lanes 1 and 2). Staining of GABAR1a subunits in co-expressing cells is more intense compared to cells expressing the
25 GABAR1a subunit alone, suggesting that HG20 subunits facilitate GABAR1a expression. Figure 25B shows the results of immunoblotting using an anti-FLAG-HG20 antibody. Immunoblotting of the solubilized membranes using the anti-FLAG-HG20 antibody shows selective expression of FLAG-HG20 subunits in FLAG-HG20
30 alone expressing cells (lane 6) and murine GABAR1a /FLAG-HG20 co-expressing cells (lane 8), but not in mock transfected and murine GABAR1a alone expressing cells (lanes 5 and 7). Staining of HG20 subunits in co-expressing cells is more intense compared to cells expressing the HG20 subunit alone, suggesting that GABAR1a
35 subunits facilitate HG20 expression. Figure 25C shows the results of immunoprecipitation with an anti-FLAG-HG20 antibody followed by

immunoblotting with an anti-murine GABA_BR1a antibody. GABA_BR1a /HG20 heterodimers are observed only in murine GABA_BR1a /FLAG-HG20 co-expressing cells due to the fact that the GABA_BR1a subunit was co-immunoprecipitated with the FLAG-HG20 subunit using the FLAG antibody and detected with GABA_BR1a antibodies (lane 12). GABA_BR1a subunits are not detected in mock-transfected cells and cells expressing GABA_BR1a alone or FLAG-HG20 (lanes 9-11). Figure 25D shows the results of immunoprecipitation with an anti-murine GABA_BR1a antibody followed by immunoblotting with an anti-FLAG-HG20 antibody. GABA_BR1a /HG20 heterodimers are observed only in murine GABA_BR1a /FLAG-HG20 co-expressing cells due to the fact that the FLAG-HG20 subunit was co-immunoprecipitated using the GABA_BR1a antibodies and detected with FLAG antibody (lane 16). No FLAG-HG20 subunits are detected in mock-transfected cells or cells expressing murine GABA_BR1a alone or FLAG-HG20 (lanes 13-15). The immunoblots shown are from 1-3 independent experiments.

Figure 26A-B shows some of the motifs in the N-termini of GABA_B receptor subunits and related genes. Figure 26A shows an alignment of murine GABA_BR1a (mGABA_B1a; a portion of SEQ.ID.NO.:20), human GABA_BR1a (hGABA_B1a; a portion of SEQ.ID.NO.:21), HG20 (hGABA_B2; a portion of SEQ.ID.NO.:2), metabotropic glutamate receptor 1 (mGluR1; SEQ.ID.NO.:44), and two *E. coli* proteins (LivK (SEQ.ID.NO.:45) and LivBP (SEQ.ID.NO.:46)). Figure 26B is a schematic drawing showing the location of the various motifs in murine GABA_BR1a that are expected to be involved in heterodimer formation of GABA_BR1a with HG20.

Figure 27 shows an expanded view of the coiled-coil region of homology between HG20 (hGABA_B2; shown is a portion of SEQ.ID.NO.:2) and murine GABA_BR1a (mGABA_B1a; a portion of SEQ.ID.NO.:20). Also shown is the corresponding region of human GABA_BR1a (hGABA_B1a; a portion of SEQ.ID.NO.:21).

DETAILED DESCRIPTION OF THE INVENTION

For the purposes of this invention:

"Substantially free from other proteins" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%,

free of other proteins. Thus, for example, an HG20 protein preparation that is substantially free from other proteins will contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-HG20 proteins. Whether a given HG20 protein preparation is substantially free from other proteins can be determined by such conventional techniques of assessing protein purity as, *e.g.*, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) combined with appropriate detection methods, *e.g.*, silver staining or immunoblotting.

"Substantially free from other nucleic acids" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other nucleic acids. Thus, for example, an HG20 DNA preparation that is substantially free from other nucleic acids will contain, as a percent of its total nucleic acid, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-HG20 nucleic acids. Whether a given HG20 DNA preparation is substantially free from other nucleic acids can be determined by such conventional techniques of assessing nucleic acid purity as, *e.g.*, agarose gel electrophoresis combined with appropriate staining methods, *e.g.*, ethidium bromide staining, or by sequencing.

An HG20 polypeptide has "substantially the same biological activity" as native HG20 (*i.e.*, SEQ.ID.NO.:2) if that polypeptide has a K_d for a ligand that is no more than 5-fold greater than the K_d of native HG20 for the same ligand. An HG20 polypeptide also has "substantially the same biological activity" as HG20 if that polypeptide can form heterodimers with either a GABABR1a or GABABR1b polypeptide, thus forming a functional GABAB receptor.

"Functional GABAB receptor" refers to a heterodimer of HG20 and either GABABR1a or GABABR1b where the heterodimer displays a functional response when exposed to GABA agonists. Examples of functional responses are: pigment aggregation in *Xenopus* melanophores, modulation of cAMP levels, coupling to inwardly rectifying potassium channels, mediation of late inhibitory postsynaptic potentials in neurons, increase in potassium conductance, and decrease in calcium conductance. One skilled in the art would be familiar with a

variety of methods of measuring the functional responses of G-protein coupled receptors such as the GABA_B receptor (see, *e.g.*, Lerner, 1994, Trends Neurosci. 17:142-146 [changes in pigment distribution in melanophore cells]; Yokomizo et al., 1997, Nature 387:620-624 [changes in cAMP or calcium concentration; chemotaxis]; Howard et al., 1996, Science 273:974-977 [changes in membrane currents in *Xenopus* oocytes]; McKee et al., 1997, Mol. Endocrinol. 11:415-423 [changes in calcium concentration measured using the aequorin assay]; Offermanns & Simon, 1995, J. Biol. Chem. 270:15175, 15180 [changes in inositol phosphate levels]). Depending upon the cells in which heterodimers of HG20 and either GABA_BR1a or GABA_BR1b are expressed, and thus the G-proteins with which the heterodimers are coupled, certain of such methods may be appropriate for measuring the functional responses of such heterodimers. It is well with the competence of one skilled in the art to select the appropriate method of measuring functional responses for a given experimental system.

A GABA_BR1a or GABA_BR1b polypeptide has "substantially the same biological activity" as a native GABA_BR1a or GABA_BR1b polypeptide if that polypeptide has a K_d for an amino acid, amino acid analogue, GABA_B receptor agonist, or GABA_B receptor antagonist such as CGP71872, GABA, saclofen, (-)baclofen, or (L)-glutamic acid that is no more than 5-fold greater than the K_d of a native GABA_BR1a or GABA_BR1b polypeptide for the same amino acid, amino acid analogue, GABA_B receptor agonist, or GABA_B receptor antagonist. A GABA_BR1a or GABA_BR1b polypeptide also has "substantially the same biological activity" as a native GABA_BR1a or GABA_BR1b polypeptide if that polypeptide can form heterodimers with an HG20 polypeptide, thus forming a functional GABA_B receptor. Native GABA_BR1a or GABA_BR1b polypeptides include the murine GABA_BR1a sequence shown as SEQ.ID.NO.:20; the rat GABA_BR1a or GABA_BR1b polypeptides disclosed in Kaupmann et al., 1997, Nature 386:239-246; the human GABA_BR1a sequence disclosed in GenBank accession number AJ012185 (SEQ.ID.NO.:21); and the protein encoded by the DNA sequence disclosed in GenBank accession number Y11044 (SEQ.ID.NO.:23).

A "conservative amino acid substitution" refers to the replacement of one amino acid residue by another, chemically similar,

amino acid residue. Examples of such conservative substitutions are: substitution of one hydrophobic residue (isoleucine, leucine, valine, or methionine) for another; substitution of one polar residue for another polar residue of the same charge (e.g., arginine for lysine; glutamic acid for aspartic acid).

The present invention relates to the identification and cloning of HG20, a novel G-protein coupled receptor-like protein that represents a subunit for the GABAB receptor. The present invention provides DNA encoding HG20 that is substantially free from other nucleic acids. The present invention also provides recombinant DNA molecules encoding HG20 as well as isolated DNA molecules encoding HG20. Following the cloning of HG20 by the present inventors, a sequence highly similar to the sequence of HG20 was deposited in GenBank by Clark et al. (GenBank accession number AF056085), by White et al. (GenBank accession number AJ012188), and by Borowsky et al. (GenBank accession number AF074483). Two ESTs (GenBank accession number T07621, deposited June 30, 1993, and GenBank accession number Z43654, deposited September 21, 1995) each contain partial sequences of HG20 cDNA.

The present invention provides a DNA molecule substantially free from other nucleic acids comprising the nucleotide sequence shown in Figure 1 as SEQ.ID.NO.:1. Analysis of SEQ.ID.NO.:1 revealed that it contains a long open reading frame at positions 293-3,115. Thus, the present invention also provides a DNA molecule substantially free from other nucleic acids comprising the nucleotide sequence of positions 293-3,115 of SEQ.ID.NO.:1. The present invention also provides an isolated DNA molecule comprising the nucleotide sequence of positions 293-3,115 of SEQ.ID.NO.:1.

Sequence analysis of the open reading frame of the HG20 DNA revealed that it encodes a protein of 941 amino acids with a calculated molecular weight of 104 kd and a predicted signal peptide. The predicted amino acid sequence of HG20 is 36% identical to the metabotropic GABA receptor-like sequence GABABR1a described in Kaupmann (see above) throughout the entire sequence, and thus HG20 most likely represents a novel metabotropic GABA receptor or receptor subunit. *In situ* hybridization showed that HG20 RNA is highly expressed in the cortex, thalamus, hippocampus, and cerebellum of the

brain, showing overlapping distribution with GABABR1a RNA as judged by *in situ* hybridization as well as with the expression of GABAB receptors as judged by pharmacological studies. HG20 RNA exhibits restricted distribution in the periphery, with low abundance of the 6.5 kb RNA in the heart, spleen, and pancreas and high levels in the adrenal gland. HG20 recombinantly expressed in COS-1 cells showed no specific binding for [³H](+)-baclofen, and when expressed in *Xenopus* oocyte and *Xenopus* melanophore functional assays, showed no activity to GABA, (-)-baclofen, and glutamic acid.

10 The novel DNA sequences of the present invention encoding HG20, in whole or in part, can be linked with other DNA sequences, *i.e.*, DNA sequences to which HG20 is not naturally linked, to form "recombinant DNA molecules" containing HG20. Such other sequences can include DNA sequences that control transcription or translation
15 such as, *e.g.*, translation initiation sequences, promoters for RNA polymerase II, transcription or translation termination sequences, enhancer sequences, sequences that control replication in microorganisms, or that confer antibiotic resistance. The novel DNA sequences of the present invention can be inserted into vectors such as
20 plasmids, cosmids, viral vectors, or yeast artificial chromosomes.

 The present invention also includes isolated forms of DNA encoding HG20. By "isolated DNA encoding HG20" is meant DNA encoding HG20 that has been isolated from a natural source or produced by recombinant means. Use of the term "isolated" indicates that DNA
25 encoding HG20 is not present in its normal cellular environment. Thus, an isolated DNA encoding HG20 may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that isolated DNA encoding HG20 is the only DNA present, but instead means that isolated DNA
30 encoding HG20 is at least 95% free of non-nucleic acid material (*e.g.*, proteins, lipids, carbohydrates) naturally associated with the DNA encoding HG20. Thus, DNA encoding HG20 that is expressed in bacteria or even in eukaryotic cells which do not naturally (*i.e.*, without human intervention) contain it through recombinant means is "isolated
35 DNA encoding HG20."

Included in the present invention are DNA sequences that hybridize to SEQ.ID.NO.:1 under stringent conditions. By way of example, and not limitation, a procedure using conditions of high stringency is as follows: Prehybridization of filters containing DNA is carried out for 2 hr. to overnight at 65°C in buffer composed of 6X SSC, 5X Denhardt's solution, and 100 µg/ml denatured salmon sperm DNA. Filters are hybridized for 12 to 48 hrs at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 hr in a solution containing 2X SSC, 0.1% SDS. This is followed by a wash in 0.1X SSC, 0.1% SDS at 50°C for 45 min. before autoradiography.

Other procedures using conditions of high stringency would include either a hybridization carried out in 5XSSC, 5X Denhardt's solution, 50% formamide at 42°C for 12 to 48 hours or a washing step carried out in 0.2X SSPE, 0.2% SDS at 65°C for 30 to 60 minutes.

Reagents mentioned in the foregoing procedures for carrying out high stringency hybridization are well known in the art. Details of the composition of these reagents can be found in, *e.g.*, Sambrook, Fritsch, and Maniatis, 1989, Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press. In addition to the foregoing, other conditions of high stringency which may be used are well known in the art.

Another aspect of the present invention includes host cells that have been engineered to contain and/or express DNA sequences encoding HG20. Such recombinant host cells can be cultured under suitable conditions to produce HG20. An expression vector containing DNA encoding HG20 can be used for expression of HG20 in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Cell lines derived from mammalian species which are suitable for recombinant expression of HG20 and which are commercially available, include but are not limited to, L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK293 (ATCC CRL 1573), Raji

(ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, and *Xenopus* oocytes. In particular embodiments, the recombinant cells expressing HG20 protein co-express a GABA_BR1a or GABA_BR1b protein, thus forming a functional GABA_B receptor comprising a heterodimer of HG20 and either GABA_BR1a or GABA_BR1b. In particular embodiments, the recombinant cells have been transfected with expression vectors that direct the expression of HG20 and GABA_BR1a or GABA_BR1b.

Cells that are particularly suitable for expression of the HG20 protein are melanophore pigment cells from *Xenopus laevis*. Such melanophore pigment cells can be used for functional assays that employ recombinant expression of HG20 in a manner similar to the use of such melanophore pigment cells for the functional assay of other recombinant GPCRs (Graminski et al., 1993, J. Biol. Chem. 268:5957-5964; Lerner, 1994, Trends Neurosci. 17:142-146; Potenza & Lerner, 1992, Pigment Cell Res. 5:372-378; Potenza et al., 1992, Anal. Biochem. 206:315-322). Especially preferred are *Xenopus* melanophore pigment cells co-expressing HG20 and GABA_BR1a or GABA_BR1b, in which HG20 has formed a heterodimer with GABA_BR1a or GABA_BR1b, thus forming a functional GABA_B receptor. The presence of functional GABA_B receptors in such cells can be determined by the use of assays such as the pigment aggregation assay described herein. Other assays that reflect a decrease in cAMP levels mediated by exposure to GABA or other agonists of GABA_B receptors would also be suitable.

Also preferred are stably or transiently transfected HEK293 cells co-expressing HG20 and GABA_BR1a or GABA_BR1b, in which HG20 has formed a heterodimer with GABA_BR1a or GABA_BR1b, thus forming a functional GABA_B receptor. The presence of functional GABA_B receptors in such cells can be determined by the use of assays such as those that measure cAMP levels as described herein.

Also preferred are *Xenopus* oocytes co-expressing HG20 and GABA_BR1a or GABA_BR1b, in which HG20 has formed a heterodimer with GABA_BR1a or GABA_BR1b, thus forming a functional GABA_B receptor. The presence of functional GABA_B receptors in such

cells can be determined by the use of assays that measure coupling of functional GABA_B receptors comprising heterodimers of HG20 and GABA_BR1a or GABA_BR1b to inwardly rectifying potassium channels (especially the Kir3 family).

5 In order to produce the above-described cells co-expressing HG20 and GABA_BR1a or GABA_BR1b, expression vectors comprising DNA encoding HG20 and GABA_BR1a or GABA_BR1b can be transfected into the cells. HG20 and GABA_BR1a or GABA_BR1b can be transfected separately, each on its own expression vector, or, alternatively, a single
10 expression vector encoding both HG20 and GABA_BR1a or GABA_BR1b can be used.

A variety of mammalian expression vectors can be used to express recombinant HG20, GABA_BR1a, or GABA_BR1b in mammalian cells. Commercially available mammalian expression vectors which
15 are suitable include, but are not limited to, pMC1neo (Stratagene), pSG5 (Stratagene), pcDNA1 and pcDNA1amp, pcDNA3, pcDNA3.1, pCR3.1 (Invitrogen), EBO-pSV2-neo (ATCC 37593), pBPV-1(8-2) (ATCC 37110), pDBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), and the PT7TS oocyte
20 expression vector (or similar expression vectors containing the globin 5' UTR and the globin 3' UTR). The choice of vector will depend upon cell type used, level of expression desired, and the like. Following expression in recombinant cells, HG20, GABA_BR1a, GABA_BR1b, or heterodimers of HG20 and either GABA_BR1a or GABA_BR1b can be
25 purified to a level that is substantially free from other proteins by conventional techniques, *e.g.*, salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography, hydrophobic interaction chromatography, and preparative gel electrophoresis. Also, membrane preparations
30 comprising HG20, GABA_BR1a, GABA_BR1b, or heterodimers of HG20 and either GABA_BR1a or GABA_BR1b can be prepared. Especially preferred are membrane preparations that comprise heterodimers of HG20 and either GABA_BR1a or GABA_BR1b in which the heterodimers represent functional GABA_B receptors.

35 The present invention includes a method of producing HG20 protein comprising:

- (a) transfecting a host cell with an expression vector comprising DNA that encodes an HG20 protein;
- (b) growing the host cells under conditions such that HG20 protein is produced; and
- 5 (c) recovering HG20 protein from the host cells.

In particular embodiments, the method of recovering HG20 protein involves obtaining membrane preparations that contain HG20 protein from the host cells. In particular embodiments, such membrane preparations contain heterodimers of HG20 protein and GABABR1a or
10 GABABR1b protein that form functional GABAB receptors.

The present invention includes a method of expressing a truncated HG20 protein comprising:

- (a) transfecting a host cell with an expression vector comprising DNA that encodes an HG20 protein that has been truncated
15 at the amino or carboxyl terminus;
- (b) culturing the transfected cells of step (a) under conditions such that the truncated HG20 protein is expressed.

Truncated HG20 proteins are those HG20 proteins in which contiguous portions of the N terminus or C terminus have been
20 removed. For example, positions 52-941 of SEQ.ID.NO.:2 represents a truncated HG20 protein. Truncated HG20 proteins may be fused in frame to non-HG20 amino acid sequences, as, *e.g.*, in the FLAG-HG20 construct described herein.

The present invention includes a method of producing
25 functional GABAB receptors in cells comprising:

- (a) transfecting cells with:
 - (1) an expression vector that directs the expression of HG20 in the cells; and
 - (2) an expression vector that directs the
30 expression of GABABR1a or GABABR1b in the cells;
- (b) culturing the cells under conditions such that heterodimers of HG20 and GABABR1a or GABABR1b are formed where the heterodimers constitute functional GABAB receptors.

In particular embodiments of the above methods, the cells
35 are eukaryotic cells. In other embodiments, the cells are mammalian cells. In still other embodiments, the cells are COS cells, *e.g.*, COS-7

cells (ATCC CRL 1651) or COS-1 cells (ATCC CRL 1650); HEK293 cells (ATCC CRL 1573); or *Xenopus* melanophores.

In particular embodiments, the HG20 protein comprises the amino acid sequence shown in SEQ.ID.NO.:2. In particular
5 embodiments, the HG20 protein is a truncated HG20 protein. In particular embodiments, the truncated HG20 protein comprises amino acids 52-941 of SEQ.ID.NO.:2. In particular embodiments, the truncated HG20 protein is a chimeric HG20 protein.

The present invention includes HG20 protein substantially
10 free from other proteins. The amino acid sequence of the full-length HG20 protein is shown in Figure 2 as SEQ.ID.NO.:2. Thus, the present invention includes polypeptides comprising HG20 protein substantially free from other proteins where the polypeptides comprise the amino acid sequence SEQ.ID.NO.:2. The present invention also includes
15 polypeptides comprising HG20 proteins lacking a signal sequence. Examples of amino acid sequences of HG20 proteins lacking a signal sequence are:

Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
20 Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
25 Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

The present invention also includes DNA encoding the above-described HG20 proteins lacking a signal sequence. Thus, *e.g.*,
30 the present invention includes a DNA molecule comprising a nucleotide sequence selected from the group consisting of:

Positions 293-3,115 of SEQ.ID.NO.:1;
Positions 317-3,115 of SEQ.ID.NO.:1;
Positions 395-3,115 of SEQ.ID.NO.:1;
35 Positions 398-3,115 of SEQ.ID.NO.:1;
Positions 404-3,115 of SEQ.ID.NO.:1;
Positions 407-3,115 of SEQ.ID.NO.:1;

Positions 416-3,115 of SEQ.ID.NO.:1;
Positions 422-3,115 of SEQ.ID.NO.:1;
Positions 428-3,115 of SEQ.ID.NO.:1;
Positions 446-3,115 of SEQ.ID.NO.:1; and
Positions 461-3,115 of SEQ.ID.NO.:1.

5 As with many receptor proteins, it is possible to modify many of the amino acids of HG20, particularly those which are not found in the ligand binding domain, and still retain substantially the same biological activity as the original protein. Thus this invention
10 includes modified HG20 polypeptides which have amino acid deletions, additions, or substitutions but that still retain substantially the same biological activity as native HG20. It is generally accepted that single amino acid substitutions do not usually alter the biological activity of a protein (see, *e.g.*, Molecular Biology of the Gene, Watson et al., 1987,
15 Fourth Ed., The Benjamin/Cummings Publishing Co., Inc., page 226; and Cunningham & Wells, 1989, Science 244:1081-1085). Accordingly, the present invention includes polypeptides where one amino acid substitution has been made in SEQ.ID.NO.:2 or in one of the HG20 polypeptides lacking a signal sequence listed above, wherein the
20 polypeptides still retain substantially the same biological activity as native HG20. The present invention also includes polypeptides where two or more amino acid substitutions have been made in SEQ.ID.NO.:2 or in one of the HG20 polypeptides lacking a signal sequence listed above, wherein the polypeptides still retain substantially the same biological
25 activity as native HG20. In particular, the present invention includes embodiments where the above-described substitutions are conservative substitutions. In particular, the present invention includes embodiments where the above-described substitutions do not occur in the ligand-binding domain of HG20. In particular, the present invention
30 includes embodiments where amino acid changes have been made in the positions of HG20 where the amino acid sequence of HG20 differs from the amino acid sequence of GABABR1b (see Figure 8).

The present invention also includes C-terminal truncated forms of HG20, particularly those which encompass the extracellular
35 portion of the receptor, but lack the intracellular signaling portion of the receptor. Such truncated receptors are useful in various binding assays described herein, for crystallization studies, and for structure-activity-

relationship studies. Accordingly, the present invention includes an HG20 protein substantially free from other proteins having the amino acid sequence of positions 1-480 of SEQ.ID.NO.:2.

O'Hara et al., 1993, Neuron 11:41-52 (O'Hara) reported that
5 the amino terminal domains of several metabotropic glutamate receptors showed amino acid sequence similarities to the amino termini of several bacterial periplasmic binding proteins. O'Hara used this similarity to predict, and then experimentally confirm, that these amino
10 terminal domains correspond to the location of the ligand binding domains of these metabotropic glutamate receptors.

The present inventors have discovered a region of amino acid sequence in the N-terminal domain of HG20 that is similar to the amino acid sequence of the bacterial periplasmic binding protein Leucine, Isoleucine, Valine (Alanine and Threonine) Binding Protein (LIVAT-BP) of *Pseudomonas aeruginosa*. See Figure 6. The region
15 shown is about 25% identical between the two proteins. This is above the maximum identity of 17% reported by O'Hara between any one metabotropic glutamate receptor and any one periplasmic binding protein and indicates that the region of HG20 depicted is highly likely to
20 contain the ligand binding domain.

Accordingly, the present invention includes a polypeptide representing the ligand binding domain of HG20 that includes amino acids 63-259 of SEQ.ID.NO.:2. Also provided are chimeric proteins comprising amino acids 63-259 of SEQ.ID.NO.:2.

25 Romano et al., 1996, J. Biol. Chem. 271:28612-28616 demonstrated that metabotropic glutamate receptors are often found as homodimers formed by an intermolecular disulfide bond. The location of the cysteines responsible for the disulfide bond was found to be in the amino terminal 17kD of the receptors. Transmembrane interactions
30 may also contribute to functional GABAB receptor dimer formation, as previously reported for the dopamine D2 receptor and β 2-adrenergic receptor (Ng et al., 1996, Biochem. Biophys. Res. Comm. 227:200-204; Hebert et al., 1996, J. Biol. Chem. 271, 16384-16392). Accordingly, the present invention includes dimers of HG20 proteins. In particular
35 embodiments, the HG20 protein has an amino acid selected from the group consisting of:

SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
5 Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
10 Positions 52-941 of SEQ.ID.NO.:2;
Positions 57-941 of SEQ.ID.NO.:2; and
Positions 1-480 of SEQ.ID.NO.:2.

It has been found that, in some cases, membrane spanning regions of receptor proteins can be used to inhibit receptor function (Ng et al., 1996, Biochem. Biophys. Res. Comm. 227:200-204; Hebert et al., 15 1996, J. Biol. Chem. 271, 16384-16392; Lofts et al., Oncogene 8:2813-2820). Accordingly, the present invention provides peptides derived from the seven membrane spanning regions of HG20 and their use to inhibit HG20 or GABA_B receptor function. Such peptides can include the whole 20 or parts of the membrane spanning domains.

The present invention also includes isolated forms of HG20 proteins. By "isolated HG20 protein" is meant HG20 protein that has been isolated from a natural source or produced by recombinant means. Use of the term "isolated" indicates that HG20 protein is not present in 25 its normal cellular environment. Thus, an isolated HG20 protein may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that an isolated HG20 protein is the only protein present. but instead means that an isolated HG20 protein is at least 95% free of non-amino 30 acid material (*e.g.*, nucleic acids, lipids, carbohydrates) naturally associated with the HG20 protein. Thus, an HG20 protein that is expressed through recombinant means in bacteria or even in eukaryotic cells which do not naturally (*i.e.*, without human intervention) express it is an "isolated HG20 protein."

35 The present invention also includes chimeric HG20 proteins. By chimeric HG20 protein is meant a contiguous polypeptide sequence of HG20 fused in frame to a polypeptide sequence of a non-

5 HG20 protein. For example, the N-terminal domain and seven transmembrane spanning domains of HG20 fused at the C-terminus in frame to a G protein would be a chimeric HG20 protein. Another example of a chimeric HG20 protein would be a polypeptide comprising the FLAG epitope fused in frame at the amino terminus of amino acids 52-941 of SEQ.ID.NO.:2.

10 The present invention also includes HG20 proteins that are in the form of multimeric structures, *e.g.*, dimers. Such multimers of other metabotropic G-protein coupled receptors are known (Hebert et al., 1996, J. Biol. Chem. 271, 16384-16392; Ng et al., 1996, Biochem. Biophys. Res. Comm. 227, 200-204; Romano et al., 1996, J. Biol. Chem. 271, 28612-28616).

15 Preferred forms of dimers of HG20 are heterodimers comprising HG20 and other G-protein coupled receptors (GPCRs). Such GPCRs could be, *e.g.*, other subunits of GABA_B receptors, proteins from *C. elegans* showing homology to HG20 (see Figure 24), or human GPCRs that are homologs of the *C. elegans* proteins. Particularly preferred forms of heterodimers are heterodimers of HG20 and either GABA_BR1a or GABA_BR1b. It has been found by the present inventors that such
20 heterodimers exhibit functional properties of GABA_B receptors while monomers or homodimers of HG20, GABA_BR1a, or GABA_BR1b do not exhibit functional properties. Another likely heterodimer partner for HG20 is the protein corresponding to the sequence deposited in GenBank at accession number 3776096.

25 The strongest evidence that functional GABA_B receptors require both HG20 and GABA_BR1a or GABA_BR1b comes from studies demonstrating that co-transfection and co-expression of both HG20 and either GABA_BR1a or GABA_BR1b is necessary in order for the detection of GABA_B receptor functional responses. Transfection and expression
30 of HG20, GABA_BR1a, or GABA_BR1b alone does not lead to the production of functional GABA_B receptors.

For example, in *Xenopus* melanophores co-expressing HG20 and GABA_BR1a, but not in melanophores expressing HG20 or GABA_BR1a alone, or in mock transfected melanophores, GABA
35 mediated a dose-dependent pigment aggregation response that could be inhibited with the GABA_B receptor specific CGP71872 antagonist. This pigment aggregation response is associated with a decrease in

intracellular cAMP levels. Such a decrease has been confirmed in HEK293 cells. Also, co-expression of HG20 and GABA_BR1a in *Xenopus* oocytes resulted in the stimulation of inwardly rectifying potassium currents (Kirs). Native functional GABA_B receptors have been reported
5 to couple to Kirs (Misgeld et al., 1995, Prog. Neurobiol. 46:423-462).

Consistent with the need for both HG20 and GABA_BR1a for detection of functional GABA_B receptors in transfected cells, the present inventors have demonstrated that HG20 and GABA_BR1a form
10 heterodimers by immunoprecipitation of HG20 followed by immunoblotting with a GABA_BR1a antibody.

That a functional GABA_B receptor requires both HG20 and either GABA_BR1a or GABA_BR1b is also suggested by the observation that GABA_BR1a or GABA_BR1b, recombinantly expressed in the absence of HG20, binds ligand with much reduced affinity compared to the
15 affinity of native GABA_B receptors. Also, characterization of the tissue distribution of each of the receptors by *in situ* hybridization histochemistry in rat brain revealed co-localization of HG20 and GABA_BR1a transcripts in many brain regions, including cortex, at both the regional and cellular levels.

20 The *Xenopus* melanophore pigment aggregation/dispersion assay has been shown to be highly suitable for monitoring agonist activation of Gi-, Gq-, and Gs-coupled receptors (Potenza et al., 1992, Anal. Biochem. 206:315-322; Lerner, 1994, Trends Neurosci. 17:142-146). Agonist activation of Gi-coupled receptors expressed in melanophores results in
25 pigment aggregation via a reduction in intracellular cAMP levels, whereas activation of Gs- and Gq-coupled receptors results in pigment dispersion via elevations in intracellular cAMP and calcium levels, respectively. Melanophores transfected separately with either GABA_BR1a or HG20 showed no pigment aggregation or dispersion
30 response following treatment with up to 1 mM concentrations of (L)-glutamic acid, GABA, or prototypic GABAergic agonists: (-)baclofen, 3-aminopropyl-(methyl)phosphonic acid, cis-4-aminocrotonic acid, piperidine-4-sulfonic acid (data not shown). Similarly, both receptors
35 failed to couple to K⁺ channels in *Xenopus* oocytes under patch-clamp conditions when transfected separately (data not shown). However, in melanophores transiently co-transfected with GABA_BR1a and HG20, GABA mediated a dose-dependent aggregation response with an IC₅₀

value of 3-7 μ M (n=3). This aggregation was absent in mock-transfected cells and in cells transfected with GABA_BR1a or HG20 alone (Figure 11). The GABA-mediated activity represented 42-56% (n=3) of a control cannabinoid receptor subtype 2 response (Figure 11, inset), and could be inhibited by the CGP71872 antagonist (n=3), indicating it was GABA_B receptor specific (Figure 11). GABA_BR1a was expressed by subcloning full-length GABA_BR1a into the NheI-NotI site of pcDNA3.1 or pCIneo; HG20 was expressed as a FLAG-HG20 chimeric protein. See Examples 11 and 20 for further experimental details of expression vectors used, transfection conditions, assay conditions, etc. for the above-described co-expression studies.

The functional data arising from co-expression of GABA_BR1a and HG20 receptors were confirmed in HEK293 cells. HEK293 cells transfected with and stably expressing GABA_BR1a and HG20 were selected based on expression of receptor message as determined by dot blot analyses. In cell lines stably expressing the individual receptors, we observed small and inconsistent responses in assays to examine agonist-mediated modulation of cAMP synthesis. However, transient transfection of HEK293 cells stably expressing GABA_BR1a (rgb1a-50) with an HG20 expression plasmid and transient transfection of HEK293 cells stably expressing HG20 (hgb2-42) with a GABA_BR1a expression plasmid significantly enhanced the ability of baclofen and GABA to inhibit forskolin-stimulated cAMP synthesis. Rgb1a-50 cells transfected with HG20 exhibited a 28% reduction in forskolin-stimulated cAMP synthesis with 30 μ M baclofen and a 40% decrease with 30 μ M GABA plus 100 μ M aminooxyacetic acid (AOAA; a GABA transaminase inhibitor) and 100 μ M nipecotic acid (a GABA uptake inhibitor) (Figure 12B). A 34% reduction in forskolin-stimulated cAMP synthesis was observed for hgb2-42 cells transfected with GABA_BR1a treated with baclofen and a 43% decrease was observed for GABA plus AOAA and nipecotic acid (Figure 12B). While inhibition of cAMP synthesis was sometimes observed with rgb1a-50 cells transfected with GABA_BR1a and hgb2-42 cells transfected with HG20, these effects were small and inconsistent (0-20% inhibition; Figure 12B). Neither baclofen nor GABA plus AOAA and nipecotic acid in the absence of forskolin had any affect on cAMP synthesis (Figure 12B). In addition,

wild-type HEK293 cells did not exhibit baclofen- or GABA-mediated inhibition of forskolin-stimulated cAMP synthesis (Figure 12B). These data demonstrate that the functional GABA_B receptor requires both GABA_BR1a and HG20. For experimental details of these studies in

5 HEK293 cells, see Example 12.

Co-expression of the GABA_BR1a and HG20 with the inwardly rectifying potassium channels Kir 3.1/3.2 in *Xenopus* oocytes resulted in a significant stimulation of inwardly rectifying potassium current (Kir) in response to GABA [301 +/- 20.6 %, (n=3) increase over
10 control current] measured at -80 mV which could subsequently be washed out with control solution (Figure 13). Modulation of Kir 3.1/3.2 was not seen in oocytes expressing GABA_BR1a or HG20 individually, even in the presence of Gi α 1 (Figure 13). See Example 21 for details.

To determine whether receptor intermolecular interactions
15 accounted for the functional activity that was observed following the co-expression of recombinant GABA_BR1a and HG20, membranes from cells co-expressing GABA_BR1a and HG20 or the individual proteins were first immunoprecipitated using anti-FLAG antibodies (to detect the recombinant FLAG-HG20 chimeric proteins) followed by
20 immunoblotting with a GABA_BR1a-specific antibody. As seen in Figure 14, lanes 1-3, no GABA_BR1a immunoreactivity was detected in samples prepared from mock vector transfected cells, FLAG-HG20 alone expressing cells, and GABA_BR1a alone expressing cells
25 immunoprecipitated with the FLAG-antibody. Since immunoreactive species were detected only in cells co-expressing HG20 and GABA_BR1a, this experiment demonstrates that HG20 and GABA_BR1a can only be co-immunoprecipitated as part of a complex (Figure 14, lane 4). Based on the predicted molecular mass of a heterodimer of HG20 and GABA_BR1a, the ~250+ and ~130 kDa species may represent a
30 heterodimer and GABA_BR1a monomers, respectively. The stability of the HG20/GABA_BR1a heterodimer in denaturing and reducing conditions suggests that SDS-stable transmembrane interactions form the heterodimer, as reported previously for β 2 adrenergic and dopamine D2 receptors (Ng et al., 1996, Biochem. Biophys. Res. Comm. 227:200-204; Hebert et al., 1996, J. Biol. Chem. 271, 16384-16392). The monomer might
35 result from partial disruption, subsequent to immunoprecipitation, of N-terminal Sushi repeats, C-terminal alpha-helical interacting domains

(*e.g.*, coiled-coils) present in HG20 and GABA_BR1a subunits, transmembrane interactions, or disulfide bonds that contribute to forming the heterodimer.

Particular examples of such regions likely to be involved in forming the heterodimer are shown in Figure 23. Regions such as those shown in Figure 23, as well as polypeptides comprising such regions are expected to be useful for the purpose of modulating the formation of heterodimers involving HG20 and thus controlling GABA_B receptor activity. Accordingly, the present invention includes polypeptides comprising the coiled-coil domains of HG20, GABA_BR1a, and GABA_BR1b. In particular, the present invention includes polypeptides comprising an amino acid sequence selected from the group consisting of: positions 756-829 of SEQ.ID.NO.:2; positions 779-814 of SEQ.ID.NO.:2; positions 886-949 of SEQ.ID.NO.:21; and positions 889-934 of SEQ.ID.NO.:21; where the polypeptides do not contain other contiguous amino acid sequences longer than 5 amino acids from a GABA_B receptor subunit. The present invention also includes heterodimers of such polypeptides. In more general terms, the present invention includes comprising a coiled-coil domain from a first GABA_B receptor subunit and no other contiguous amino acid sequences longer than 5 amino acids from the first GABA_B receptor subunit where the coiled-coil domain is present in the C-terminus of the first GABA_B receptor subunit and mediates heterodimerization of the first GABA_B receptor subunit with a second GABA_B receptor subunit.

In addition to the coiled-coil domains discussed above, a variety of regions of HG20 and GABA_BR1a are expected to be important for heterodimer formation. Motif analysis of the N-terminus of murine GABA_BR1a revealed seven consensus N-linked glycosylation sites and three putative short consensus repeats (SCRs) of ~60 amino acids each: amino acids 27-96 and amino acids 102-157 (GABA_BR1a specific), and amino acids 183-245 (common to GABA_BR1b (Kaupmann et al., 1997, Nature 386:239-246) and HG20 (Jones et al., 1998, Nature 396:674-679; White et al., 1998, Nature 396:679-682; Kaupmann et al., 1998, Nature 396:683-687; Kuner et al., 1999, Science 283:74-77) not described previously (Figure 26A-B). Since SCRs are known to play important roles in protein-protein interactions in a wide variety of complement

proteins, adhesion proteins, and selectins (Chou and Heinrikson, 1997, J. Protein Chem. 16:765-773; Perkins et al., 1998, Biochemistry 27:4004-4012), of which the latter shows weak amino acid identity to murine GABABR1a, these SCRs, together with the coiled-coil domains
5 discussed above in the carboxyl tails of GABABR1a and HG20 (Figure 23), are expected to be involved in the heterodimerization of GABABR1a and HG20.

Therefore, the present invention includes a polypeptide comprising an SCR domain from a first GABAB receptor subunit and
10 no other contiguous amino acid sequences longer than 5 amino acids from the first GABAB receptor subunit where the SCR domain is present in the N-terminus of the first GABAB receptor subunit and mediates heterodimerization of the first GABAB receptor subunit with a second GABAB receptor subunit. In particular embodiments, the SCR
15 is selected from the group consisting of: positions 27-96 of SEQ.ID.NO.:20; positions 102-157 of SEQ.ID.NO.:20; positions 183-245 of SEQ.ID.NO.:20; positions 28-97 of SEQ.ID.NO.:21; positions 103-158 of SEQ.ID.NO.:21; positions 184-246 of SEQ.ID.NO.:21; positions 4-22 of SEQ.ID.NO.:2; positions 23-49 of SEQ.ID.NO.:2; and positions 72-135 of
20 SEQ.ID.NO.:2.

As in the metabotropic glutamate receptors (mGLURs), the second intracellular loop of murine GABABR1a is rich in basic amino acids which may play a role in G-protein-interactions (reviewed by Pin and Duvoisin, 1995, Neuropharmacology 34:1-26), and, as in the
25 mGLURs, the carboxyl tail of murine GABABR1a contains a PDZ protein-interacting module (serine-arginine-valine, amino acids 953-955) which has been shown for mGLURs to play an important role in the interactions among the signaling components of synaptic junctions (Brakeman et al. 1997, Nature 386:284-288). The murine GABABR1a
30 receptor also contains potential protein kinase C and casein kinase II recognition sites predicted using ProSearch (Kolakowski et al., 1992, Biotechniques 13:919-921).

The present invention also relates to the identification and cloning of the murine GABABR1a receptor, the murine ortholog of the
35 rat GABABR1a receptor described in Kaupmann et al., 1997, Nature 386:239-246 (Kaupmann). The present invention provides DNA encoding murine GABABR1a that is substantially free from other nucleic acids.

The present invention also provides recombinant DNA molecules encoding murine GABABR1a.

The present invention provides a DNA molecule encoding murine GABABR1a that is substantially free from other nucleic acids and comprises the nucleotide sequence shown in Figure 15 as SEQ.ID.NO.:19. The open reading frame of SEQ.ID.NO.:19, encoding mouse GABABR1a protein, is positions 1-2,880, with positions 2,881-2,883 representing a stop codon. Thus, the present invention also provides a DNA molecule substantially free from other nucleic acids comprising the nucleotide sequence of positions 1-2,880 of SEQ.ID.NO.:19.

Sequence analysis of the open reading frame of the murine GABABR1a DNA revealed that it encodes a mature protein (*i.e.*, lacking a signal sequence) of 942 amino acids with a predicted molecular weight of 106.5 kDa that is 99% identical to rat GABABR1a (described in Kaupmann), with only six amino acid changes overall. Murine GABABR1a protein shares 31% overall amino acid identity to HG20.

CGP71872 is a photoaffinity ligand specific for GABABR1a receptors ($K_d = 1.0 \pm 0.2$ nM) that can be cross-linked to rat GABABR1a (Kaupmann et al., 1997, Nature 386:239-246). In crude membranes prepared from COS-7 cells transiently transfected with murine GABABR1a, [¹²⁵I]CGP71872 photolabelled a major band at ~130 kDa representing the mature (presumably glycosylated) protein and an additional band at approximately twice that molecular weight, possibly representing dimers (Figure 9). Ligand-binding species could also be detected with affinity purified GABABR1a antibodies 1713.1 (raised against the peptide acetyl-DVNSRRDILPDYELKLC-amide; a portion of SEQ.ID.NO.:20) and 1713.2 (raised against the peptide acetyl-CATLHNPTRVKLFK-amide; a portion of SEQ.ID.NO.:20) (Figure 9). In contrast, FLAG-tagged HG20 protein did not bind the high-affinity CGP71872 ligand, although expression of the protein was confirmed by immunoblot analysis (Figure 9).

Displacement of [¹²⁵I]CGP71872 binding to recombinant murine GABABR1a was in the appropriate rank order of potency for GABAergic ligands: CGP71872 > SKF-97541 (3-aminopropyl(methyl)-phosphinic acid) > GABA > (-)baclofen > saclofen > (L)-glutamic acid.. Interestingly, recombinant rat GABABR1a exhibits 10-25 fold lower affinity for agonists than native GABAB receptors in brain (Kaupmann

et al., 1997, *Nature* 386:239). Although the reason for this discrepancy remains unclear, a recent report indicated that recombinant GABA_BR1a may require additional cellular components for functional targeting to the plasma membrane (Couve et al., 1998, *J. Biol. Chem.* 273:26361-26367). Thus, GABA_BR1a alone, without such additional components, might be expected to exhibit somewhat altered ligand binding characteristics.

In the binding experiments discussed above using GABA_BR1a alone, surprisingly, dose-dependent displacement was not detected for (+)baclofen, and the affinities of agonists (GABA, SKF-97541, and (-)baclofen) and partial agonists ((+)baclofen, saclofen, (L)-glutamic acid) but not the affinity of antagonist (CGP71872) for the recombinant GABA_BR1a were markedly lower compared to native receptors in rat brain (Table 1). Agonist affinities of co-expressed HG20 and GABA_BR1a were examined in membranes prepared from cells co-expressing GABA_BR1a and FLAG-tagged HG20. Competition of [¹²⁵I]CGP71872 binding in these membranes showed recovery of high-affinity ligand binding comparable to native receptors in rat brain (Table 1). The simplest explanation for these results is that the high-affinity agonist binding pocket may comprise interactions between the N-terminal domains of HG20 and GABA_BR1a that form the heterodimer.

Table 1

Ligand	rat cortex*	gb1a	gb1a/gb2
CGP71872	0.5 nM	0.52 - 0.67 nM	0.15 - 0.27 nM
GABA	2.5 uM	42.55 - 68.38 uM	1.77 - 2.55 uM
SKF-97541**	not determined	11.09 - 11.47 uM	0.80 - 0.96 uM
(-)Baclofen	0.5 uM	31.46 - 53.70 uM	3.92 - 7.78 uM
(+)Baclofen	not determined	no fit	1.25 - 3.94 mM
Saclofen	156 uM	280.5 - 365.0 uM	119.4 - 131.4 uM
L-Glutamate	not determined	119.4 - 285.0 mM	116.2 - 201.6 mM

* reported by Kaupmann et al., (1997) *Nature* 388, 239-246
 ** 3-aminopropyl(methyl)phosphinic acid

In Table 1, gb1a refers to GABA_BR1a and gb1a/gb2 refers to HG20/ GABA_BR1a heterodimers.

Co-localization studies were performed to determine if mRNAs for GABA_BR1a and HG20 co-exist in the same cells in the brain. Figure 10A-B shows equivalent levels of GABA_BR1a and HG20

hybridization in adjacent coronal sections of rat parietal cortex, indicating that messages for both receptors are expressed in this brain region. Radiolabelled and fluorescent probes for the two receptors were used to look at the cellular level where it was observed that message for both receptors is expressed in the same cells (Example 13 and Figure 10C-E). In the parietal cortex and all other major brain regions studied, including the hippocampus, thalamus, cerebellum, and vestibular ganglion, GABABR1a and HG20 mRNAs are co-localized in the same cells. These results suggest that the functional native GABAB receptors found in these cells involve both GABABR1a and HG20. Co-immunoprecipitation, functional, and anatomical data described herein converge to strongly support the argument that the native, functional GABAB receptor is a heterodimer of GABABR1a and HG20. This work is particularly exciting because it represents the first example of a heteromeric G protein-coupled receptor.

The novel murine GABABR1a DNA sequences of the present, in whole or in part, can be linked with other DNA sequences, *i.e.*, DNA sequences to which GABABR1a DNA is not naturally linked, to form "recombinant DNA molecules" encoding murine GABABR1a. Such other sequences can include DNA sequences that control transcription or translation such as, *e.g.*, translation initiation sequences, promoters for RNA polymerase II, transcription or translation termination sequences, enhancer sequences, sequences that control replication in microorganisms, or that confer antibiotic resistance. The novel DNA sequences of the present invention can be inserted into vectors such as plasmids, cosmids, viral vectors, or yeast artificial chromosomes.

The present invention also includes isolated forms of DNA encoding GABABR1a. By "isolated DNA encoding GABABR1a" is meant DNA encoding GABABR1a that has been isolated from a natural source or produced by recombinant means. Use of the term "isolated" indicates that DNA encoding GABABR1a is not present in its normal cellular environment. Thus, an isolated DNA encoding GABABR1a may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that isolated DNA encoding GABABR1a is the only DNA present, but instead means that isolated DNA encoding GABABR1a is at

least 95% free of non-nucleic acid material (e.g., proteins, lipids, carbohydrates) naturally associated with the DNA encoding GABABR1a. Thus, DNA encoding GABABR1a that is expressed in bacteria or even in eukaryotic cells which do not naturally (i.e., without
5 human intervention) contain it through recombinant means is "isolated DNA encoding GABABR1a."

Another aspect of the present invention includes host cells that have been engineered to contain and/or express DNA sequences encoding murine GABABR1a. Such recombinant host cells can be
10 cultured under suitable conditions to produce murine GABABR1a protein. An expression vector containing DNA encoding the murine GABABR1a protein can be used for expression of the murine GABABR1a protein in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria
15 such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Cell lines derived from mammalian species which are suitable for recombinant expression of the murine
20 GABABR1a protein and which are commercially available, include but are not limited to, L cells L-M(TK-) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa
25 (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus melanophores*, and *Xenopus oocytes*.

A variety of mammalian expression vectors can be used to express recombinant murine GABABR1a in mammalian cells. Commercially available mammalian expression vectors which are
30 suitable include, but are not limited to, pMC1neo (Stratagene), pSG5 (Stratagene), pcDNAI and pcDNAIamp, pcDNA3, pcDNA3.1, pCR3.1 (Invitrogen), EBO-pSV2-neo (ATCC 37593), pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), and the PT7TS oocyte
35 expression vector (or similar expression vectors containing the globin 5' UTR and the globin 3' UTR). Following expression in recombinant cells,

the murine GABA β R1a protein can be purified by conventional techniques to a level that is substantially free from other proteins.

Other cells that are particularly suitable for expression of the murine GABA β R1a protein are immortalized melanophore pigment cells from *Xenopus laevis*. Such melanophore pigment cells can be used for functional assays using recombinant expression of murine GABA β R1a in a manner similar to the use of such melanophore pigment cells for the functional assay of other recombinant GPCRs (Graminski et al., 1993, J. Biol. Chem. 268:5957-5964; Lerner, 1994, Trends Neurosci. 17:142-146; Potenza & Lerner, 1992, Pigment Cell Res. 5:372-378; Potenza et al., 1992, Anal. Biochem. 206:315-322).

The present invention includes a method of producing the murine GABA β R1a protein comprising:

- (a) transfecting a host cell with a expression vector comprising DNA that encodes the murine GABA β R1a protein;
- (b) growing the host cells under conditions such that the murine GABA β R1a protein is produced; and
- (c) recovering the murine GABA β R1a protein from the host cells.

In particular embodiments, the method of recovering the murine GABA β R1a protein may involve obtaining membrane preparations from the host cells that contain the murine GABA β R1a protein. Such membrane preparations may contain heterodimers of GABA β R1a protein and HG20 protein that form functional GABA β receptors.

In particular embodiments, the cells are eukaryotic cells. In other embodiments, the cells are mammalian cells. In still other embodiments, the cells are COS cells, in particular COS-7 cells (ATCC CRL 1651), COS-1 cells (ATCC CRL 1650), HEK293 cells (ATCC CRL 1573), or *Xenopus* melanophores.

The present inventors have discovered that, when either HG20 or GABA β R1a subunits are recombinantly expressed separately, *i.e.*, in different cells, very little or no expression is observed. It is only when HG20 and GABA β R1a subunits are recombinantly co-expressed, *i.e.*, expressed in the same cells at the same time, that high level expression of HG20 and GABA β R1a is observed (see Figure 25). Given

the close relationship among GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20 (see Figure 24), and the close relationship that is expected to be found between other isoforms of GABA_BR1a and GABA_BR1b, it is believed that co-expression of HG20 and either GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b will also result in increased expression of HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b as compared to expression of these proteins separately.

Accordingly, the present invention includes a method of co-expressing HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b so as to result in an increase in expression of HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b as compared to expression when HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b are expressed separately. In particular embodiments, the level of expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b is measured in the co-expressing cells. In particular embodiments, the level of expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b is measured by immunoblot or by immunoprecipitation/immunoblotting methods.

Thus, the present invention includes a method of increasing expression of HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b comprising:

- (a) recombinantly expressing HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in the same cells;
- (b) measuring the expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b, where a measurement of

detectable expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b indicates that increased expression has been achieved.

5 In particular embodiments, the measurement of expression is carried out by immunoblotting with or without immunoprecipitation.

In other embodiments, the method also comprises the steps of recombinantly expressing HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b separately, measuring the level of expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in the separately expressing cells, and comparing the amount of expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in the separately expressing cells to the amount of expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in the co-expressing cells.

20 Accordingly, the present invention includes a method of increasing expression of HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b comprising:

(a) recombinantly expressing HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in the same cells to form co-expressing cells;

(b) recombinantly expressing HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in different cells to form separately expressing cells;

(c) measuring the expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in the co-expressing cells;

(d) measuring the expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other

isoforms of GABA_BR1a and GABA_BR1b in the separately expressing cells;

where if the amount of expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other
5 isoforms of GABA_BR1a and GABA_BR1b is greater in the co-expressing cells as compared to the separately expressing cells, this indicates that increased expression has been achieved.

In particular embodiments, the measurement of expression is carried out by immunoblotting with or without
10 immunoprecipitation.

The present invention includes murine GABA_BR1a protein substantially free from other proteins. The amino acid sequence of the full-length murine GABA_BR1a protein is shown in Figure 16 as
15 SEQ.ID.NO.:20. Thus, the present invention includes polypeptides comprising the murine GABA_BR1a protein substantially free from other proteins having the amino acid sequence SEQ.ID.NO.:20. The present invention also includes murine GABA_BR1a protein lacking a signal sequence as well as DNA encoding such a protein. Such a murine GABA_BR1a protein lacking a signal sequence is represented by
20 amino acids 18-960 of SEQ.ID.NO.:20.

The present invention includes modified murine GABA_BR1a polypeptides which have amino acid deletions, additions, or substitutions but that still retain substantially the same biological activity as native murine GABA_BR1a protein. The present invention
25 includes polypeptides where one amino acid substitution has been made in SEQ.ID.NO.:20 or in a polypeptide represented by SEQ.ID.NO.:20 lacking a signal sequence, wherein the polypeptides still retain substantially the same biological activity as native murine GABA_BR1a protein. The present invention also includes polypeptides where two or
30 more amino acid substitutions have been made in SEQ.ID.NO.:20 or in a polypeptide represented by SEQ.ID.NO.:20 lacking a signal sequence, wherein the polypeptides still retain substantially the same biological activity as native murine GABA_BR1a protein. In particular, the present invention includes embodiments where the above-described
35 substitutions are conservative substitutions. In particular, the present invention includes embodiments where the above-described

substitutions do not occur in the ligand-binding domain of native murine GABA_BR1a protein. In particular, the present invention includes embodiments where amino acid changes have been made in positions of native murine GABA_BR1a protein where the amino acid sequence of native murine GABA_BR1a protein differs from the amino acid sequence of HG20 when the amino acid sequences of native murine GABA_BR1a protein and HG20 are aligned in a manner similar to the alignment of the amino acid sequences of GABA_BR1b protein and HG20 shown in Figure 8.

10 The present invention also includes isolated forms of murine GABA_BR1a proteins. By "isolated murine GABA_BR1a protein" is meant murine GABA_BR1a protein that has been isolated from a natural source or produced by recombinant means. Use of the term "isolated" indicates that murine GABA_BR1a protein is not present in its normal cellular environment. Thus, an isolated murine GABA_BR1a protein may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that an isolated murine GABA_BR1a protein is the only protein present, but instead means that an isolated murine GABA_BR1a protein is at least 95% free of non-amino acid material (e.g., nucleic acids, lipids, carbohydrates) naturally associated with the murine GABA_BR1a protein. Thus, an murine GABA_BR1a protein that is expressed in bacteria or even in eukaryotic cells which do not naturally (i.e., without human intervention) express it through recombinant means is an "isolated murine GABA_BR1a protein."

25 The present invention also provides ligand-binding domains of murine GABA_BR1a protein. A FASTA search of the database GenBank (bacterial division) using the N-terminal domain of murine GABA_BR1a (amino acid positions 147-551 of SEQ.ID.NO.:20) as the probe reveals a match with the *E.coli* leucine-specific binding protein (livK) (22% identity over 339 amino acids), whereas no match to any bacterial amino acid binding protein is found using the receptor sequence inclusive of the region that includes the seven transmembrane domains (TM 1-7; amino acid positions 552-960) as a probe. The ligand-binding domain(s) of GABA_BR1a was also experimentally determined. Photoaffinity [¹²⁵I]CGP71872 labeling experiments provided direct physical evidence that the N-terminal extracellular domain but not a C-

terminal fragment of GABA_BR1a (comprising TM1-7 and inclusive to the carboxyl tail) is responsible for ligand-binding (see Examples 14-19 and Figure 17B).

Accordingly, the present invention includes a polypeptide comprising the ligand binding domain of murine GABA_BR1a. In preferred embodiments, the polypeptide comprises amino acids 147-551 of SEQ.ID.NO.:20.

The present invention includes methods of identifying compounds that specifically bind to the GABA_B receptor, as well as compounds identified by such methods. The specificity of binding of compounds showing affinity for the GABA_B receptor is shown by measuring the affinity of the compounds for recombinant cells expressing HG20 and either GABA_BR1a or GABA_BR1b, or for membranes from such cells. Expression of the GABA_B receptor and screening for compounds that bind to the GABA_B receptor or that inhibit the binding of a known, radiolabeled ligand of the GABA_B receptor, *e.g.*, an amino acid or a GABA analogue such as (-)baclofen, to these cells, or membranes prepared from these cells, provides an effective method for the rapid selection of compounds with high affinity for the GABA_B receptor. Other radiolabeled ligands that might be used are ibotenic acid, the amino acids glutamate and glycine, other amino acids, decarboxylated amino acids, or any of the other GABA_B receptor ligands disclosed herein or known in the art. Such ligands need not necessarily be radiolabeled but can also be nonisotopic compounds that can be used to displace bound radiolabeled compounds or that can be used as activators in functional assays. Compounds identified by the methods disclosed herein are likely to be agonists or antagonists of the GABA_B receptor and may be peptides, proteins, or non-proteinaceous organic molecules.

Therefore, the present invention includes assays by which GABA_B receptor agonists and antagonists can be identified. Methods for identifying agonists and antagonists of other receptors are well known in the art and can often be adapted to identify agonists and antagonists of the GABA_B receptor. Accordingly, the present invention includes a method for determining whether a substance binds GABA_B receptors

and is thus a potential agonist or antagonist of the GABA_B receptor that comprises:

- (a) providing cells comprising an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b;
 - (b) culturing the cells under conditions such that HG20 and GABA_BR1a or GABA_BR1b are expressed and heterodimers of HG20 and GABA_BR1a or GABA_BR1b are formed;
 - (c) exposing the cells to a labeled ligand of GABA_B receptors in the presence and in the absence of the substance;
 - (d) measuring the binding of the labeled ligand to the heterodimers of HG20 and GABA_BR1a or GABA_BR1b in the presence and in the absence of the substance;
- where if the amount of binding of the labeled ligand is less in the presence of the substance than in the absence of the substance, then the substance is a potential agonist or antagonist of GABA_B receptors.

Examples of ligands of GABA_B receptors are: CGP71872, GABA, saclofen, (-)baclofen, glycine, and (L)-glutamic acid.

The present invention also includes a method for determining whether a substance is capable of binding to GABA_B receptors, *i.e.*, whether the substance is a potential agonist or an antagonist of GABA_B receptors, where the method comprises:

- (a) providing test cells comprising an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b;
- (b) culturing the test cells under conditions such that HG20 and GABA_BR1a or GABA_BR1b are expressed and heterodimers of HG20 and GABA_BR1a or GABA_BR1b are formed;
- (c) exposing the test cells to the substance;
- (d) measuring the amount of binding of the substance to the test cells;
- (e) measuring the amount of binding of the substance to control cells;
- (f) comparing the amount of binding of the substance to the test cells with the amount of binding of the substance to control cells;

where if the amount of binding of the substance to the test cells is greater than the amount of binding of the substance to control cells, then the substance is capable of binding to GABA_B receptors;

where the control cells are essentially the same as the test cells except that the control cells do not comprise an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b.

Once a substance has been identified by the above-described methods, determining whether the substance is an agonist or antagonist can then be accomplished by the use of functional assays such as those described herein.

In particular embodiments, the cells are transfected with an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b.

In particular embodiments, the binding affinity of the substance for the test cells is determined. In particular embodiments, such binding affinity is between 1nM and 200 mM; preferably between 5 nM and 1 mM; more preferably between 10 nM and 100 μM; and even more preferably between 10 nM and 100 nM.

The conditions under which step (c) of the above-described methods is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

In a particular embodiment of the above-described methods, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), or *Xenopus* melanophores.

The assays described above can be carried out with cells that have been transiently or stably transfected with an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b. Transfection is meant to include any method known in the

art for introducing HG20 and GABA_BR1a or GABA_BR1b into the test cells. For example, transfection includes calcium phosphate or calcium chloride mediated transfection, lipofection, infection with a retroviral construct, and electroporation. In particular embodiments, a single
5 expression vector encodes HG20 and GABA_BR1a or GABA_BR1b.

Where binding of the substance or ligand is measured, such binding can be measured by employing a labeled substance or ligand. The substance or ligand can be labeled in any convenient manner known to the art, *e.g.*, radioactively, fluorescently,
10 enzymatically.

In particular embodiments of the above-described methods, the substance or ligand is an amino acid or an amino acid analogue such as CGP71872, GABA, saclofen, (-)baclofen, glycine, and (L)-glutamic acid.

15 In particular embodiments of the above-described methods, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

In particular embodiments of the above-described methods, HG20 comprises an amino acid sequence selected from the group consisting of:

20 SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
25 Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
30 Positions 57-941 of SEQ.ID.NO.:2.

In particular embodiments, GABA_BR1a is murine GABA_BR1a and has the amino acid sequence SEQ.ID.NO.:20. In particular embodiments, GABA_BR1a is rat GABA_BR1a and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In particular embodiments, GABA_BR1b is rat GABA_BR1b and has
35 the amino acid sequence reported in Kaupmann et al., 1997, Nature

386:239-246. In particular embodiments, GABA_BR1a is human GABA_BR1a and has an amino acid sequence selected from the group consisting of: SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

The above-described methods can be modified in that,
5 rather than exposing cells to the substance, membranes can be prepared from the cells and those membranes can be exposed to the substance. Such a modification utilizing membranes rather than cells is well known in the art with respect to other receptors and is described in, *e.g.*, Hess et al., 1992, Biochem. Biophys. Res. Comm. 184:260-268.

10 As a further modification of the above-described method, RNA encoding HG20 and GABA_BR1a or GABA_BR1b can be prepared as, *e.g.*, by *in vitro* transcription using a plasmid containing HG20 and a plasmid containing GABA_BR1a or GABA_BR1b under the control of a bacteriophage T7 promoter, and the RNA can be microinjected into
15 *Xenopus* oocytes in order to cause the expression of HG20 and GABA_BR1a or GABA_BR1b in the oocytes. Substances are then tested for binding to the heterodimer of HG20 and GABA_BR1a or GABA_BR1b expressed in the oocytes. Alternatively, rather than detecting binding, the effect of the substances on the electrophysiological properties of the
20 oocytes can be determined.

The present invention includes assays by which GABA_B receptor agonists and antagonists may be identified by their ability to stimulate or antagonize a functional response mediated by the GABA_B receptor in cells that have been co-transfected with and that co-express
25 HG20 and GABA_BR1a or GABA_BR1b.

Accordingly, the present invention provides a method of identifying agonists and antagonists of HG20 comprising:

- (a) providing test cells by transfecting cells with:
 - (1) an expression vector that directs the
30 expression of HG20 in the cells; and
 - (2) an expression vector that directs the expression of GABA_BR1a or GABA_BR1b in the cells;
- (b) exposing the test cells to a substance that is suspected of being an agonist of the GABA_B receptor;
- 35 (c) measuring the amount of a functional response of the test cells that have been exposed to the substance;

(d) comparing the amount of the functional response exhibited by the test cells with the amount of the functional response exhibited by control cells;

5 wherein if the amount of the functional response exhibited by the test cells differs from the amount of the functional response exhibited by the control cells, the substance is an agonist or antagonist of the GABA_B receptor;

10 where the control cells are cells that have not been transfected with HG20 and GABA_BR1a or GABA_BR1b but have been exposed to the substance or are test cells that have not been exposed to the substance.

In particular embodiments of the above-described methods, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

15 In particular embodiments of the above-described methods, HG20 comprises an amino acid sequence selected from the group consisting of:

SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
20 Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
25 Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

In particular embodiments, GABA_BR1a is murine GABA_BR1a and has the amino acid sequence SEQ.ID.NO.:20. In
30 particular embodiments, GABA_BR1a is rat GABA_BR1a and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In particular embodiments, GABA_BR1b is rat GABA_BR1b and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In particular embodiments, GABA_BR1a is human
35 GABA_BR1a and has an amino acid sequence selected from the group consisting of: SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

In particular embodiments, the functional response is selected from the group consisting of: changes in pigment distribution in melanophore cells; changes in cAMP or calcium concentration; and changes in membrane currents in *Xenopus* oocytes. In particular
5 embodiments, the change in pigment distribution is pigment aggregation; the change in cAMP concentration is a decrease in cAMP concentration; the change in membrane current is the modulation of an inwardly rectifying potassium current.

In a particular embodiment of the above-described method,
10 the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells: L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92),
15 NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C1271 (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, or *Xenopus* oocytes.

In a particular embodiment of the above-described method, the cells are transfected with separate expression vectors that direct the
20 expression of HG20 and either GABA_BR1a or GABA_BR1b in the cells. In other embodiments, the cells are transfected with a single expression vector that direct the expression of both HG20 and GABA_BR1a or GABA_BR1b in the cells.

In a particular embodiment, the cells are *Xenopus*
25 melanophores and the functional response is pigment aggregation. In another embodiment, the cells are HEK293 cells and the functional response is a decrease in cAMP level. In another embodiment, the cells are *Xenopus* oocytes and the functional response is the production of an inwardly rectifying potassium current.

30 The conditions under which step (b) of the method is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: e.g., physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

35 The above-described assay can be easily modified to form a method to identify antagonists of the GABA_B receptor. Such a method comprises:

- (a) providing cells by transfecting cells with:
- (1) an expression vector that directs the expression of HG20 in the cells; and
- (2) an expression vector that directs the expression of GABABR1a or GABABR1b in the cells;
- (b) exposing the cells to a substance that is a known agonist of the GABAB receptor;
- (c) measuring the amount of a functional response of the cells that have been exposed to the known agonist;
- (d) exposing the cells concurrently to the known agonist and to a substance that is suspected of being an antagonist of the GABAB receptor;
- (e) measuring the amount of a functional response of the cells that have been exposed to the substance and the known agonist;
- (f) comparing the amount of the functional response measured in step (c) with the amount of the functional response measured in step (e);
- wherein if the amount of the functional response measured in step (c) is greater than the amount of the functional response measured in step (e), the substance is an antagonist of the GABAB receptor.

Additional types of functional assays that can be used to identify agonists and antagonists of GABAB receptors include transcription-based assays. Transcription-based assays involve the use of a reporter gene whose transcription is driven by an inducible promoter whose activity is regulated by a particular intracellular event such as, *e.g.*, changes in intracellular calcium levels that are caused by the interaction of a receptor with a ligand. Transcription-based assays are reviewed in Rutter et al., 1998, *Chemistry & Biology* 5:R285-R290.

The transcription-based assays of the present invention rely on the expression of reporter genes whose transcription is activated or repressed as a result of intracellular events that are caused by the interaction of an agonist with a heterodimer of HG20 and either GABABR1a or GABABR1b where the heterodimer forms a functional GABAB receptor.

An extremely sensitive transcription based assay is disclosed in Zlokarnik et al., 1998, *Science* 279:84-88 (Zlokarnik) and also

in U.S. Patent No. 5,741,657. The assay disclosed in Zlokarnik and U.S. Patent No. 5,741,657 employs a plasmid encoding β -lactamase under the control of an inducible promoter. This plasmid is transfected into cells together with a plasmid encoding a receptor for which it is desired to
5 identify agonists. The inducible promoter on the β -lactamase is chosen so that it responds to at least one intracellular signal that is generated when an agonist binds to the receptor. Thus, following such binding of agonist to receptor, the level of β -lactamase in the transfected cells increases. This increase in β -lactamase is made measurable by treating
10 the cells with a cell-permeable dye that is a substrate for β -lactamase. The dye contains two fluorescent moieties. In the intact dye, the two fluorescent moieties are close enough to one another that fluorescent resonance energy transfer (FRET) can take place between them. Following cleavage of the dye into two parts by β -lactamase, the two
15 fluorescent moieties are located on different parts, and thus can drift apart. This increases the distance between the fluorescent moieties, thus decreasing the amount of FRET that can occur between them. It is this decrease in FRET that is measured in the assay.

One skilled in the art can modify the assay described in
20 Zlokarnik and U.S. Patent No. 5,741,657 to form an assay for identifying agonists of GABA_B receptors by using an inducible promoter to drive β -lactamase that is activated by an intracellular signal generated by the interaction of agonists and the GABA_B receptor. To produce the GABA_B receptor, a plasmid encoding HG20 and a plasmid encoding
25 GABA_BR1a or GABA_BR1b would be transfected into the cells. The cells would be exposed to the cell-permeable dye and then exposed to substances suspected of being agonists of the GABA_B receptor. Those substances that cause a decrease in FRET are likely to actually be agonists of the GABA_B receptor.

30 Accordingly, the present invention includes a method for identifying agonists of the GABA_B receptor comprising:

- (a) transfecting cells with:
 - (1) an expression vector that directs the
expression of HG20 in the cells;
 - (2) an expression vector that directs the
35 expression of GABA_BR1a or GABA_BR1b in the cells;

(3) an expression vector that directs the expression of β -lactamase under the control of an inducible promoter that is activated by an intracellular signal generated by the interaction of agonists and the GABA_B receptor;

5 (b) exposing the cells to a substrate of β -lactamase that is a cell-permeable dye that contains two fluorescent moieties where the two fluorescent moieties are on different parts of the dye and cleavage of the dye by β -lactamase allows the two fluorescent moieties to drift apart;

10 (c) measuring the amount of fluorescent resonance energy transfer (FRET) in the cells in the absence of the substance of step (d);

(d) exposing the cells to a substance that is suspected of being an agonist of the GABA_B receptor;

15 (e) measuring the amount of FRET in the cells after exposure of the cells to the substance;

wherein if the amount of FRET in the cells measured in step (e) is less than the amount of FRET measured in the cells in step (c), then the substance is an agonist of the GABA_B receptor.

20 Substeps (1)-(3) of step (a) can be practiced in any order.

The assay described above can be modified to an assay for identifying antagonists of the GABA_B receptor. Such modification would involve the use of β -lactamase under the control of a promoter that is repressed by at least one intracellular signal generated by interaction of an agonist with the GABA_B receptor and would also involve running the assay in the presence of a known agonist. When the cells are exposed to substances suspected of being antagonists of the GABA_B receptor, β -lactamase will be induced, and FRET will decrease, only if the substance tested is able to counteract the effect of the agonist, *i.e.*, only if the substance tested is actually an antagonist.

30 Accordingly, the present invention includes a method for identifying antagonists of the GABA_B receptor comprising:

(a) transfecting cells with:

35 (1) an expression vector that directs the expression of HG20 in the cells;

(2) an expression vector that directs the expression of GABA_BR1a or GABA_BR1b in the cells;

- (3) an expression vector that directs the expression of β -lactamase under the control of an inducible promoter that is repressed by at least one intracellular signal generated by interaction of an agonist with the GABA_B receptor;
- 5 (b) exposing the cells to a known agonist of the GABA_B receptor;
- (c) exposing the cells to a substrate of β -lactamase that is a cell-permeable dye that contains two fluorescent moieties where the two fluorescent moieties are on different parts of the dye and cleavage of the dye by β -lactamase allows the two fluorescent moieties to drift
10 apart;
- (d) measuring the amount of fluorescent resonance energy transfer (FRET) in the cells in the absence of the substance of step (e);
- 15 (e) exposing the cells to a substance that is suspected of being an antagonist of the GABA_B receptor;
- (f) measuring the amount of FRET in the cells after exposure of the cells to the substance;
- wherein if the amount of FRET in the cells measured in
20 step (f) is less than the amount of FRET measured in the cells in step (d), then the substance is an antagonist of the GABA_B receptor.

Substeps (1)-(3) of step (a) can be practiced in any order.

In particular embodiments of the assays employing β -lactamase described above, the cells are eukaryotic cells. In particular
25 embodiments, the cells are mammalian cells. In particular embodiments, the cells are selected from the group consisting of: L cells L-M(TK-) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC
30 CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, and *Xenopus* oocytes.

In other embodiments, the inducible promoter that is repressed by at least one intracellular signal generated by interaction of
35 an agonist with the GABA_B receptor is a promoter that is repressed by decreases in cAMP levels or changes in potassium currents.

In other embodiments, the inducible promoter that is activated by at least one intracellular signal generated by interaction of an agonist with the GABA_B receptor is a promoter that is activated by decreases in cAMP levels or changes in potassium currents.

5 In other embodiments, the known agonist is selected from the group consisting of: GABA, saclofen, (-)baclofen, glycine, and (L)-glutamic acid.

In other embodiments, β -lactamase is TEM-1 β -lactamase from *Escherichia coli*.

10 In other embodiments, the substrate of β -lactamase is CCF2/AM (Zlokarnik et al., 1998, Science 279:84-88).

In other embodiments, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

15 In other embodiments of the above-described methods, HG20 comprises an amino acid sequence selected from the group consisting of:

SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
20 Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
25 Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

In other embodiments, GABA_BR1a is murine GABA_BR1a and has the amino acid sequence SEQ.ID.NO.:20. In other
30 embodiments, GABA_BR1a is rat GABA_BR1a and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In other embodiments, GABA_BR1b is rat GABA_BR1b and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In other embodiments, GABA_BR1a is human GABA_BR1a and has an
35 amino acid sequence selected from the group consisting of: SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

In particular embodiments, the cells express a promiscuous G-protein, e.g., Gα15 or Gα16.

In particular embodiments, the inducible promoter is a promoter that is activated or repressed by NF-κB or NFAT.

5 The assays described above could be modified to identify inverse agonists. In such assays, one would expect a decrease in β-lactamase activity. Similarly, inverse agonists can be identified by modifying the functional assays that were described previously where those functional assays monitored decreases in cAMP levels. In the
10 case of assays for inverse agonists, increases in cAMP levels would be observed.

Other transcription-based assays that can be used to identify agonists and antagonists of the GABAB receptor rely on the use of green fluorescent proteins or luciferase as reported genes. An
15 example of such an assay comprises:

- (a) transfecting cells with:
 - (1) an expression vector that directs the expression of HG20 in the cells;
 - (2) an expression vector that directs the
20 expression of GABABR1a or GABABR1b in the cells;
 - (3) an expression vector that directs the expression of green fluorescent protein (GFP) under the control of an inducible promoter that is activated by an intracellular signal generated by the interaction of agonists and the GABAB receptor;
- 25 (b) measuring the amount of fluorescence from GFP in the cells;
- (c) exposing the cells to a substance that is suspected of being an agonist of the GABAB receptor;
- (d) measuring the amount of fluorescence from GFP in
30 the cells that have been exposed to the substance;
- wherein if the amount of fluorescence from GFP in the cells measured in step (b) is less than the amount of fluorescence from GFP measured in the cells in step (d), then the substance is an agonist of the GABAB receptor.

35 The present invention also includes assays for the identification of agonists or antagonists of GABAB receptors that are based upon FRET between a first and a second fluorescent dye where the

first dye is bound to one side of the plasma membrane of a cell expressing a heterodimer of HG20 and GABABR1a or GABABR1b and the second dye is free to shuttle from one face of the membrane to the other face in response to changes in membrane potential. In certain
5 embodiments, the first dye is impenetrable to the plasma membrane of the cells and is bound predominately to the extracellular surface of the plasma membrane. The second dye is trapped within the plasma membrane but is free to diffuse within the membrane. At normal (*i.e.*,
10 negative) resting potentials of the membrane, the second dye is bound predominately to the inner surface of the extracellular face of the plasma membrane, thus placing the second dye in close proximity to the first dye. This close proximity allows for the generation of a large amount of FRET between the two dyes. Following membrane
15 depolarization, the second dye moves from the extracellular face of the membrane to the intracellular face, thus increasing the distance between the dyes. This increased distance results in a decrease in FRET, with a corresponding increase in fluorescent emission derived from the first dye and a corresponding decrease in the fluorescent emission from the second dye. See figure 1 of González & Tsien, 1997,
20 Chemistry & Biology 4:269-277. See also González & Tsien, 1995, Biophys. J. 69:1272-1280 and U.S. Patent No. 5,661,035.

 In certain embodiments, the first dye is a fluorescent lectin or a fluorescent phospholipid that acts as the fluorescent donor. Examples of such a first dye are: a coumarin-labeled
25 phosphatidylethanolamine (*e.g.*, N-(6-chloro-7-hydroxy-2-oxo-2H--1-benzopyran-3-carboxamidoacetyl)-dimyristoylphosphatidyl-ethanolamine) or N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-dipalmitoylphosphatidylethanolamine); a fluorescently-labeled lectin (*e.g.*, fluorescein-labeled wheat germ agglutinin). In certain
30 embodiments, the second dye is an oxonol that acts as the fluorescent acceptor. Examples of such a second dye are: bis(1,3-dialkyl-2-thiobarbiturate)trimethineoxonols (*e.g.*, bis(1,3-dihexyl-2-thiobarbiturate)trimethineoxonol) or pentamethineoxonol analogues (*e.g.*, bis(1,3-dihexyl-2-thiobarbiturate)pentamethineoxonol; or bis(1,3-
35 dibutyl-2-thiobarbiturate)pentamethineoxonol). See González & Tsien, 1997, Chemistry & Biology 4:269-277 for methods of synthesizing various dyes suitable for use in the present invention. In certain embodiments,

the assay may comprise a natural carotenoid, *e.g.*, astaxanthin, in order to reduce photodynamic damage due to singlet oxygen.

Accordingly, the present invention provides a method of identifying agonists of GABA_B receptors comprising:

- 5 (a) providing test cells comprising:
 - (1) an expression vector that directs the expression of HG20 in the cells;
 - (2) an expression vector that directs the expression of GABA_BR1a or GABA_BR1b in the cells;
 - 10 (3) an expression vector that directs the expression of an inwardly rectifying potassium channel;
 - (4) a first fluorescent dye, where the first dye is bound to one side of the plasma membrane; and
 - (5) a second fluorescent dye, where the second
15 fluorescent dye is free to shuttle from one face of the plasma membrane to the other face in response to changes in membrane potential;
 - (b) exposing the test cells to a substance that is suspected of being an agonist of the GABA_B receptor;
 - (c) measuring the amount of fluorescence resonance
20 energy transfer (FRET) in the test cells that have been exposed to the substance;
 - (d) comparing the amount of FRET exhibited by the test cells that have been exposed to the substance with the amount of FRET exhibited by control cells;
 - 25 wherein if the amount of FRET exhibited by the test cells is less than the amount of FRET exhibited by the control cells, the substance is an agonist of the GABA_B receptor;
- where the control cells are either (1) cells that are essentially the same as the test cells except that they do not comprise at
30 least one of the items listed at (a) (1)-(5) but have been exposed to the substance; or (2) test cells that have not been exposed to the substance.

The above-described assay can be easily modified to form a method to identify antagonists of the GABA_B receptor. Such a method comprises:

- 35 (a) providing test cells comprising:
 - (1) an expression vector that directs the expression of HG20 in the cells;

(2) an expression vector that directs the expression of GABABR1a or GABABR1b in the cells;

(3) an expression vector that directs the expression of an inwardly rectifying potassium channel;

5 (4) a first fluorescent dye, where the first dye is bound to one side of the plasma membrane; and

(5) a second fluorescent dye, where the second fluorescent dye is free to shuttle from one face of the plasma membrane to the other face in response to changes in membrane potential;

10 (b) exposing the test cells to a known agonist of the GABAB receptor in the presence of a substance that is suspected of being an antagonist of the GABAB receptor;

(c) exposing the test cells to the known agonist of the GABAB receptor in the absence of the substance that is suspected of being
15 an antagonist of the GABAB receptor;

(d) measuring the amount of fluorescence resonance energy transfer (FRET) in the test cells of steps (b) and (c);

(e) comparing the amount of FRET exhibited by the test cells of steps (b) and (c);

20 where if the amount of FRET exhibited by the test cells of step (b) is greater than the amount of FRET exhibited by the test cells of step (c), the substance is an antagonist of the GABAB receptor.

In particular embodiments of the above-described methods, the expression vectors are transfected into the test cells.

25 In particular embodiments of the above-described methods, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

In particular embodiments of the above-described methods, HG20 comprises an amino acid sequence selected from the group consisting of:

30 SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
35 Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;

Positions 46-941 of SEQ.ID.NO.:2;

Positions 52-941 of SEQ.ID.NO.:2; and

Positions 57-941 of SEQ.ID.NO.:2.

- In particular embodiments of the above-described methods,
- 5 GABABR1a is murine GABABR1a and has the amino acid sequence SEQ.ID.NO.:20. In particular embodiments, GABABR1a is rat GABABR1a and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In particular embodiments, GABABR1b is rat GABABR1b and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In particular embodiments, GABABR1a
- 10 is human GABABR1a and has an amino acid sequence selected from the group consisting of: SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

- Inwardly rectifying potassium channels that are suitable
- 15 for use in the methods of the present invention are disclosed in, *e.g.*, Misgeld et al., 1995, Prog. Neurobiol. 46:423-462; North, 1989, Br. J. Pharmacol. 98:13-23; Gahwiler et al., 1985, Proc. Natl. Acad. Sci USA 82:1558-1562; Andrade et al., 1986, Science 234:1261.

- In particular embodiments of the above-described methods,
- 20 the first fluorescent dye is selected from the group consisting of: a fluorescent lectin; a fluorescent phospholipid; a coumarin-labeled phosphatidylethanolamine; N-(6-chloro-7-hydroxy-2-oxo-2H--1-benzopyran-3-carboxamidoacetyl)-dimyristoylphosphatidyl-ethanolamine); N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-
- 25 dipalmitoylphosphatidylethanolamine); and fluorescein-labeled wheat germ agglutinin.

- In particular embodiments of the above-described methods, the second fluorescent dye is selected from the group consisting of: an oxonol that acts as the fluorescent acceptor; bis(1,3-dialkyl-2-thiobarbiturate)trimethineoxonols; bis(1,3-dihexyl-2-thiobarbiturate)trimethineoxonol; bis(1,3-dialkyl-2-thiobarbiturate)quatramethineoxonols; bis(1,3-dialkyl-2-thiobarbiturate)pentamethineoxonols; bis(1,3-dihexyl-2-thiobarbiturate)pentamethineoxonol; bis(1,3-dibutyl-2-thiobarbiturate)pentamethineoxonol; and bis(1,3-dialkyl-2-thiobarbiturate)hexamethineoxonols.
- 30
- 35

In a particular embodiment of the above-described methods, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573),
5 Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, or *Xenopus* oocytes.

10 In a particular embodiment of the above-described methods, the cells are transfected with separate expression vectors that direct the expression of HG20 and either GABA_BR1a or GABA_BR1b in the cells. In other embodiments, the cells are transfected with a single expression vector that direct the expression of both HG20 and GABA_BR1a or
15 GABA_BR1b in the cells.

The conditions under which step (b) of the first method described above and steps (b) and (c) of the second method described above are practiced are conditions that are typically used in the art for the study of protein-ligand interactions: e.g., physiological pH; salt
20 conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

The GABA_B receptor belongs to the class of proteins known as G-protein coupled receptors (GPCRs). GPCRs transmit signals across cell membranes upon the binding of ligand. The ligand-bound
25 GPCR interacts with a heterotrimeric G-protein, causing the G α subunit of the G-protein to disassociate from the G β and G γ subunits. The G α subunit can then go on to activate a variety of second messenger systems.

Generally, a particular GPCR is only coupled to a
30 particular type of G-protein. Thus, to observe a functional response from the GPCR, it is necessary to ensure that the proper G-protein is present in the system containing the GPCR. It has been found, however, that there are certain G-proteins that are "promiscuous." These promiscuous G-proteins will couple to, and thus transduce a
35 functional signal from, virtually any GPCR. See Offermanns & Simon, 1995, J. Biol. Chem. 270:15175, 15180 (Offermanns). Offermanns described a system in which cells are transfected with expression

vectors that result in the expression of one of a large number of GPCRs as well as the expression of one of the promiscuous G-proteins $G\alpha 15$ or $G\alpha 16$. Upon the addition of an agonist of the GPCR to the transfected cells, the GPCR was activated and was able, via $G\alpha 15$ or $G\alpha 16$, to
5 activate the β isoform of phospholipase C, leading to an increase in inositol phosphate levels in the cells.

Therefore, by making use of these promiscuous G-proteins as in Offermanns, it is possible to set up functional assays for the GABA_B receptor, even in the absence of knowledge of the G-protein with which
10 the GABA_B receptor is coupled *in vivo*. One possibility for utilizing promiscuous G-proteins in connection with the GABA_B receptor includes a method of identifying agonists of the GABA_B receptor comprising:

(a) providing cells that express HG20, GABA_BR1a or
15 GABA_BR1b, and a promiscuous G-protein, where HG20 and either GABA_BR1a or GABA_BR1b form a heterodimer representing a functional GABA_B receptor;

(b) exposing the cells to a substance that is a suspected agonist of the GABA_B receptor;

20 (c) measuring the level of inositol phosphates in the cells;

where an increase in the level of inositol phosphates in the cells as compared to the level of inositol phosphates in the cells in the absence of the suspected agonist indicates that the substance is an
25 agonist of the GABA_B receptor.

Levels of inositol phosphates can be measured by monitoring calcium mobilization. Intracellular calcium mobilization is typically assayed in whole cells under a microscope using fluorescent dyes or in cell suspensions via luminescence using the aequorin assay.

30 In methods related to those described above, rather than using changes in inositol phosphate levels as an indication of GABA_B receptor function, potassium currents are measured. This is feasible since the GABA_B receptor, like other metabotropic receptors, is expected to be coupled to potassium channels. Thus, one could measure GABA_B
35 receptor coupling to GIRK2 channels or to other potassium channels in oocytes.

In a particular embodiment of the above-described method, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573),
5 Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), or *Xenopus* oocytes.

10 In a particular embodiment of the above-described method, the cells are transfected with expression vectors that direct the expression of HG20, GABA_BR1a or GABA_BR1b, and the promiscuous G-protein in the cells.

The conditions under which step (b) of the method is
15 practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

In a particular embodiment of the above-described method,
20 the promiscuous G-protein is selected from the group consisting of Gα15 or Gα16. Expression vectors containing Gα15 or Gα16 are known in the art. See, *e.g.*, Offermanns; Buhl et al, 1993, FEBS Lett. 323:132-134; Amatruda et al., 1993, J. Biol. Chem. 268:10139-10144.

The above-described assay can be easily modified to form a
25 method to identify antagonists of the GABA_B receptor. Such a method is also part of the present invention and comprises:

- (a) providing cells that express HG20, GABA_BR1a or GABA_BR1b, and a promiscuous G-protein;
- (b) exposing the cells to a substance that is an agonist of
30 the GABA_B receptor;
- (c) subsequently or concurrently to step (b), exposing the cells to a substance that is a suspected antagonist of the GABA_B receptor;
- (d) measuring the level of inositol phosphates in the
cells;

35 where a decrease in the level of inositol phosphates in the cells in the presence of the suspected antagonist as compared to the level of inositol phosphates in the cells in the absence of the suspected

antagonist indicates that the substance is an antagonist of the GABA_B receptor.

In a particular embodiment of the above-described method, the agonist is an amino acid such as GABA, glutamate, glycine, or
5 amino acid analogues such as (-)baclofen.

In a particular embodiment of the above-described method, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK-) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK293 (ATCC CRL
10 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), or *Xenopus* oocytes.

15 The conditions under which steps (b) and (c) of the method are practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

20 In a particular embodiment of the above-described method, the cells are transfected with expression vectors that direct the expression of HG20, GABA_BR1a or GABA_BR1b, and the promiscuous G-protein in the cells.

In a particular embodiment of the above-described method, the promiscuous G-protein is selected from the group consisting of Gα15 or Gα16.

In particular embodiments of the above-described methods, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

In other embodiments of the above-described methods, HG20 comprises an amino acid sequence selected from the group
30 consisting of:

SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
35 Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;

Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
5 Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

In other embodiments, GABABR1a is murine GABABR1a and has the amino acid sequence SEQ.ID.NO.:20. In other
embodiments, GABABR1a is rat GABABR1a and has the amino acid
10 sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In
other embodiments, GABABR1b is rat GABABR1b and has the amino
acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In
other embodiments, GABABR1a is human GABABR1a and has an
amino acid sequence selected from the group consisting of:
15 SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

While the above-described methods are explicitly directed to
testing whether "a" substance is an agonist or antagonist of the GABAB
receptor, it will be clear to one skilled in the art that such methods can
be adapted to test collections of substances, *e.g.*, combinatorial libraries,
20 to determine whether any members of such collections are activators or
inhibitors of the GABAB receptor. Accordingly, the use of collections of
substances, or individual members of such collections, as the substance
in the above-described methods is within the scope of the present
invention.

25 The present invention includes pharmaceutical
compositions comprising agonists and antagonists of GABAB receptors
that have been identified by the above-described methods. The agonists
and antagonists are generally combined with pharmaceutically
acceptable carriers to form pharmaceutical compositions. Examples of
30 such carriers and methods of formulation of pharmaceutical
compositions containing agonists and antagonists and carriers can be
found in Remington's Pharmaceutical Sciences. To form a
pharmaceutically acceptable composition suitable for effective
administration, such compositions will contain a therapeutically
35 effective amount of the agonists and antagonists.

Therapeutic or prophylactic compositions are administered
to an individual in amounts sufficient to treat or prevent conditions

where GABA_B receptor activity is abnormal. The effective amount can vary according to a variety of factors such as the individual's condition, weight, gender, and age. Other factors include the mode of administration. The appropriate amount can be determined by a skilled physician.

Compositions can be used alone at appropriate dosages. Alternatively, co-administration or sequential administration of other agents can be desirable.

The compositions can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration. For example, the compositions can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection. Likewise, they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.

Advantageously, compositions can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily. Furthermore, compositions can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

The dosage regimen utilizing the compositions is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal, hepatic and cardiovascular function of the patient; and the particular composition thereof employed. A physician of ordinary skill can readily determine and prescribe the effective amount of the composition required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of composition within

the range that yields efficacy without toxicity requires a regimen based on the kinetics of the composition's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a composition.

- 5 Agonists and antagonists identified by the above-described methods are useful in the same manner as well-known agonists and antagonists of other GABA_B receptors. For example, (-) baclofen is a known agonist of GABA_B receptors and, in racemic form, is a clinically useful muscle relaxant known as LIORESAL® (Bowery & Pratt, 1992, 10 Arzneim.-Forsch./Drug Res. 42:215-223 [Bowery & Pratt]). Similarly, the agonists and antagonists of GABA_B receptors identified by the methods of the present invention are expected to be useful as muscle relaxants. Bowery & Pratt, at Table 1, page 219, list the therapeutic potential of GABA_B receptor agonists and antagonists. For agonists, the 15 therapeutic potential is said to include use as muscle relaxants and anti-asthmatics. For antagonists, the therapeutic potential is said to include use as antidepressants, anticonvulsants, nootropics, and anxiolytics. Additionally, at page 220, left column, Bowery & Pratt list some additional therapeutic uses for the GABA_B receptor agonist (-) 20 baclofen: treatment of trigeminal neuralgia and reversal of ethanol withdrawal symptoms. Given the wide range of utility displayed by known agonists and antagonists of GABA_B receptors, it is clear that those skilled in the art would consider the agonists and antagonists identified by the methods of the present invention to be 25 pharmacologically useful. In addition, it is believed that such agonists and antagonists will also be useful in the treatment of epilepsy, neuropsychiatric disorders, and dementias.

- When screening compounds in order to identify potential pharmaceuticals that specifically interact with a target receptor, it is 30 necessary to ensure that the compounds identified are as specific as possible for the target receptor. To do this, it is necessary to screen the compounds against as wide an array as possible of receptors that are similar to the target receptor. Thus, in order to find compounds that are potential pharmaceuticals that interact with receptor A, it is necessary 35 not only to ensure that the compounds interact with receptor A (the "plus target") and produce the desired pharmacological effect through receptor A, it is also necessary to determine that the compounds do not

interact with receptors B, C, D, etc (the "minus targets"). In general, as part of a screening program, it is important to have as many minus targets as possible (see Hodgson, 1992, Bio/Technology 10:973-980, at 980). HG20 protein, DNA encoding HG20 protein, GABABR1a protein, DNA
5 encoding GABABR1a protein, and recombinant cells that have been engineered to express HG20 protein and GABABR1a protein have utility in that they can be used as "minus targets" in screens design to identify compounds that specifically interact with other G-protein coupled receptors, *i.e.*, non-GABAB receptors.

10 The present invention also includes antibodies to the HG20 protein. Such antibodies may be polyclonal antibodies or monoclonal antibodies. The antibodies of the present invention are raised against the entire HG20 protein or against suitable antigenic fragments of the protein that are coupled to suitable carriers, *e.g.*, serum albumin or
15 keyhole limpet hemocyanin, by methods well known in the art. Methods of identifying suitable antigenic fragments of a protein are known in the art. See, *e.g.*, Hopp & Woods, 1981, Proc. Natl. Acad. Sci. USA 78:3824-3828; and Jameson & Wolf, 1988, CABIOS (Computer Applications in the Biosciences) 4:181-186. Particularly suitable peptides are: amino acids
20 357-371 of SEQ.ID.NO.:2 and amino acids 495-511 of SEQ.ID.NO.:2. Also, anti-peptide antisera can be generated by immunization of New Zealand White rabbits with a KLH-conjugation of a 20 amino acid synthetic peptide corresponding to residues 283-302 of HG20
(GWYEPSWWEQVHTEANSSRC) (a portion of SEQ.ID.NO.:2).

25 For the production of polyclonal antibodies, HG20 protein or an antigenic fragment, coupled to a suitable carrier, is injected on a periodic basis into an appropriate non-human host animal such as, *e.g.*, rabbits, sheep, goats, rats, mice. The animals are bled periodically and sera obtained are tested for the presence of antibodies to the injected
30 antigen. The injections can be intramuscular, intraperitoneal, subcutaneous, and the like, and can be accompanied with adjuvant.

For the production of monoclonal antibodies, HG20 protein or an antigenic fragment, coupled to a suitable carrier, is injected into an appropriate non-human host animal as above for the production of
35 polyclonal antibodies. In the case of monoclonal antibodies, the animal is generally a mouse. The animal's spleen cells are then immortalized, often by fusion with a myeloma cell, as described in Kohler & Milstein,

1975, Nature 256:495-497. For a fuller description of the production of monoclonal antibodies, see Antibodies: A Laboratory Manual, Harlow & Lane, eds., Cold Spring Harbor Laboratory Press, 1988.

Gene therapy may be used to introduce HG20 polypeptides into the cells of target organs. Nucleotides encoding HG20 polypeptides can be ligated into viral vectors which mediate transfer of the nucleotides by infection of recipient cells. Suitable viral vectors include retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, and polio virus based vectors. Alternatively, nucleotides encoding HG20 polypeptides can be transferred into cells for gene therapy by non-viral techniques including receptor-mediated targeted transfer using ligand-nucleotide conjugates, lipofection, membrane fusion, or direct microinjection. These procedures and variations thereof are suitable for *ex vivo* as well as *in vivo* gene therapy. Gene therapy with HG20 polypeptides will be particularly useful for the treatment of diseases where it is beneficial to elevate HG20 activity.

The following non-limiting examples are presented to better illustrate the invention.

20

EXAMPLE 1

Cloning and sequencing of HG20

A cDNA fragment encoding full-length HG20 can be isolated from a human fetal brain cDNA library by using the polymerase chain reaction (PCR) employing the following primer pair:

25

HG20.F139 5'-CCGTTCTGAGCCGAGCCG -3' (SEQ.ID.NO.:3)
HG20.R3195 5'-TCCGCAGCCAGAGCCGACAG-3' (SEQ.ID.NO.:4)

The above primer pair is meant to be illustrative only. Those skilled in the art would recognize that a large number of primer pairs, based upon SEQ.ID.NO.:1, could also be used.

PCR reactions can be carried out with a variety of thermostable enzymes including but not limited to AmpliTaq, AmpliTaq Gold, Vent polymerase. For AmpliTaq, reactions can be carried out in 10 mM Tris-Cl, pH 8.3, 2.0 mM MgCl₂, 200 μM for each dNTP, 50 mM

35

KCl, 0.2 μ M for each primer, 10 ng of DNA template, 0.05 units/ μ l of AmpliTaq. The reactions are heated at 95°C for 3 minutes and then cycled 35 times using the cycling parameters of 95°C, 20 seconds, 62°C, 20 seconds, 72°C, 3 minutes. In addition to these conditions, a variety of
5 suitable PCR protocols can be found in PCR Primer, A Laboratory Manual, edited by C.W. Dieffenbach and G.S. Dveksler, 1995, Cold Spring Harbor Laboratory Press.

A suitable cDNA library from which a clone encoding HG20 can be isolated would be a random primed fetal brain cDNA library
10 consisting of approximately 4.0 million primary clones constructed in the plasmid vector pBluescript (Stratagene, LaJolla, CA). The primary clones of such a library can be subdivided into pools with each pool containing approximately 20,000 clones and each pool can be amplified separately.

15 By this method, a cDNA fragment (SEQ.ID.NO.:1) encoding an open reading frame of 941 amino acids (SEQ.ID.NO.:2) is obtained. This cDNA fragment can be cloned into a suitable cloning vector or expression vector. For example, the fragment can be cloned into the mammalian expression vector pcDNA3.1 (Invitrogen, San Diego, CA).
20 HG20 protein can then be produced by transferring an expression vector containing SEQ.ID.NO.:1 or portions thereof into a suitable host cell and growing the host cell under appropriate conditions. HG20 protein can then be isolated by methods well known in the art.

Alternatively, other cDNA libraries made from human
25 tissues that express HG20 RNA can be used with PCR primers HG20.F139 and HG20.R3195 in order to amplify a cDNA fragment encoding full-length HG20. Suitable cDNA libraries would be those prepared from cortex, cerebellum, testis, ovary, adrenal gland, thyroid, or spinal cord.

30 As an alternative to the above-described PCR method, a cDNA clone encoding HG20 can be isolated from a cDNA library using as a probe oligonucleotides specific for HG20 and methods well known in the art for screening cDNA libraries with oligonucleotide probes. Such methods are described in, e.g., Sambrook et al., 1989, *Molecular*
35 *Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K., Vol. I, II.

Oligonucleotides that are specific for HG20 and that can be used to screen cDNA libraries are:

	HG20.F46	5'-GGGATGATCATGGCCAGTGC-3' (SEQ.ID.NO.:5)
5	HG20.R179	5'-GGATCCATCAAGGCCAAAGA-3' (SEQ.ID.NO.:6)
	HG21.F43	5'-GCCGCTGTCTCCTTCCTGA-3' (SEQ.ID.NO.:7)
	HG21.R251	5'-TTGGTTCACACTGGTGACCGA-3' (SEQ.ID.NO.:8)
	HG20.R123	5'-TTCACCTCCCTGCTGTCTTG-3' (SEQ.ID.NO.:9)
	HG20.F1100	5'-CAGGCGATTCCAGTTCACCTCA-5' (SEQ.ID.NO.:10)
10	HG20.F1747	5'-GAACCAAGCCAGCACATCCC-3' (SEQ.ID.NO.:11)
	HG20.R54	5'-CCTCGCCATACAGAACTCC-3' (SEQ.ID.NO.:12)
	HG20.R75	5'-GTGTCATAGAGCCGCAGGTC-3' (SEQ.ID.NO.:13)
	HG20.F139	5'-CCGTTCTGAGCCGAGCCG-3' (SEQ.ID.NO.:3)
	HG20.R3195	5'-TCCGCAGCCAGAGCCGACAG-3' (SEQ.ID.NO.:4)

15

Membrane-spanning proteins, such as GABAB receptors, when first translated generally possess an approximately 16 to 40 amino acid segment known as a signal sequence. Signal sequences direct the nascent protein to be transported through the endoplasmic reticulum membrane, following which signal sequences are cleaved from the protein. Signal sequences generally contain from 4 to 12 hydrophobic residues but otherwise possess little sequence homology. The Protein Analysis tool of the GCG program (Genetics Computer Group, Madison, Wisconsin), a computer program capable of identifying likely signal sequences, was used to examine the N terminus of HG20. Several likely candidates for cleavage sites which would generate mature HG20 protein, i.e., protein lacking the signal sequence, were identified. The results are shown in Figure 3.

30

EXAMPLE 2

Expression of HG20 in normal and diseased adrenal tissue

Northern blots were performed to measure the amount of HG20 RNA in normal and diseased adrenal tissue. The results are shown in Table 2 below. The amount of the approximately 6.5 kb HG20 transcript is shown normalized to the amount of β -actin transcript.

35

Table 2

<u>Pathology</u>	<u>Profile</u>	<u>HG20</u> <u>RNA</u>	<u>Actin</u> <u>RNA</u>	<u>HG20</u> <u>/actin</u>
Pheochromocytoma	M, 30 yr	0.47	0.74	0.64
Adrenal carcinoma cortex	M, 69 yr	0.61	0.80	0.76
Adrenal adenoma cortex	M, 69 yr	0.62	1.15	0.54
Normal Adrenal	M, 26 yr	1.00	1.00	1.00

5 The results shown in Table 2 indicate that HG20 expression is decreased in diseased states of the adrenal gland. Thus, increasing the concentration of HG20 in such diseased states is likely to be pharmacologically useful. Accordingly, one skilled in the art would expect agonists of HG20 to be pharmacologically useful.

10

EXAMPLE 3

Tissue distribution of various HG20 RNA transcripts

15 Table 3, below, shows the results of experiments to measure the amount of HG20 RNA transcripts of various lengths in various tissues. The results shown were derived from a multiple tissue Northern blot that was hybridized overnight in expressHyb solution (Clontech). Washing conditions were: 0.1X SSC, 0.1% SDS, at 60°C. A 32P-random primer labelled Eco RI fragment containing the full-length native HG20 DNA was used as a hybridization probe. The greater
20 the number of plus signs in a particular tissue, the greater was the amount of HG20 RNA detected in that tissue.

Table 3

Tissue	6.5 kb	4.5 kb	4.0 kb	1.8 kb
cerebellum	++	+		
cerebral cortex	++++	+		
medulla	+	+		
occipital pole	+	+		
frontal lobe	+++	+		
temporal lobe	+++	+		
putamen	++	+		
spinal cord n=2	++	+		
amygdala	+++			
caudate nucleus	+	+		
corpus callosum	+	+		
hippocampus	++	+		
whole brain	+++	+		
substantia nigra	+	+		
subthalamic nucleus	+	+		
thalamus	++	+		
spleen		+		
thymus n=2		++		
prostate		++		
testis n=2	++	+	+++	
ovary		++	+	+
small intestine n=2		++		
colon (mucosal lining)		++		
peripheral blood leucocytes		++		
stomach n=2	+	+		
thyroid n=2	++	++++		
lymph node		+		
trachea		++		
adrenal gland	+++	+++	+	++++
bone marrow		++		
heart	+	++		
brain	+++++			
placenta		+		
lung		+		
liver		+		
skeletal muscle	+	++		
kidney		+		
pancreas	+	+		
adrenal medulla	+++			+
adrenal cortex	+++++		++	++

The distribution of HG20 RNA shown in Table 3 suggests that HG20 mediates activities of the central and peripheral nervous system.

5

EXAMPLE 4

Distribution of HG20 mRNA in brain

Using in situ hybridisation, the distribution of HG20 mRNA in squirrel monkey brain was studied. Antisense oligonucleotide probes to HG20 were generated on an Applied Biosystems Model 394 DNA synthesiser and purified by preparative polyacrylamide electrophoresis. Probe 1: 5'ATC-TGG-GTT-TGT-TCT-CAG-GGT-GAT-GAG-CTT-CGG-CAC-GAA-TAC-CAG 3' (SEQ.ID.NO.:14); Probe2: 5' GCT-CTG-TGA-TCT-TCA-TTC-GCA-GGC-GAT-GGT-TTT-CTG-ACT-GTA-GGC 3' (SEQ.ID.NO.:15). Each oligonucleotide was 3'-end labelled with [³⁵S] deoxyadenosine 5'-(thiotriphosphate) in a 30:1 molar ratio of ³⁵S-isotope:oligonucleotide using terminal deoxynucleotidyl transferase for 15 min at 37°C in the reaction buffer supplied (Boehringer). Radiolabelled oligonucleotide was separated from unincorporated nucleotides using Sephadex G50 spin columns. The specific activities of the labelled probes in several labelling reactions varied from 1.2-2.3 x 10⁹ cpm/mg. Squirrel monkey brains were removed and fresh frozen in 1 cm blocks. 12 mm sections were taken and fixed for *in situ* hybridisation. Hybridisation of the sections was carried out according to the method of Sirinathsinghji et al., 1993, Neuroreports 4:175-178. Briefly, sections were removed from alcohol, air dried and 5 x10⁵ cpm of each ³⁵S-labelled probe (both oligonucleotides) in 100 ml of hybridisation buffer was applied to each slide. Labelled "antisense" probe was also used in the presence of an excess (100x) concentration of unlabelled antisense probe to define non-specific hybridisation. Parafilm coverslips were placed over the sections which were incubated overnight (about 16 hr) at 37°C. Following hybridisation the sections were washed for 1 hr at 57°C in 1xSSC, then rinsed briefly in 0.1xSSC, dehydrated in a series of alcohols, air dried, and exposed to Amersham Hyperfilm bmax X-ray film.

Autoradiographs were analysed using a MCID computerised image analysis system (Image Research Inc., Ontario, Canada).

Highest levels of mRNA for HG20 were found in the hippocampus (dentate gyrus, CA3, CA2, and CA1). High levels were also seen in cortical regions (frontal, cingulate, temporal parietal, entorhinal, and visual) and the cerebellum, although medial septum, thalamic nuclei (medial-dorsal and lateral posterior), lateral geniculates, red nucleus, reticular formation, and griseum pontis all show expression of message. While there are many similarities with the distribution reported for the GABA_B receptor mRNA in rat, one marked difference is that expression of HG20 mRNA in the monkey caudate and putamen is below the level of detection while cortical levels are high. In the rat, the GABA_B receptor mRNA appears equally expressed in striatum as in cortex. Figure 4 illustrates these results.

EXAMPLE 5

Attempted recombinant expression of full-length HG20 protein

Following the cloning of HG20 DNA, attempts were made to express full-length HG20 protein (941 amino acids) using various eukaryotic cell lines and expression vectors. The cell lines that were used were: COS-7 cells, HEK293 cells, and frog melanophores. The expression vectors that were used to attempt to express the full-length HG20 protein were: pCR3.1 and pcDNA3.1 (Invitrogen, San Diego, CA) and pciNEO (promega)

All of the attempts to express full-length HG20 described above were unsuccessful. See, *e.g.*, Figure 7, second bar from the left, marked "HG20." See also Figure 5A, lane 1. Although the reason for these failures is not known, it is possible that the highly GC rich nature of the region of the HG20 mRNA that encodes amino acids 1-51 results in the formation of secondary structure in the mRNA that impedes translation. It was only after the construction of an expression vector that encodes a truncated HG20 protein, lacking the first 51 amino acids, that HG20 was successfully expressed. Figure 5A-B shows the results of the successful expression of an HG20 protein having amino acids 52-941. It is expected that expression of HG20 proteins having amino acids 53-

941, 54-941, 55-941, etc., could be accomplished in a similar manner. It is also expected that expression of HG20 proteins having the above-described amino termini but having different carboxyl termini could be accomplished in a similar manner as well. Thus, the expression of an HG20 protein having an amino terminus as listed above and having a truncated carboxyl terminus could be accomplished. Alternatively, the carboxyl terminus could be fused to non-HG20 amino acid sequences, forming a chimeric HG20 protein. It is also possible to express HG20 having an amino terminus listed above as a chimeric protein with non-HG20 sequences fused to the amino terminus.

Figure 5A shows the expression of amino acids 52-941 of HG20 as part of a chimeric or fusion protein with the FLAG epitope fused to the amino terminus of the HG20 sequences in a coupled *in vitro* transcription/translation experiment. Figure 5B shows the expression of amino acids 52-941 of HG20 as part of a chimeric or fusion protein with the FLAG epitope fused to the amino terminus of the HG20 sequences in COS-7 cells and melanophores. The expression vector used in this experiment was pcDNA3.1. The expression constructs used in Figure 5A-B also encoded a cleavable signal sequence from the influenza hemagglutinin gene that has been shown to facilitate the membrane insertion of G-protein coupled receptors (Guan et al., 1992, J. Biol. Chem. 267:21995-21998) and the fusion proteins were detected with anti-FLAG antibody. The expression constructs had also been engineered to contain a Kozak consensus sequence prior to the initiating ATG. The amino acid sequences of the hemagglutinin signal sequence and the FLAG epitope were:

[MKTHIALSYIFCLVFA] [DYKDDDDK] SEQ.ID.NO:17

HA signal peptide FLAG epitope

Amino acids 57-941 have been expressed in mammalian cells as part of a chimeric protein. A chimeric construct of HG20 was made that consisted of bases -224 to 99 of the bovine GABA_A α 1 gene, a sequence encoding the c-myc epitope tag (amino acid residues 410-419 of the human oncogene product c-myc), a cloning site encoding the amino acid asparagine, and DNA encoding residues 57-941 of HG20. The resultant

chimeric protein has the amino acid sequence shown below, with the construct cloned into pcDNA1.1Amp (Invitrogen, San Diego, CA).

5 ___Bovine alpha 1 signal seq_____ ___c-myc___ ___
 MKKSPGLSDYLDWAWTLFLSTLTGRSYGQPSLQD EQKLISEEDL N
 res. 57-941 HG20
 SIMGLMPLT... (SEQ.ID.NO.:18)

10 The three periods "..." indicate that the chimeric protein sequence extends until amino acid 941 of HG20.

15 The cell surface expression of this construct was verified using a cell surface ELISA technique. Briefly, HEK293 cells were seeded at ~1x10⁵ cells per well in a 24 well tissue culture plate and allowed to adhere for 24 hours. Each well was transfected with a total of 1 µg of
 20 DNA. In addition to tagged and un-tagged HG20 constructs, c-myc tagged GABA_A α1 was transfected with GABA_A β1 as a positive control for cell surface expression. Two days after transfection, the cells were assayed for surface expression of the c-myc epitope using the 9E10 monoclonal antibody raised to the c-myc epitope, followed by HRP (horse
 25 radish peroxidase) conjugated anti-mouse antibody (Promega) and colormetric development using K-Blue (Bionostics). The results are shown in Figure 7. Figure 7 demonstrates that when HG20 is part of a chimeric protein, it can be expressed well in mammalian cells but that when attempts are made to express full-length HG20 (amino acids 1-941)
 directly, *i.e.*, not as part of a chimeric protein, essentially no expression is observed.

EXAMPLE 6

Construction of Full Length Murine GABABR1a Coding Region

30 Using a combination of TFASTX (Pearson et al., 1997, Genomics 46:24-36) and TBLASTX (Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402) searching programs against dbEST: Database of Expressed Sequence Tags (URL <http://www.ncbi.nlm.nih.gov/dbEST/index.html>), we identified partial cDNA clones in the EST collection
 35 which encoded murine GABABR1a using the rat GABA_B receptor

subunit cDNAs (GenBank Accession Numbers Y10369 and Y10370) as probe sequences (Kaupmann et al., 1997, Nature 386:239-246). Two of these ESTs (IMAGE Consortium clone identification numbers 472408 and 319196) were obtained (Research Genetics, Birmingham, Ala). The

5 DNA sequences of both cDNA clones were determined using standard methods on an ABI 373a automated sequencer (Perkin-Elmer-Applied Biosystems, Foster City, CA).

The partial cDNAs were assembled by long accurate PCR using the following oligonucleotides: 472408 sense: 5' - GC GAATTC

10 GGTACC ATG CTG CTG CTG CTG CTG GTG CCT - 3' (SEQ.ID.NO.:24), 472408 antisense: 5' - GG GAATTC TGG ATA TAA CGA GCG TGG GAG TTG TAG ATG TTA AA - 3' (SEQ.ID.NO.:25), 319196 sense: 5' - CCA GAATTC CCA GCC CAA CCT GAA CAA TC - 3' (SEQ.ID.NO.:26), 319196 antisense: 5' - CG GCGGCCGC TCA CTT GTA

15 AAG CAA ATG TA - 3' (SEQ.ID.NO.:27) which amplified two fragments corresponding to the 5' 2,100 basepairs and 3' 1,000 basepairs of the murine GABAR1a coding region. The PCR conditions were 200 ng of cDNA template, 2.5 units of Takara LA Taq (PanVera, Madison, WI), 25 mM TAPS (pH 9.3), 50 mM KCl, 2.5 mM MgCl₂, 1 mM 2-

20 mercaptoethanol, 100 mM each dNTP and 1 mM each primer with cycling as follows 94°C 1 min, 9 cycles of 98°C for 20 seconds, 72°C-56°C (decreases 2°C per cycle), 72°C for 30 seconds, followed by 30 cycles of 98°C for 20 seconds, 60°C for 3 minutes. A final extension at 72°C for 10 minutes was performed. PCR products were cloned into the TA-Cloning

25 vector pCRII-TOPO (Invitrogen, San Diego, CA) following the manufacturers directions. Cloned PCR products were confirmed by DNA sequencing. To form full-length cDNA, the pCINeo mammalian expression vector was digested with EcoRI and NotI. The EcoRI fragment from PCR cloning of 472408 and the EcoRI/NotI product from

30 PCR cloning of 319196 were ligated in a three part ligation with digested pCINeo vector. The resulting clones were screened by restriction digestion with SstI which cuts once in the vector and once in the 472408 derived fragment. The resulting expression clone is 2,903 basepairs in length. The overall cDNA length, including untranslated sequences,

35 inferred from the full length of the two ESTs is 4,460 basepairs.

EXAMPLE 7

Preparation of membrane fractions

P2 membrane fractions were prepared at 4°C as follows. Tissues or cells were washed twice with cold PBS, collected by centrifugation at 100xg for 7 min, and resuspended in 10 ml of buffer A: 5 mM Tris-HCl, 2 mM EDTA containing (1X) protease inhibitor cocktail Complete® tablets (Boehringer Mannheim), pH 7.4 at 4°C. Tissues or cells were disrupted by polytron homogenization, centrifuged at 100xg for 7 min to pellet unbroken cells and nuclei, and the supernatant collected. The resulting pellet was homogenized a second time in 10 ml of buffer A, centrifuged as described above and supernatant fractions saved. The pooled S1 supernatant was centrifuged at high speed (27 000xg for 20 min) and the pellet was washed once with buffer A, centrifuged (27 000xg for 20 min) and resuspended in buffer A to make the P2 membrane fraction, and stored at -80°C. Protein content was determined using the Bio-Rad Protein Assay Kit according to manufacturer instructions.

EXAMPLE 8

Receptor filter-binding assays

Competition of [¹²⁵I]CGP71872 binding experiments were performed with ~7 µg P2 membrane protein and increasing concentrations of cold ligand (10⁻¹²-10⁻³ M). The concentration of radioligand used in the competition assays was 1 nM (final). Each concentration was examined in duplicate and incubated for 2 hours at 22°C in the dark in a total volume of 250 µL binding buffer: 50 mM Tris-HCl, 2.5 mM CaCl₂ (pH 7.4) with (1X) protease inhibitor cocktail Complete® tablets. Bound ligand was isolated by rapid filtration through a Brandel 96 well cell harvester using Whatman GF/B filters. Data were analysed by nonlinear least-squares regression using the computer-fitting program GraphPad Prism version 2.01 (San Diego).

EXAMPLE 9

Photoaffinity labelling

P2 membranes were resuspended in binding buffer and incubated in the dark with 1 nM final concentration [¹²⁵I]CGP71872 (2200 Ci/mmol) in a final volume of 1 ml for 2 h at 22°C. The membranes were centrifuged at 27,000xg for 10 min and the pellet was washed in ice-cold binding buffer, centrifuged at 27,000xg for 20 min, resuspended in 1 ml of ice-cold binding buffer, and exposed on ice 2 inches from 360 nm ultraviolet light for 10 min. Photolabelled membranes were washed, pelleted by centrifugation, and solubilized in sample buffer (50 mM Tris-HCl pH 6.5, 10% SDS, 10% glycerol, and 0.003% bromophenol blue with 10% 2-mercaptoethanol). Samples were electrophoresed on precast NOVEX 10% Tris-glycine gels, fixed, dried, and exposed to Kodak XAR film with an intensifying screen at -70°C.

EXAMPLE 10

Immunoprecipitation and immunoblotting of GABA_B receptors

Digitonin solubilized FLAG-tagged HG20 receptors were immunoprecipitated with a mouse anti-FLAG M2 antibody affinity resin (Kodak IBI) and immunoblot analysis conducted as previously described (Ng et al., 1996, Biochem. Biophys. Res. Comm. 227:200-204). Following washing of the immunoprecipitate, the pellet was resuspended in SDS sample buffer and subjected to SDS-PAGE and immunoblotted with affinity purified GABA_BR1a-specific antibodies 1713.1 (raised against the peptide acetyl-DVNSRRDILPDYELKLC-amide (a portion of SEQ.ID.NO.:20)) and 1713.2 (raised against the peptide acetyl-CATLHNPTRVKLF EK-amide (a portion of SEQ.ID.NO.:20)).

EXAMPLE 11

Melanophore functional assay

Growth of *Xenopus laevis* melanophores and fibroblasts was performed as described previously (Potenza et al., 1992, Anal. Biochem. 206:315-322). The cells (obtained from Dr. M.R. Lerner, Yale University) were collected by centrifugation at 200xg for 5 min at 4°C, and resuspended at 5 x 10⁶ cells per ml in ice cold 70% PBS, pH 7.0. DNA encoding the relevant GPCR was transiently transfected into melanophores by electroporation using a BTX ECM600 electroporator (Genetronics, Inc., San Diego, CA). To monitor the efficiency of transfection, two internal control GPCRs were used independently (pcDNA1amp-cannabinoid 2 and pcDNA3-thromboxane A2; (Lerner, 1994, Trends Neurosci. 17:142-146)). Cells were electroporated using the following settings: capacitance of 325 microfarad, voltage of 450 volts, and resistance of 720 ohms. Following electroporation, cells were mixed with fibroblast-conditioned growth medium and plated onto flat bottom 96 well microtiter plates (NUNC). 24 hrs after the transfection, the media was replaced with fresh fibroblast-conditioned growth media and incubated for an additional day at 27°C prior to assaying for receptor expression. For Gs/Gq-coupling responses (resulting in pigment dispersion), cells were incubated in 100 µl of 70% L-15 media containing 15 mM HEPES, pH 7.3, and melatonin (0.8 nM final concentration) for 1 hr in the dark at room temperature, and then incubated in the presence of melatonin (0.8 nM final concentration) for 1 h in the dark at room temperature to induce pigment aggregation. For Gi-coupled responses (resulting in pigment aggregation), cells were incubated in the presence of 100 µl/well of 70% L-15 media containing 2.5% fibroblast-conditioned growth medium, 2 mM glutamine, 100 µg /ml streptomycin, 100 units/ml penicillin and 15 mM HEPES, pH 7.3, for 30 min in the dark at room temperature to induce pigment dispersion. Absorbance readings at 600 nm were measured using a Bio-Tek Elx800 Microplate reader (ESBE Scientific) before (Ai) and after (Af) incubation with ligand (GABA; 1.5 hr in the dark at room temperature).

EXAMPLE 12

Stable and transient transfections and determination of cAMP response in HEK293 cells

HG20 and murine GABABR1a cDNAs were subcloned into
5 pcDNA3.1 (Invitrogen, San Diego, CA) and used to transfect HEK293
cells. Stably expressing cells were identified after selection in geneticin
(0.375 mg/ml) by dot blot analysis. For co-expression experiments, the
stable cell lines hgb2-42 (expressing HG20) and rglb1a-50 (expressing
10 murine GABABR1a) were transiently transfected with murine
GABABR1a and HG20, respectively, in pcDNA3.1 and cells were
assayed for cAMP responses.

Wild-type HEK293 cells, or HEK293 cells stably and
transiently expressing HG20 and murine GABABR1a receptors were
lifted in 1X PBS, 2.5 mM EDTA, counted, pelleted and resuspended at 1.5×10^5
15 cells per 100 μ l in Krebs-Ringer-Hepes medium (Blakely et al., 1991,
Anal. Biochem. 194:302-308), 100 mM Ro 20-1724 (RBI) and incubated at
37°C for 20 min. 100 μ l of cells was added to 100 μ l of prewarmed (37°C,
10 min) Krebs-Ringer-Hepes medium, 100 mM Ro 20-1724 without or
with agonist and/or 10 μ M forskolin. Incubations with GABA included
20 100 μ M aminooxyacetic acid (a GABA transaminase inhibitor) to prevent
breakdown of GABA and 100 μ M nipecotic acid to block GABA uptake.
Following a 20 min incubation at 37°C, the assay was terminated by
setting the cells on ice and centrifuging at 2,000 rpm for 5 min at 4°C.
175 ml of assay solution was removed and replaced with 175 ml of 0.1 N
25 hydrochloric acid, 0.1 mM calcium chloride and cells were set on ice for
30 min and then stored at -20°C. cAMP determinations were made
using a solid phase modification (Maidment et al., 1989, Neurosci.
33:549-557) of the cAMP radioimmunoassay described by Brooker et al.
1979, Adv. Cyclic Nucl. Res. 10:1-33) and previously reported in Clark et
30 al., 1998, Mol. Endocrinol. 12:193-206). Immulon II removable wells
(Dynatech; Chantilly, VA) were coated overnight with 100 μ l of protein G
(1mg/ml in 0.1M NaHCO₃, pH 9.0) at 4°C. Prior to use, protein G-coated
plates were rinsed with PBS-gelatin-Tween (phosphate buffered saline
containing 0.1% gelatin, 0.2% Tween-20) 3 times quickly, and then once
35 for 30 minutes. Following the rinse with PBS-gelatin-Tween, the RIA

was set up by adding 100 μ l 50 mM sodium acetate, pH 4.75, cAMP standards or aliquots from treated cells, 5,000-7,000 cpm 125 I-succinyl cAMP, and 25 μ l of a sheep antibody to cAMP diluted in 50 mM sodium acetate, pH 4.75 (Atto instruments; dilution of stock to 2.5×10^{-5} ,
 5 determined empirically) to the plates in a final volume of 175 μ l. Plates were incubated 2 hr at 37°C or overnight at 4°C, rinsed 3 times with sodium acetate buffer, blotted dry, and then individual wells were broken off and bound radioactivity was determined in a gamma counter.

10

EXAMPLE 13

In situ hybridization for co-localization experiments

Preparation of rat brain sections, prehybridization and hybridization of rat brain slices was performed as described previously (Bradley et al., 1992, J. Neurosci. 12:2288-2302;
 15 <http://intramural.nimh.nih.gov/lcmr/snge/Protocol.html>). Adjacent coronal rat brain sections were hybridized with labeled antisense and sense riboprobes directed against HG20 (GenBank accession number AF058795) or murine GABABR1a.

HG20 probes were generated by amplification of HG20 with
 20 JC216 (T3 promotor/primer and bases 1172-1191) paired with JC217 (T7 promotor/primer and bases 1609-1626) or with JC218 (T3 promotor/primer and bases 2386-2405) paired with JC219 (T7 promotor/primer and bases 2776-2793):
 (JC216: cgcgcaattaaccctcactaaaggACAACAGCAAACGTTTCAGGC
 25 (SEQ.ID.NO.:28);
 JC217: gcgcgtaatacg actcactatagggCATGCCTATGATGGTGAG
 (SEQ.ID.NO.:29);
 JC218: cgcgcaattaaccctcactaaagg CTGAGGACAAACCCTGACGC
 (SEQ.ID.NO.:30);
 30 JC219: gcgcgtaatacgactcactatagggGATGTC TTCTATGGGGTC;
 (SEQ.ID.NO.:31)).

Murine GABABR1a probes were generated by amplification of murine GABABR1a with JC160 (T3 promotor/primer and bases 631-648) paired with JC161 (T7 promotor/primer and bases 1024-1041):

(JC160: cgcgcaattaaccctcactaaaggAAGCTTATCCACCACGAC
(SEQ.ID.NO.:32);
JC161:gcgcgtaa tacgactcactatagggAGCTGGATCCGAGAAGAA
(SEQ.ID.NO.:33)).

- 5 For colocalization experiments, murine GABABR1a probes
were labeled with digoxigenin-UTP and detected using a peroxidase-
conjugated antibody to digoxigenin and TSA amplification involving
biotinyl tyramide and subsequent detection with streptavidin-conjugated
fluorescein. HG20 probes were radiolabelled
10 ([http://intramural.nimh.nih.gov/lcmr/snge/Protocol.
html](http://intramural.nimh.nih.gov/lcmr/snge/Protocol.html)). For individual hybridizations, murine GABABR1a and HG20
riboprobes were radiolabeled with ³⁵S-UTP and detected as described
previously (Bradley et al., 1992, J. Neurosci. 12:2288-2302;
<http://intramural.nimh.nih.gov/lcmr/snge/Protocol.html>). Brain slices
15 were either hybridized with individual radiolabelled probes or, for
colocalization studies, simultaneously with probes to both murine
GABABR1a and HG20 receptors. Detection of the radiolabeled HG20
probe was performed after detection of the digoxigenin-labeled rgl
probe on the same brain slices.

20

EXAMPLE 14

Construction of N-terminal and C-terminal fragments of murine GABABR1a

- The N-terminal fragment of murine GABABR1a,
25 comprising amino acid positions 1-625, was generated by PCR. The
coding sequence of the N-terminal fragment was amplified by using
primer pairs: NFP-CJ7843F139 (5'- ACC ACT GCT AGC ACC GCC ATG
CTG CTG CTG CTG CTT CTG C -3'; SEQ.IS.NO.:34) and NRP-CJ7844
(3'- GG GTG CGA GCA ATA TAG GTC TTA AGG GTC GGC CGC
30 CGG CGT CAC CA -5'; ; SEQ.IS.NO.:35). Similarly, the C-terminal
fragment, amino acid positions 588-942, was generated by PCR using
primer pairs: CFP-CJ7845 (5'- ACC ACT GCT AGC ACC GCC ATG
CAG AAA CTC TTT ATC TCC GTC TCA GTT CTC TCC AGC-3'; ;
SEQ.IS.NO.:36) and CRP-CJ7846 (3'- CAG CTC ATG TAA ACG AAA
35 TGT TCA CTC GCC GGC CGC CGG CGT CAC CA-5'; ; SEQ.IS.NO.:37).

PCR reactions were carried out using the Advantage-HF PCR kit (Clontech, Paolo Alto, CA) with 0.2 ng of murine GABABR1a DNA as the template, and 10 μ M of each primer according to manufacturer instructions. The PCR conditions were as follows: precycle
5 denaturation at 94°C for 1 min, and then 35 cycles at 94°C (15 s), annealing and extension at 72°C (3 min), followed by a final extension for 3 min at 72°C. The PCR products, N-gb 1a and C-gb 1a DNA, flanked by Nhe1 and Not1 sites, were digested and subcloned into the Nhe1/Not1 site of pcDNA3.1 (Invitrogen, San Diego, Ca).

10

EXAMPLE 15

Cell culture and preparation of membrane fractions for binding experiments using N-terminal and C-terminal GABABR1a fragments

COS-7 cells (ATCC) were cultured in DMEM, 10% bovine
15 serum, 25 mM HEPES, and antibiotics and transiently transfected with murine gb1a/pcDNA3.1 (encoding full-length GABABR1a), N-gb 1a/pcDNA3.1 (encoding the N-terminal fragment of GABABR1a; see Example 14) or C-gb 1a/pcDNA3.1 (encoding the C-terminal fragment of GABABR1a; see Example 14) using Lipofectamine reagent (Gibco BRL)
20 following the conditions recommended by the manufacturer. At 48 h post-transfection, P2 membrane fractions were prepared at 4°C as follows: Cells were washed twice with cold PBS, collected by centrifugation at 100xg for 7 min, and resuspended in 10 ml of buffer A: 5 mM Tris-HCl, 2 mM EDTA containing (1X) protease inhibitor cocktail
25 Complete® tablets (Boehringer Mannheim), pH 7.4 at 4°C. Cells were disrupted by polytron homogenization, centrifuged at 100xg for 7 min to pellet unbroken cells and nuclei, and the supernatant collected. The resulting pellet was homogenized a second time in 10 ml of buffer A, centrifuged as described above and supernatant fractions saved. The
30 pooled S1 supernatant was centrifuged at high speed (27,000xg for 20 min) and the pellet was washed once with buffer A, centrifuged (27,000xg for 20 min), resuspended in buffer A to make the P2 membrane fraction, and stored at -80°C. Protein content was determined using the Bio-Rad Protein Assay Kit according to manufacturer instructions.

EXAMPLE 16

In vitro transcription/translation of GABA_BR1a and N-terminal and C-terminal fragments

- 5 *In vitro* transcription coupled translation reactions were performed in the presence of [³⁵S]-methionine in the TNT Coupled Reticulocyte Lysate system (Promega, WI) using the pcDNA3.1 plasmid containing the full-length GABA_BR1a, N-gb1a, and C-gb1a DNAs. Translation products were analysed by electrophoresis on 8-16% Tris-
10 Glycine gradient gels (Novex pre-cast gel system) under denaturing and reducing conditions. Gels were fixed, treated with enlightening fluid (NEN), dried and exposed to Kodak X-AR film at -70°C for 4 to 24 h. Analysis of the results of these *in vitro* transcription coupled translation reactions confirmed that the constructs whose production is described in
15 Example 14 directed the expression of the appropriate GABA_BR1a fragments (see Figure 17A).

EXAMPLE 17

Immunoblot analysis for experiments with N-terminal and C-terminal fragments of GABA_BR1a

- 20 The expression of full-length and N-terminal and C-terminal GABA_BR1a fragments *in vivo* was confirmed by immunoblot analysis. Membranes were solubilized in SDS sample buffer consisting of 50 mM Tris-HCl pH 6.5, 10% SDS, 10% glycerol, and 0.003%
25 bromophenol blue with 10% 2-mercaptoethanol and separated on SDS-PAGE. The full-length receptor and N-terminal fragment were detected using affinity purified rabbit GABA_BR1a polyclonal antibody 1713.1 (acetyl-DVNSRRDILPDYELKLC-amide; a portion of SEQ.ID.NO.:20) and 1713.2 (acetyl-CATLHNPTRVKLF EK-amide; a portion of
30 SEQ.ID.NO.:20) (Quality Control Biochemicals (Hopkinton, MA). The C-terminal fragment was detected using a GABA_BR1a antibody raised against the C-terminal tail of the receptor (acetyl-PSEPPDRLS CDGSRVHLLYK-amide; SEQ.ID.NO.:20) (Chemicon Int.,

Inc., Canada).

EXAMPLE 18

5 Receptor filter-binding assays for experiments with N-terminal and C-terminal fragments of GABAR1a

Competition of [¹²⁵I] CGP71872 binding experiments were performed with ~7 µg P2 membrane protein and increasing concentrations of cold ligand (10⁻¹²-10⁻³ M). The concentration of radioligand used in the competition assays was 1 nM (final). Each concentration was examined in duplicate and incubated for 2 hr at 22°C in the dark in a total volume of 250 µL binding buffer: 50 mM Tris-HCl, 2.5 mM CaCl₂ (pH 7.4) with (1X) protease inhibitor cocktail Complete® tablets. Bound ligand was isolated by rapid filtration through a Brandel 96 well cell harvester using Whatman GF/B filters. Data were analysed by nonlinear least-squares regression using the computer-fitting program GraphPad Prism version 2.01 (San Diego).

EXAMPLE 19

20 Photoaffinity labeling for experiments with N-terminal and C-terminal fragments of GABAR1a

P2 membranes were resuspended in binding buffer, and incubated in the dark with 1 nM final concentration [¹²⁵I]CGP71872 (2200 Ci/mmol) in a final volume of 1 ml for 2 h at 22°C. The membranes were centrifuged at 27,000xg for 10 min and the pellet was washed in ice-cold binding buffer, centrifuged at 27,000xg for 20 min and resuspended in 1 ml of ice-cold binding buffer and exposed on ice 2 inches from 360 nm ultraviolet light for 10 min. Photolabeled membranes were washed and membranes pelleted by centrifugation and solubilized in sample buffer (50 mM Tris-HCl pH 6.5, 10% SDS, 10% glycerol, and 0.003% bromophenol blue with 10% 2-mercaptoethanol). Samples were electrophoresed on precast NOVEX 10% Tris-glycine gels,

fixed, dried, and exposed to Kodak XAR film with an intensifying screen at -70°C .

EXAMPLE 20

5

Construction of the FLAG epitope-tagged HG20 and detection of expression in vitro and in COS-1 cells

10 The FLAG epitope-tagged HG20 receptor subunit was constructed by PCR using a sense primer encoding a modified influenza hemagglutinin signal sequence (MKTIALSYIFCLVFA; a portion of SEQ.ID.NO.:17) (Jou et al., 1980, Cell 19:683-696) followed by an antigenic FLAG epitope (DYKDDDDK; a portion of SEQ.ID.NO.:17) and DNA
15 encoding amino acids 52-63 of HG20 and an antisense primer encoding amino acids 930-941 of the HG20 in a high-fidelity PCR reaction with HG20/pCR 3.1 as a template. HG20/pCR 3.1 is a plasmid that contains full-length HG20 (SEQ.ID.NO.:2) cloned into pCR3.1. The nucleotide
20 sequences of the sense and antisense primers are: sense: 5'-GCC GCT AGC GCC ACC ATG AAG ACG ATC ATC GCC CTG AGC TAC ATC TTC TGC CTG GTA TTC GCC GAC TAC AAG GAC GAT GAT GAC AAG AGC AGC CCG CCG CTC TCC ATC ATG GGC CTC ATG CCG CTC-3', (SEQ.ID.NO.:38); antisense: 5'-GCC TCT AGA TTA CAG GCC CGA GAC CAT GAC TCG GAA GGA GGG TGG CAC-3' (SEQ.ID.NO.:39). The PCR conditions were: precycle denaturation at
25 94°C for 1 min, 94°C for 30 sec, annealing and extension at 72°C for 4 min for 25 cycles, followed by a 7 min extension at 72°C . The PCR product, SF-HG20 DNA, flanked by NheI and XbaI sites was subcloned into the NheI/XbaI site of pcDNA3.1 (Invitrogen, San Diego, Ca) to give rise to the expression construct SF-HG20/pcDNA3.1. The sequence of
30 this construct was verified on both strands.

The SF-HG20 receptor was expressed in an *in vitro* coupled transcription/translation reaction using the TNT Coupled Reticulocyte Lysate system (Promega, WI) in the presence of $[^{35}\text{S}]$ methionine according to the manufacturer instructions. Radiolabeled proteins
35 were analyzed by electrophoresis on 8-16% Tris-Glycine gradient gels (Novex pre-cast gel system) under denaturing and reducing conditions.

Gels were fixed and treated with Enlightening fluid (NEN), dried and exposed to Kodak X-AR film at -70°C.

COS-1 cells (ATCC, CRL 1650) were cultured in DMEM, 10% bovine serum, 25 mM HEPES, pH 7.4, and 10 units/mL penicillin- 10
5 µg/mL streptomycin. Transient transfection of COS-1 cells with SF-HG20/pcDNA 3.1 was carried out using Lipofectamine reagent (Gibco BRL) following the conditions recommended by the manufacturer. At 48 h post-transfection, crude membranes were prepared and receptors were solubilized with digitonin and immunoprecipitated with anti-
10 FLAG M2 affinity gel resin (IBI) under previously described conditions (Ng et al., 1993). The immunoprecipitate was washed and solubilized in SDS sample buffer, sonicated, electrophoresed, and blotted on to nitrocellulose membrane as described (Ng et al., 1993). The FLAG-tagged HG20 receptor was detected using an anti-FLAG antibody (Santa
15 Cruz Biotech., Inc.) by following a chemilumescence protocol of the manufacturer (NEN).

EXAMPLE 21

Kir channel activity in *Xenopus* oocytes

20 With the following modifications, *Xenopus* oocytes were isolated as described (Hébert et al., 1994, Proc. R. Soc. Lond. B 256:253-261) from live frogs supplied by Boreal, Inc. After a brief (10 min) hypertonic shock with 125 mM potassium phosphate pH 6.5, oocytes were allowed to recover in Barth's solution for 1-2 hr. cDNA constructs
25 for human Kir 3.1, Kir 3.2 channel isoforms (generous gifts from Dr. Hubert Van Tol, University of Toronto), and G α 1 (a generous gift of Dr. Maureen Linder, Washington University) were linearized by restriction enzymes and purified using GeneClean (Bio 101). Murine GABA β R1a or FLAG-HG20 clones were subcloned into pT7TS (a generous gift of Dr.
30 Paul Krieg, University of Texas) before linearization and transcription. Capped cRNA was made using T7 RNA polymerase and the mMessage mMachine (Ambion). Individual oocytes were injected with 5-10 ng (in 25-50 nL) of Kir3.1 and Kir3.2 constructs with mRNAs for murine GABA β R1a or FLAG-HG20 and in combination with G α 1 as well. Kir
35 currents were also evaluated in oocytes co-injected with Kir3.1, Kir3.2,

murine GABA_BR1a and FLAG-HG20 mRNAs. Currents were recorded after 48 hr. Standard recording solution was KD-98, 98 mM KCl, 1 mM MgCl₂, 5 mM K-HEPES, pH 7.5, unless otherwise stated.

Microelectrodes were filled with 3 M KCl and had resistances of 1-3 MW and 0.1-0.5 MW for voltage and current electrodes, respectively. In addition, current electrodes were backfilled with 1% agarose (in 3M KCl) to prevent leakage as described (Hébert et al., 1994, Proc. R. Soc. Lond. B 256:253-261). Recordings were made at room temperature using a Geneclamp 500 amplifier (Axon Instruments). Oocytes were voltage clamped and perfused continuously with different recording solutions. Currents were evoked by 500 msec voltage commands from a holding potential of -10 mV, delivered in 20 mV increments from -140 to 60 mV to test for inward rectifying potassium currents. Data were recorded at a holding potential of -80 mV and drugs were added to the bath with a fast perfusion system. Data collection and analysis were performed using pCLAMP v6.0 (Axon Instruments) and Origin v4.0 (MicroCal) software. For subtraction of endogenous and leak currents, records were obtained in ND-96, 96 mM NaCl, 2 mM KCl, 1 mM MgCl₂, 5 mM Na-HEPES and these were subtracted from recordings in KD-98 before further analysis.

EXAMPLE 22

Radiation Hybrid mapping of HG20

Radiation hybrid analysis assigned the HG20 gene to chromosome 9, placing it 4.81 cR from the WI-8684 marker on the GeneBridge 4 panel of 93 RH clones of the whole human genome. Searching of the OMIM database with D9S176 and D9S287 markers proximal to the HG20 gene revealed it to map proximal to the hereditary sensory neuropathy type 1 (HSN-1) locus, a ~8 cM region flanked by D9S176 and 9S318 (Nicholson et al., 1996, Nature Genetics 13, 101-104) (Figure 20). HSN-1 is the most common form of a group of degenerative disorders of sensory neurons characterized by a progressive degeneration of dorsal root ganglion and motor neurons that lead to distal sensory loss, distal muscle wasting and weakness, and neural deafness, among a number of other neuronally related deficits

(Nicholson et al., 1996, Nature Genetics 13, 101-104). FCMD (Fukuyama congenital muscular dystrophy) and DYS (dysautonomia, another type of HSN) also map to this area. Candidate gene(s) in these disorders are likely critical to the development, survival, and differentiation of neurons.

A human BAC library was screened using the EcoRI fragment containing the full-length HG20 DNA, and end-sequencing was performed on BAC clones designated 6D18, 168K19, 486B24, and 764N4. The primer pair: ngfl17+ (5'-AAC AGT CAA AAC CCA CCC AG-3'; SEQ.ID.NO.:40) and ngfl17- (5'-AAC AGT TTC CAG CTG TGC CT-3'; SEQ.ID.NO.:41) were identified for radiation hybrid mapping of the HG20 gene on the GENEBRIDGE 4 panel. BAC library screening and radiation hybrid mapping were performed by Research Genetics (Huntsville, AL).

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

WHAT IS CLAIMED:

1. An isolated DNA molecule encoding an HG20 polypeptide comprising an amino acid sequence selected from the group consisting of:
- 5
- SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
10 Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
15 Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.
2. The isolated DNA molecule of claim 1 comprising a nucleotide sequence selected from the group consisting of:
- 20
- SEQ.ID.NO.:1;
Positions 293-3,115 of SEQ.ID.NO.:1;
Positions 317-3,115 of SEQ.ID.NO.:1;
Positions 395-3,115 of SEQ.ID.NO.:1;
Positions 398-3,115 of SEQ.ID.NO.:1;
25 Positions 404-3,115 of SEQ.ID.NO.:1;
Positions 407-3,115 of SEQ.ID.NO.:1;
Positions 416-3,115 of SEQ.ID.NO.:1;
Positions 422-3,115 of SEQ.ID.NO.:1;
Positions 428-3,115 of SEQ.ID.NO.:1;
30 Positions 446-3,115 of SEQ.ID.NO.:1; and
Positions 461-3,115 of SEQ.ID.NO.:1.
3. An isolated DNA molecule that hybridizes under stringent conditions to the DNA molecule of claim 2.
- 35
4. An expression vector comprising the DNA of claim 1.

5. A recombinant host cell comprising the expression vector of claim 4.
- 5 6. The recombinant cell of claim 5 further comprising an expression vector comprising DNA encoding a protein selected from the group consisting of:
- 10 7. A protein, substantially free from other proteins, comprising an HG20 protein having an amino acid sequence selected from the group consisting of:
- 15 SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
20 Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.
- 25 8. A heterodimer comprising the protein of claim 7 and a G-protein coupled receptor protein where the heterodimer is substantially free from other proteins.
- 30 9. The heterodimer of claim 8 where the heterodimer is held together by N-terminal Sushi repeats, C-terminal alpha-helical interacting domains, coiled-coil domains, transmembrane interactions, or disulfide bonds.
- 35 10. A polypeptide comprising a coiled-coil domain from a first GABA_B receptor subunit and no other contiguous amino acid sequences longer than 5 amino acids from the first GABA_B receptor subunit where the coiled-coil domain is present in the C-terminus of the

GABA_B receptor subunit and mediates heterodimerization of the first GABA_B receptor subunit with a second GABA_B receptor subunit.

11. The polypeptide of claim 10 where the coiled-coil
5 domain is selected from the group consisting of: positions 756-829 of SEQ.ID.NO.:2; positions 779-814 of SEQ.ID.NO.:2; positions 886-949 of SEQ.ID.NO.:21; and positions 889-934 of SEQ.ID.NO.:21.

12. An isolated DNA molecule encoding a GABA_BR1a
10 polypeptide comprising the amino acid sequence SEQ.ID.NO.:20.

13. A protein, substantially free from other proteins,
comprising a GABA_BR1a protein having the amino acid sequence
15 SEQ.ID.NO.:20.

14. A method for determining whether a substance binds
GABA_B receptors and is thus a potential agonist or antagonist of the
GABA_B receptor that comprises:

(a) providing cells comprising an expression vector
20 encoding HG20 and an expression vector encoding GABA_BR1a or
GABA_BR1b;

(b) culturing the cells under conditions such that HG20
and GABA_BR1a or GABA_BR1b are expressed and heterodimers of HG20
and GABA_BR1a or GABA_BR1b are formed;

25 (c) exposing the cells to a labeled ligand of GABA_B
receptors in the presence and in the absence of the substance;

(d) measuring the binding of the labeled ligand to the
heterodimers of HG20 and GABA_BR1a or GABA_BR1b;

30 where if the amount of binding of the labeled ligand is less
in the presence of the substance than in the absence of the substance,
then the substance is a potential agonist or antagonist of GABA_B
receptors.

15. A method of identifying agonists and antagonists of
35 HG20 comprising:

(a) providing test cells by transfecting cells with:

- (1) an expression vector that directs the expression of HG20 in the cells; and
- (2) an expression vector that directs the expression of GABABR1a or GABABR1b in the cells;
- 5 (b) exposing the test cells to a substance that is suspected of being an agonist of the GABAB receptor;
- (c) measuring the amount of a functional response of the test cells that have been exposed to the substance;
- (d) comparing the amount of the functional response
- 10 exhibited by the test cells with the amount of the functional response exhibited by control cells;
- wherein if the amount of the functional response exhibited by the test cells differs from the amount of the functional response exhibited by the control cells, the substance is an agonist or antagonist of
- 15 the GABAB receptor;
- where the control cells are cells that have not been transfected with HG20 and GABABR1a or GABABR1b but have been exposed to the substance or are test cells that have not been exposed to the substance.

20

16. A method of producing functional GABAB receptors in cells comprising:
- (a) transfecting cells with:
- (1) an expression vector that directs the
- 25 expression of HG20 in the cells; and
- (2) an expression vector that directs the expression of GABABR1a or GABABR1b in the cells;
- (b) culturing the cells under conditions such that heterodimers of HG20 and GABABR1a or GABABR1b are formed where
- 30 the heterodimers constitute functional GABAB receptors.

17. An antibody that binds specifically to HG20 where HG20 has an amino acid sequence selected from the group consisting of:
- SEQ.ID.NO.:2;
- 35 Positions 9-941 of SEQ.ID.NO.:2;
- Positions 35-941 of SEQ.ID.NO.:2;
- Positions 36-941 of SEQ.ID.NO.:2;

Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
5 Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

18. A method of expressing a truncated version of HG20
10 protein comprising:

(a) transfecting a host cell with a expression vector that
encodes an HG20 protein that has been truncated at the amino
terminus;

(b) culturing the transfected cells of step (a) under
15 conditions such that the truncated HG20 protein is expressed.

19. A chimeric HG20 protein having an amino acid
sequence of HG20 selected from the group consisting of:

20 Positions 51-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2;
Positions 53-941 of SEQ.ID.NO.:2;
Positions 54-941 of SEQ.ID.NO.:2;
Positions 55-941 of SEQ.ID.NO.:2;
Positions 56-941 of SEQ.ID.NO.:2;
25 Positions 57-941 of SEQ.ID.NO.:2; and
Positions 58-941 of SEQ.ID.NO.:2;

covalently linked at the N-terminus with a non-HG20 amino acid
sequence.

1/32
FIGURE 1A

1 CCGCCCTCCC CCGGCCGAGC TCCAGGGCTG CCGCCTAGCA GCTCCCGGCG
51 GGAGAGCGGT TCAGAGCTCG CTCCCACCCC TTCCCGGCCGT GATTGATCCG
101 TCACGGGGCGC CTCCGCTGCC GCCGCCGCCG CCGCGGCCGT TCTGAGCCGA
151 GCCGGAACCC TAGCCCGAGA CGGAGCCGGG GCCCGGGCCG GCGCCATTGC
201 GCGGGCGCCG CGGGAAGACC TTGGCGCGGG GCGGCGGGCC GGGCCAGGCC
251 ATGCGGGCCG AGTGAGCCGG CGCCCGCAGC CCGCGCGCGC GCATGGCTTC
301 CCGCGGGAGC TCCGGGCAGC CCGGGCCGCC GCCGCCGCCG CCACCGCCGC
351 CCGCGCGCCT GCTACTGCTA CTGCTGCTGC CGCTGCTGCT GCCTCTGGCG
401 CCGGGGGCCT GGGGCTGGGC GCGGGGCGCC CCCCAGCCGC CGCCAGCAG
451 CCGCGCGCTC TCCATCATGG GCCTCATGCC GCTACCAAG GAGGTGGCCA
501 AGGGCAGCAT CGGGCGCGGT GTGCTCCCCG CCGTGGAACT GGCCATCGAG
551 CAGATCCGCA ACGAGTCACT CCTGCGCCCC TACTTCCTCG ACCTGCGGCT
601 CTATGACAGC GAGTGCAGCA ACGAAAAGG GTTGAAAGCC TTCTACGATG
651 CAATAAAATA CGGGCCGAAC CACTTGATGG TGTGAGGAG CGTCTGTCCA
701 TCCGTACAT CCATCATTGC AGAGTCCCTC CAAGGCTGGA ATCTGGTGCA
751 GCTTTCTTTT GCTGCAACCA CGCTGTTCT AGCCGATAAG AAAAAATACC
801 CTTATTTCTT TCGGACCGTC CCATCAGACA ATGCGGTGAA TCCAGCCATT
851 CTGAAGTTGC TCAAGCACTA CCAGTGGAAAG CGCGTGGGCA CGCTGACGCA
901 AGACGTTTCA AGGTTCTCTG AGGTGCGGAA TGACCTGACT GGAGTTGCTG
951 ATGGCGAGGA CATTGAGATT TCAGACACCG AGAGCTTCTC CAACGATCCC
1001 TGTACCAAGT TCAAAAAGCT GAAGGGGAAT GATGTGCGGA TCATCCTTGG
1051 CCAGTTTGAC CAGAATATGG CAGCAAAAGT GTTCTGTTGT GCATACGAGG
1101 AGAACATGTA TGGTAGTAAA TATCAGTGGA TCATCCGGG CTGGTACGAG
1151 CCTTCTTGGT GGGAGCAGGT GCACACGGAA GCCAACTCAT CCGCTGCGCT
1201 CCGGAAGAAT CTGCTTGCTG CCATGGAGGG CTACATTGGC GTGGATTTCG
1251 AGCCCTTGAG CTCCAAGCAG ATCAAGACCA TCTCAGGAAA GACTCCACAG
1301 CAGTATGAGA GAGAGTACAA CAACAAGCGG TCAGGCGTGG GGCCAGCAA
1351 GTTCCACGGG TACGCTACG ATGGCATCTG GGTCATCGCC AAGACACTCG
1401 AGAGGGCCAT GGAGACACTG CATGCCAGCA GCCGGCACCA GCGGATCCAG
1451 GACTTCAACT ACACGGACCA CACGCTGGGC AGGATCATCC TCAATGCCAT
1501 GAACGAGACC AACTTCTTCG GGGTACGGG TCAAGTTGTA TTCCGGAATG
1551 GGGAGAGAAT GGGGACCATT AAATTTACTC AATTTCAGA CAGCAGGGAG
1601 GTGAAGGTGG GAGAGTACAA CGCTGTGGCC GACACACTGG AGATCATCAA
1651 TGACACCATC AGGTTCCAAG GATCCGAACC ACAAAGAC AAGACCATCA
1701 TCCTGGAGCA GCTGCGGAAG ATCTCCCTAC CTCTCTACAG CATCCTCTCT
1751 GCCCTCACCA TCCTCGGGAT GATCATGGCC AGTGCTTTTC TCTTCTCAA
1801 CATCAAGAAC CGGAATCAGA AGCTCATAAA GATGTCGAGT CCATACATGA
1851 ACAACCTTAT CATCCTTGA GGGATGCTCT CTAATGCTTC CATATTTCTC
1901 TTTGGCCTTG ATGGATCCTT TGTCTCTGAA AAGACCTTG AAACACTTGG
1951 CACCGTCAGG ACCTGGATTG TCACCGTGGG CTACACGACC GCTTTTGGGG
2001 CCATGTTTGC AAAGACCTGG AGAGTCCACG CCATCTTCAA AAATGTGAAA
2051 ATGAAGAAGA AGATCATCAA GGACCAGAAA CTGCTTGTGA TCGTGGGGGG
2101 CATGCTGCTG ATCGACCTGT GTATCCTGAT CTGCTGGCAG GCTGTGGACC
2151 CCCTGCGAAG GACAGTGGAG AAGTACAGCA TGGAGCCGGA CCCAGCAGGA
2201 CGGGATATCT CCATCCGCCC TCTCCTGGAG CACTGTGAGA ACACCCATAT
2251 GACCATCTGG CTTGGCATCG TCTATGCCTA CAAGGGACTT CTCATGTTGT
2301 TCGGTTGTTT CTTAGCTTGG GAGACCCGCA ACGTCAGCAT CCCCAGCTC
2351 AACGACAGCA AGTACATCGG GATGAGTGTG TACAACGTGG GGATCATGTG
2401 CATCATCGGG GCCGCTGTCT CTTTCTGAC CCGGACCCAG CCCAATGTGC
2451 AGTTCTGCAT CGTGGCTCTG GTCATCATCT TCTGCAGCAC CATCACCTC
2501 TGCCTGGTAT TCGTGCCGAA GTCATCACC CTGAGAACAA ACCCAGATGC
2551 AGCAACGCAG AACAGGCGAT TCCAGTTCAC TCAGAAATCAG AAGAAAGAAG
2601 ATTCTAAAAC GTCCACCTCG GTCACCAGTG TGAACCAAGC CAGCACATCC
2651 CGCCTGGAGG GCCTACAGTC AGAAAACCAT CGCCTGCGAA TGAAGATCAC
2701 AGAGCTGGAT AAAGACTTGG AAGAGGTCAC CATGCAGCTG CAGGACACAC

2751 CAGAAAAGAC CACCTACATT AAACAGAACC ACTACCAAGA GCTCAATGAC
2801 ATCCTCAACC TGGGAAACTT CACTGAGAGC ACAGATGGAG GAAAGGCCAT
2851 TTIAAAAAAT CACCTCGATC AAAATCCCCA GCTACAGTGG AACACAACAG
2901 AGCCCTCTCG AACATGCAAA GATCCTATAG AAGATATAAA CTCTCCAGAA
2951 CACATCCAGC GTCGGCTGTC CCTCCAGCTC CCCATCCTCC ACCACGCCTA
3001 CCTCCCATCC ATCGGAGGCG TGGACGCCAG CTGTGTCAGC CCCTGCGTCA
3051 GCCCCACCGC CAGCCCCCGC CACAGACATG TGCCACCCTC CTTCGGAGTC
3101 ATGGTCTCGG GCCTGTAAGG GTGGGGGGCC TGGGCCCGGG GCCTCCCCCG
3151 TGACAGAACC AACTGGGCA GAGGGGTCTG CTGCAGAAAC ACTGTCGGCT
3201 CTGGCTGCGG AGAAGCTGGG CACCATGGCT GGCCTCTCAG GACCACTCGG
3251 ATGGCACTCA GGTGGACAGG ACGGGGCAGG GGGAGACTTG GCACCTGACC
3301 TCGAGCCTTA TTTGTGAAGT CCTTATTCT TCACAAAGAA GAGGAACGGA
3351 AATGGGACGT CTTCTTAAC ATCTGCAAAC AAGGAGGCGC TGGGATATCR
3401 AATTCCACCA CACTGGCGGC CCGCGCTTGS TCSTAATCAT GGTCACTAAT
3451 GTTTCCTGTG TTGAAATTGT TATCCGCTCC

FIGURE 2

1 MASPRSSGQP GPPPPPPPP ARLLLLLLP LLLPLAPGAW GWARGAPRPP
51 PSSPPLSIMG LMPLTKEVAK GSIGRGVLP VELAIEQIRN ESLLRPYFLD
101 LRLYDTECDN AKGLKAFYDA IKYGNHLMV FGGVCPSVTS IIAESLQGWN
151 LVQLSFAATT PVLADKKKYP YFFRTVPSDN AVNPAILKLL KHYQWKRVT
201 LTQDVQRFSE VRNDLTGVLY GEDIEISDTE SFSNDPCTSV KKLKGNDVRI
251 ILGQFDQNMA AKVFCCAYEE NMYGSKYQWI IPGWYEPSWW EQVHTEANSS
301 RCLRKNLLAA MEGYIGVDFE PLSSKQIKTI SGKTPQQYER EYNNKRSGVG
351 PSKFHGYAYD GIWVIKTLQ RAMETLHASS RHQRIQDFNY TDHTLGRIL
401 NAMNETNFFG VTGQVFRNG ERMGTIKFTQ FQDSREVKVG EYNAVADTLE
451 IINDTIRFQG SEPPKDKTII LEQLRKISLP LYSILSALTI LGMIMASAFI
501 FFIKNRNQK LIKMSSPYMN NLILGGMLS YASIFLGLD GSFVSEKTFE
551 TLCTVRTWIL TVGYTTAFGA MFAKTWRVHA IFKNVKMKKK IKDQKLLVI
601 VGGMLLDLC ILCWQAVDP LRRTVEKYSM EPDPAGRDIS IRPLLEHCEN
651 THMTIWLIV YAYKGLLMF GCFLAWETRN VSIPALNSDK YIGMSVYNVG
701 IMCIIGAAVS FLTRDQPNVQ FCIVALVIF CSTITLCLVF VPKLITLRTN
751 PDAATQNRFF QFTQNQKKED SKTSTSVTSV NQASTSRLEG LQSENHRLRM
801 KITELDKDLE EVTMQLQDTP EKITTYIKQNH YQELNDILNL GNFTSTDDG
851 KAILKNHLDQ NPQLQWNTTE PSRTCKDPIE DINSPEHIQR RLSLQLPILH
901 HAYLPSIGGV DASCVSPCVS PTASPRHRHV PPSFRVMVSG L

4/32

FIGURE 3A

Sequence: LPLLLPLAPGAWG-WARGAPRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQIRNE
 1 (signal) 1 (mature peptide)
 29 42

Other entries above 3.50

Score 11.1 at residue 39

Sequence: LLLLPLLLPLAPG-AWGWARGAPRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQI
 1 (signal) 1 (mature peptide)
 26 39

Score 8.6 at residue 38

Sequence: LLLLPLLLPLAP-GAWGWARGAPRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQ
 1 (signal) 1 (mature peptide)
 25 38

Score 8.1 at residue 35

Sequence: RLILLLLPLLLP-LAPGAWGWARGAPRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELA
 1 (signal) 1 (mature peptide)
 22 35

Score 7.9 at residue 36

Sequence: LLLLPLLLPL-APGAWGWARGAPRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAI
 1 (signal) 1 (mature peptide)
 23 36

Score 6.2 at residue 9

Sequence: -QPGRPPPPPPPARLILLLLPLLLPLAPGAWGWARGAPRPPSSPPLSI
 1 (signal) 1 (mature peptide)
 -4 9

Score 5.7 at residue 46

Sequence: LPLAPGAWGWARG-APRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQIRNESLLR
 1 (signal) 1 (mature peptide)
 33 46

Score 5.6 at residue 747

Sequence: IILCLVFVPKLIT-LRTNPDAAATQNRRFQFTQNKKEDSKTSTSVTSVNQASTSRLEGLQSENH
 1 (signal) 1 (mature peptide)
 734 747

Score 5.0 at residue 44

Sequence: LLLPLAPGAWGWA-RGAPRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQIRNESL
 1 (signal) 1 (mature peptide)
 31 44

Score 4.9 at residue 497

Sequence: ILSALTILGMIMA-SAFFNKKNRNQKLIKMSPPYMNNLILGGMLSYASIFLFGLDGSFVSE
 1 (signal) 1 (mature peptide)
 484 497

Score 4.5 at residue 141

Sequence: LMFVGGVCPSVTS-IIAESLQGWNLVQLSFAATTPVLADKKKYPYFFRTVPDNAVNPAILKLL[†]
 1 (signal) 1 (mature peptide)
 128 141

Score 4.4 at residue 734

FIGURE 3B

Sequence: FCIVALVIIPCST-ITLCLVFVPKLTILRTNPDAATQNRRFQFTQNQKKEDSKTSTSVTSVNQA
I (signal) I (mature peptide)
721 734
Score 4.1 at residue 165

Sequence: VQLSFAATTPVLA-DKKKYPYFFRTVPSDNAVNPAILKLLKHYQWKRVGTLTQDVQRFSEVRND
I (signal) I (mature peptide)
152 165
Score 3.6 at residue 158

Sequence: SLQGWNLVQLSFA-ATTPVLADKKKYPYFFRTVPSDNAVNPAILKLLKHYQWKRVGTLTQDVQR
I (signal) I (mature peptide)
145 158

FIGURE 4




FIGURE 5




FIGURE 6

P L T K E V A K - G S I G R - G V L P A V E L A T E Q I R N E S L L R P Y F D U R L Y D T E C O N A K G L K A F Y D A
:: :: :: :: :: :: X ::
P U T G P V A Q Y G D M Q R A G A L ---M A I E Q I N K A G G V N Q A L E G V I Y D D A C D P K Q A V A V A N K V

IKYCPNHLMVFGVCBSVTSIIAESIQGNLVQLSAATTPVLADKKKYPFEFTVPSON
.. : . : : : : .. : .. : : : : : : : : : : : :
VNDGVK--FVVGHVCSSTQPATDIYEDEGLVMITPSATAPEIT-SRGYKLIFRTIGLON

AVNPAIKLL-KHYQKRVCTLTQDVQFSE-VRNDLTGVLYGDEIEISDTESFS---ND
.:
MQSPVACKFIAMRYKVKTIAVL-IDKQQYGGCIATVEVKKTVEDAGIKNVAFEGLNAGDKD

PCTSVKCLKGNDVRII-LGQFDQNH
 : :
 FNALISKKKAGVQFVYFGGYHPEM

FIGURE 7




FIGURE 8

GABA-BR1b HG20 Consensus	MCPGCGCTPVGWPLPLLLVMAAGVAPVWASHSPHL---PRPHPRVPPHPSSERRAVYIGALFPMHSGGNP-G--CG MASPRSSQPGRRPPPPPPPARLILLLLPLLLPLAPGAWGAWGAPRPPSSPPLSINGLMPLTKEVAKGSGR M.....G.P.P.....A.....L.....R.P.P.....I.L.P.....G.G.	69 75 75
GABA-BR1b HG20 Consensus	ACQPAVMALEDVNSRRDILPDYELKLIHHOSKCDPQQAATKYLYELLYNDPIKIILMPG-CSSVSTLVAEAARMW GVLPFAVELAIEQIRN-ESLLRPYFLDLRLYDTECDNAKGLKAFYDAIKYGNHLMVFGCVSPVSTSIIESLQGW ...PAVE.A.E.....L..Y.L.L...D...CD.....K..Y.....P.....G.C.SV....AE....W	143 149 150
GABA-BR1b HG20 Consensus	NLIVLSYCGSSSPALSNRQRFPTFFRTHPSATLHNPTRVKLFKMGWKKIATIQOTTSTLDDLEERVKEAGI NLVQLSFAATTFVLADKKYPYFFRTVPNDNAVNPAILKLLKHQWKRVTGLTQDVQRFSEVRNDLTGVLYGEDI NL..LS.....P.L.....P.FFRT.PS....NP...XL.....WK...T..Q....P.....DL.....	218 224 225
GABA-BR1b HG20 Consensus	EITFRQSFSDPAVPVGNLKRQDARIIVGLFYSTEARKVFCEVYKERLFGKKYVMPLIGWYADNWF---KTYDPS EISDTEFSNDPCTSVKLLKGNQVRILQGFQDNMAKVFCCAYEENNYGSKYQWIIIPQWYEPSMWEQVHTANS EI....SF...DP...VK.LK..D.RII.G.F....A.KVFC..Y.E...G.KY.W...GWY...W....T...S	290 299 300
GABA-BR1b HG20 Consensus	INCTVEENTEAVECHITTEIVHLNPANTRSIENMTSQEFVEKLTKRLKRHPETGCFQEAPLAYDAIWAALALALN SRCLRNLLAAMEGYIGVDFEPLSSKQIKTISGKTPOQY-EREYNN-KRSCVCPSKFHGYAYDGIWVIKTLQRA ..C.....A.EG.I.....L.....IS..T.Q...E.....KR.....F.....A..L...	365 372 375
GABA-BR1b HG20 Consensus	KTSGGGGRSGVRLEDFNYYNQITTDQIYRAMNSSSFEGVSGHVVDASGRMAWTLIEDLOGGSKYKIGYYDSTI METLHASSRHQRIQDFNYTDHTLGRILNANMETNFFGVTCQVFR-NGERMCTIKFTQFQDSREVKVGEYNAVAR..DFNY...T....I..AMN...P.GV.G.VVF...G.RH.....Q.Q.....K.G.Y....	440 446 450
GABA-BR1b HG20 Consensus	DDLWSKIDRWIGGSPPADQTLVIXTFRLQKLFISVSVLSSLGIVLAVVC---LSFNIYNSHVRYIQNSQPNL DTLEIINDTIRPQCSEPPKDKTII--LEQLRKISLPLYSILSALTILGMIMASAFLLFFNIQNRNQKLIKSSPYH D.L.....GS.P.....I.....L.....S.LS.L.I.....L.FNI.N....I..S.P..	512 519 525
GABA-BR1b HG20 Consensus	NNLTAVGCSLALAAVFPGLDGYHICRSQFPFVCQARLWLLGLGSLGVCMSFTKIWMVHTVTKKEEKKEWRKT NNLIILGMLSYASIFLPGLDGSFVSEKTFETLCTVRTWILTVGYTTAFGAMFAKTWRVHAIF--KNVKHK-KKI NNL...G..L..A..F..GLDG.....P...C..R.W.L..G....G.MF.K.W.VH..F..K..K....K.	587 591 600
GABA-BR1b HG20 Consensus	LEPWKLYATVGLLVGMQVLTALWQIVDPLHRTIETFAKSEPKEDIDVLSILPOLEHCSSKKHNTWLGIFYGYKGL IRDQKLLVIVCGMLLDLCILICWQAVDPLRRTVVKYSMEPDPAGRDISIRPLEHCENHMTIWLGIIVAYKGLKL...VG.....D...L..WQ.VDPL.RT.E....E.....D.SI.P.LEHC....M..WLSI.Y.YKGL	662 666 675
GABA-BR1b HG20 Consensus	LLLLGIFLAYETKSVSTKINDHRAVGMAYNVAVLCLITAPVTMILSSQDDAFAFASLAIVFSSVITLVVLV LMLFGCFLAWETRNVSIIPALNDSKYIGMSVYVNGIMCIIGAUSFLTRDQPNVQFCIVALVIFCSTITLCLVTV L.L.G.FLA.ET..VS....ND....GN..YVNV...C.I.A.V.....Q....F....L.I.F.S.ITL...FV	737 741 750
GABA-BR1b HG20 Consensus	PKMRRLITRGE-----W-----QSETQDTHKTGSS-TNNNEEEKSRL--LEKE-----NRELEKI----- PKLYTLRINPDAAATONRRFQFTQNKEDSKTSTSVTVNQASTSRLEGQSSENHRLRMKITELDKDLEEVTMQL PK...L.T.....Q.....KT...S.T..N....SPL..L..E.....LE.....	784 816 825
GABA-BR1b HG20 Consensus	--IAEKE-----ERVSE-----LRHQLQSRQQLSRHPPPTPP--DPSGC----- QDTPEKTTYIKQNHVQELNDILNLGNFTSTDCGKAILKNHLDQNPQLQWMTTEPSRTCKDPIEDINSEHIQRR ...EK.....L.....L.....L.....QL.....P.....DP.....	820 891 900
GABA-BR1b HG20 Consensus	-----LPR-GPSEPPDRLSC-----DGSRVHLL---YK----- LSLQLPILHAYLPSIGGVASCVSPCVSPTASPRHRVPPSFRVMVSGLLP..G.....C.....R.....	844 941 950

FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13





FIGURE 14



1 atgtctgtc tgcctctt gcttcttct ctcgccccc tggcgctgg cggggctcag
61 accccaacgt tcaactcggg aggttgcag attatacat cgcctggga aggtggcat
121 aggtaccgt gcttgatcg ccagcagggt aagggcatca attctctc ttgtgactat
181 gagattgaat atgtgtccg ggtgcacgc gaagtggttg ggcacaagtg gcgcaagtgc
241 ctggccaacg gctctcggac ggataatggac acaccagtc gctgtgcgc aatctgtcc
301 aagtcttatt tgaccctgga aatatgggaag gttttctga cgggtgggga cctccagct
361 ctggatggag ccgggctgga ttctcgttg gaccttgact tccatctgtt gggcagctcc
421 cggagctctt gtatgcagg ccagtgaggc accccaage cccactgca ggtgaatcga
481 acgccacact cagaaaggcg tgcagtatac atcgggggcg tgtttccat gagcgggggc
541 tggcggggg gccaggcctg ccagcctgcg gtgagatgg cgtcggagga cgttaacage
601 cgcagagaca tctcgcgga ctagagctc aagctatcc accacagac gaagtgcgac
661 cggggcaag ccaccaaga ctgtatgaa ctacttaca acgacccat caagatcact
721 ctcatgcgcg gctgcagctc tgtgtccaca ctggtagcgc aggtgtcccg gatgtggaa
781 cttattgttc tctcatatgg ctcagctca cagccttgt caaacgcaca gegtcttca
841 acgtttctt ggacacatcc atcgcgca caaccacat ccaccgggt gaaactctc
901 gaaaaattg gctggaagaa gattgccac atcagcaga ctaccagggt cttcacttc
961 acactggatg acctggagga gctagtgaa gagctcggg ttgagtatc ttctgcagc
1021 agttttctt cagatcagc tgtgctgtt aaaaacctga agcgtcaaga tctcgaatc
1081 atcgtgggac ttcttatga gacgaagcc cggaaagtt ttgtgaggt ctataaggaa
1141 cggctgttt ggaagaagta tctctgttt ctatcggtt ggtatgctga caactgttc
1201 aaaaactatg accgtcaat caatgata ctgaaagaga tgcagtggc ggtgggggc
1261 catatacca cggagattgt catgtgaa cctgccaca ccgaagcat ttcaacatg
1321 acatcacagg aatttgtga gaaactaac aagcgctga aaagacacc tggaggagct
1381 ggagcttcc aggagtcac atcgctcat gatgtatt gggtctctc ttigtcttg
1441 aacaagact ctggaggagg tggcgctca ggaagtgcg ttgagruatt taactaac
1501 aaccagaca ttacagaca aatctaccg gccatgaact cctctcctt tgagggtgtt
1561 tctggccac tggctttga tgcacggcg tccggatgg catggagct tatcgagag
1621 ctacaggcg cgcagtaca gaagatcgc tactacga ccaacagga tgcatttcc
1681 tggctcaaa cagacaagtg gatcgaggg tctcccacg ccgacagac ctgtgtcat
1741 aagacatcc gtttctgtc acgaaactc ttatctccg tctagttct ctcagctg
1801 ggcatttgt ttgtgttgt ctgtctgtc tttaacatc acaactcca cgtctgtat
1861 atcagaatt ccagcccaa ctgaacaa ctgactgtg tctgtctc atctggcactg
1921 gtttgttgt tctctcgg gctgaggtt taacacatg ggagaacca gtctcgtt
1981 gctcgcagg ccgctcttg gctctgggc ttgggttta gtcctggcta tggctctatg
2041 ttaccaaga tctgttggt ccacagctc ttacgaaga aggaggagaa gaaggagtgg
2101 aggaagacc tagagcccg gaaactctat ccactgtgg gctcgttgt gggcatggat
2161 gctcgtact tgcctatg gtagtgttg gacctctg accgaacat tgcagcttt
2221 gcaaggagg aaccaaagga agacatgat gctccatc tgcaccgtt ggagcactgc
2281 agctccaga agatgaatac gtgctttgc attttctat gttacaagg gctcgtctg
2341 ctgtgggaa ttctttctg ttacgaacc aagagctgt ccactgaaa galcaatgac
2401 cacaggcg tggcatgct tatctaat gtgtggctc tgtctctat caetgctct
2461 gtgacctga tctttccag tcagcaggac gcagccttg cctttgctc tctggccac
2521 gttttctct cctacatca tctgtgttg cttttgtgc ccaagatgc caggtgtgac
2581 acccgagggg aatggcact tgaacgcg gagacatga aaacaggat atccaccaac
2641 aaaaacagg aagagaagtc cgcagtctg tgaaggaaa accgagaact ggaaaagatc
2701 atcgtgaga aagaggagcg cgtctctga cgtgcacat agtccagtc teggagcaa
2761 cctcgtcac ggcgtcacc cccaacacc ccagatcct ctggggcct tccaggggg
2821 cctctgagc cccctgacg gcttagtgt gatgggagtc gactacatt gctttacaag
2881 tga

FIGURE 16

MLLLLLLLFLRPLGAGGAQTPNVTSEGCQIHPWEGGIRYRGLIRDQVKAINFLPVDY
EIEYVCRGEREVGPKVRKCLANGSWTDMDTPSRCVRICSKSYLTLENGKVLTGGDLPA
LDGARVDFFRCDPDFHLVGSSRSICSQGQWSTPKPHCQVNRTPHSERRAVYIGALFPMMSGG
WPGGQACQPAVEMALEDVNSRRDILPDYELKLIHDSKCDPGQATKYLYELLYNDPIKII
LMPGCSSVSTLVAEAARMWNLIJLSYGSSSPALSNRQRFPTFFRTHPSATLHNPTRVKLF
EKWGWKKIATIQQTTEVFTSTLDDLEERVKEAGIETFRQSFFSDPAVPVKNLKRQDARI
IVGLFYETEARKVFCFVYKERLFGKKYVWFLGWYADNWFKYDPSINCTVEBMTAEV
HITTEIVMLNPANTRISINMTSQEFVEKLTKRKRHPETGGFQEAPLAYDAIWALALAL
NKTSGGGGRSGVRLEDNFYNNQITTDQIYRAMNSSSFEGVSGHVVDASGSRMAWTUEQ
LQGGSYKKIGYYDSTKDDLSWSKTDKWIGGSPPADQTLVKTFRFLSQKLFISVSVLSSL
GIVLAVVCLSRNIYNHARYIONSQPNLNNLTAVGCSLALAVVPLGLDGYHIGRSQFFP
VCQARLWLLGLGFSLSGYGSMFTKIWWWHTVFTKKEEKEWRKTLPEWKLYATVGLLVGMD
VLTIAIWQIVDPLHRTIETFAKEEPKEDIDVSILPQLEHCSSKKNMTWLGFIFYGKGLLL
LLGIFLAYETKSVSTEKINDHRAVGMAIYNVAVLCLITAPVTMILSSQQDAAFASLAI
VFSSYITLVVLFVPMRRLITRGEWQSETQDTMKTGSSTNNNEEEKSRLEKENRELEKI
IAEKEERVSELRHQLQSRQQLRSRRHPPTPPDPSSGGLPRGPSEPPDRLSCDGSRVHLLYK

FIGURE 17

^[125I]CGP71872 labeling of the GABA_B receptor N-terminal domain




FIGURE 18A

MLLLLLLAPLFLRPPGAGGAHTPNATSEGCQIIHPPWEGGIRYRGLTRDQV
KAINFLPVDYIEIYVCRGEREVVGPKVRKCLANGSWTDMTPSRCVRICS
KSYLTLENGKVFLTGGDLPALD GARADFRCDPDFHLVGSSRSICSQGGWST
PKPHCQVNRTPHSERRAVYIGALFPMSSGGWPGGQACQPAVEMALEDVNS
RRDILPDYELKLIHSDSKCDPGQATKYL YELLYNDPIKILMPGCSSVSTLV
AEAARMWNLIVLSYGSSSPALSNRQRFPTFFRTHPSATLHNPTRVKLFEKW
GWKKIATIQQTTEVFTSTLDDLEERVKEAGIEITFRQSFTSDPAVPVKNLKRQ
DARIIVGLFYETEARKVFCVYKERLFGKKYVWFLIGWYADNWFKIYDPS
INCTVDEMTEAVEGHITTEIVMLNPANTRISINMTSQEFVEKLT KRLKRHPE
ETGGFQEAPLAYDAIWALALALNKTSGGGGRSGVRLED FNYNNQTITDQI
YRAMNSSSFEGVSGHVVFDA SGSRMAWT LIEQLQGGSYKIGYYDSTKDD
LSWSKTDKWIGGSPPADQTLVKTFRFLSQKLFISVSVLSSLGIVLAVVCLSF
NTYNSHVRYIQNSQPNNLNLTAVGCSLALAAVFLGLDGYHIGRNQFPFV
CQARLWLLGLGFS LGYGSMTKIWWVHTVFTKKEEKEWRKTLEPWKLY
ATVGLLVGMDVLT LAIWQIVDPLHRTIETFAKEEPKEDIDVSILPQLEHCSS
RKMNTWLGIFYGYKGLLLLLGIFLAYETKSVSTEKINDHRAVGMAIYNVA
VLCLITAPVTMILSSQQDAFAFASLAIVFSSYITLVVLFVPMRRLITRGE
WQSEAQDTMKTGSSTNNNEEEKSRLLKENRELEKIAEKEERVSEL RHQLQ
SRQQLRSRRHPPTPPEPSGGLPRGPPEPPDRLSCDGSRVHLLYK

FIGURE 18B

1 atgttgctgc tgcgtctact ggccgccatc tctctccgcc ccccggggcgc gggcggggcg
 61 cataccacca acgccaccac agaaggttgc cagatcatac acccgccctg ggaaggggcg
 121 atcaggtacc ggggcctgac tggggaccag gtgaaggcta tcaacttct gccagtggac
 181 tatgagattg agtatgtgtg ccggggggag cgcgaggtgg tggggcccaa gctccgcaag
 241 tgcctggcca acggctcctg gacagatag gacacacca gccgctgtgt ccgaatctgc
 301 tccaaagtct attgacctt ggaaaaggg aaggtttcc tgacgggtgg ggaacctcca
 361 gctctggacg gagcccgggc ggattccgg tgtaccccg acttccatct ggtgggcagc
 421 tcccgagca tctgtagca gggccagtgg agcaccacca agccccactg ccaggtgaat
 481 cgaacgccac actcagaacg gcgcgcagtg tacaicgggg cactgtttcc catgagcggg
 541 ggctggccag ggggccaggg cggccagccc ggggtggaga tggcgctgga ggacgtgaat
 601 agccgcaggg acatcctgcc ggactatgag ctcaagctca tccaccacga cagcaagtgt
 661 gatccaggcc aagccacca gtacctatat gactgtctct acaacgacct tatcaagatc
 721 atcctatgc ctggctcag cctgtctcc acgtgtgtgg ctgaggctgc taggatgttg
 781 aacctcattg tgccttcta tggctccagc tcaccagccc tctcaaacgc gcagcgtttc
 841 cccactttct tccgaacga cccatcagcc acactccaca accctaccgg cgtgaacctc
 901 ttgaaaagt ggggctggaa gaagattgt accatccagc agaccactga ggttttact
 961 tgcactctgg acgacctgga ggaacgagtg aaggaggctg gaattgagat tacttccgc
 1021 cagagtttct tctcagatcc agctgtgcc gtaaaaaacc tgaagccca ggaatgccga
 1081 atcatctgtg gactttcta tgagactgaa gcccggaag tttttgtga ggtgtacaag
 1141 gagcgtctct tgggaagaa gtacgtctgg ttctcattg ggtgtatgc tgacaattg
 1201 ttaagatct acgaccttc tatcaactgc acagtggatg agatgactga ggcgggtggag
 1261 ggccacatca caactgagat tgtatgctg aatcctgcca ataccgcag catttcaac
 1321 atgacatccc aggaattgt ggagaaacta accaagcgac tgaagaagca ccttgaggag
 1381 acaggaggct tccaggaggc accgctggcc taigaigcca tctgggccc ggcatctggc
 1441 ctgaacaaga catctggagg aggcggccgt tctgtgtgc gcttgaggga cttaactac
 1501 aacaaccaga ccataccga ccaaatctac cgggcaatga actctctgc cttaggggt
 1561 gtctctggcc atgtgtgtt tgaigccagc ggctctcgga tggcatggac gcttatcgag
 1621 cagcttcagg gtggcagcta caagaagat ggctactatg acagcaccan ggatgactt
 1681 tcttggtcca aaacagataa atggattgga gggcccccc cagctgacca gacctgtgc
 1741 atcaagacat tccgttctt gtcacagaaa ctcttatct cgtctcagt tcttccagc
 1801 ctgggcattg tctagtctgt tgtgtgtctg tctttaaca tctacaactc acatgtccgt
 1861 tataccaga actcacagcc cnacctgaac aacctgactg ctgtgggctg ctactggct
 1921 ttactgtctg tcttccctt ggggctcgtat ggttaccaca ttggaggaa ccagtttct
 1981 ttgcttgc aggcctgctt ctggctctg ggcctgggct ttactgtgg ctacggttcc
 2041 atgttaccga agatttggg ggtccacacg gtttccaaa agaagggaaga aaagaaggag
 2101 tggaggaaga tcttgaacc ctggaagctg tatgccacag tgggcctgct ggtgggcag
 2161 gatgtctca ctctgccat ctggcagatc gtggacctc tgcaccggac catgagaca
 2221 ttgccaaag aggaacctaa ggaagatat gacgttcta tctgcccga gctggagcat
 2281 tgcagctcca ggaagatga tacatggctt ggcatttct atggtacaa ggggctgctg
 2341 ctgctgctgg gaatttctt tgcitatgag accaagagtg tgtccactga gaagatcaat
 2401 gatcaccggg ctgtgggcat ggctatctac aatgtggcag tctgtgctt catcactgct
 2461 cctgtacca tgaatctgc cagccagcag gatgagcct ttgctttgc ctctcttgc
 2521 atgtttct cctctatat cactctgtt gtgtctttg tggcaagat gcgaggctg
 2581 atcaccgag gggaaatgga gtccgaggcg caggacacca tgaagacagg gtcatcgacc
 2641 aacaacaac agggaggagaa gtcccggctg ttggagaagg agaaccgtga actggaaaag
 2701 atcattgctg agaaagagga gctgtgtctt gaactgcgc arcaactcca gtctggcag
 2761 cagctccgtt cccggcgcca cccaccgaca ccccagaac cctctggggg cctgccag
 2821 ggacccctg agcccccca ccggttagc tgtgatggga gtgagtgca ttgctttat
 2881 aagtga

FIGURE 19A

1 atgtctgtgc tgcgtctggc gccactcttc ctcgcccccc cgggcccggg cggggcgag
 61 accccaacg ccactcaga aggttgcag atcatacacc cgccttggga agggggcacc
 121 aggtaccggg gcctgactcg ggaccaggte aaggctatca acttctgcc agtggactat
 181 gagatgagt atgtgtccg gggggagcgc gaggtgtgtg gggccaaggt ccgcaagtgc
 241 ctggccaacg gctcctggac agataggac acaccagcc gctgtgtccg aatctgtcc
 301 aagtctat tgaccctga aatgggaag gtttctga cgggtggga cctccagct
 361 ctggacggag cccgggtgga ttccgggtg gaccccgact tccatctgt gggcagctcc
 421 cggagcact gtatcaggc ccagtggagc accccaagc cccactgcca ggtgaatga
 481 acgccactc cagaacggcg cgcagtgtac atcggggcac tgttccat gagcggggc
 541 tggccagggg gccaggcctg ccagcccgcg gtggagatgg cgtggaggga cgtgaatagc
 601 cgcagggaca tctgtccga ctatgagtc aagctatcc accacgacag caagtgtgat
 661 ccaggccaag ccaccaagta cctatatgag ctgtctaca acgacctat caagaratc
 721 ctatgctg gctcagctc tgtctccagc ctgtgtgtg aggtgtgtg gatgtggaac
 781 ctatgtgc ttctatgg ctcagctca ccagccctgt caaacggga ggtttccc
 841 actttccc gaagcacc atcagccaca ctcacaacc ctaccgcgt gaactctt
 901 gaaaagtgg gctggaagaa gattgtacc atccagcaga ccactgaggt ctactctg
 961 actctggag acctggagg acgagtgaag gaggttggaa ttgagatcc ttccgccag
 1021 agtttctc cagatccagc tgtgcccgc aaaaacctga agcggcagga tgcctgaac
 1081 atcgtggagc ttctatga gactgaagcc cggaaagt ttgtgaggt gtacaaggag
 1141 cgtctctg ggaagaagta cgtctgttc ctatgtgtt ggtatgtga caattgttc
 1201 aagaictacg accctctat caactgcaca gtggatgaga tgcctgaggc ggtggaggcg
 1261 cacatcaca ctgagattg catgtgaat cctgccaata cccgagcat ttccaacg
 1321 acatcccagg aattgtgga gaaactaac aagcagctga aaagacacc tgaggagaca
 1381 ggaggctcc aggaggcac gctggcctat gatgccatc gggcctggc actggccctg
 1441 aacaagacat ctggaggagg cggccgtct ggtgtgccc tggagactt caactacaac
 1501 aaccagacca ttaccagca aatctaccg gcaatgaat ctctgctt tgagggtgtc
 1561 tctggccatg tgggtttga tgcagcggc tctggatgg catggagct tatcgagcag
 1621 cctcagggtg gcagctaca gaagattgg tactatgaca gcaccaagga tgaattcc
 1681 tggccaaaa cagataaag gatggaggg tccccccag ctgaccagac cctgtctatc
 1741 aagacattcc gttctgtc acagaaatc ttatctcg tctagttc ctccagcctg
 1801 ggcatgtcc tagctgtgt ctgtctgc tttaacatc acaatcaca tgtccgtat
 1861 atccagaact cacagccca cctgaacac ctgactgtg tggcgtctc actggctta
 1921 gctctgtct tccccctgg gctcgtgtt taccacatg ggaggaaaca gtttcttc
 1981 gctgcccagg cncgctctg gctcctggc ctgggctta gctgggcta cggttccatg
 2041 ttaccaaga ttgggtggg ccacacggc ttccaaaga aggaaganaa gaaggagtgg
 2101 aggaagactc tggaaacctg gaagctgtat gccacagtgg gcctgtgtt gggcaggat
 2161 gttctactc tgcacatg gcagatcgt gacctctgc accggacct ttgacatt
 2221 gccaaaggag aacctaggga agatattgac gtctctatc tccccagct ggagcatgc
 2281 agctccagga agatgaatc atggctggc atttctatg gttacaagg gctgtgtctg
 2341 ctgtgggaa tcttctgc ttatgagacc aagagtgtt ccactgagaa gatcaatg
 2401 caccgggctg tggcagtcg tatctacaat gggcagtc tgtgctcat cactgtctc
 2461 gtcaccatg ttctgtccag ccagcaggat gcagcctg cctgtctc tctgcca
 2521 gtttctct cctatcac tttgtgtg ctctgtgc ccaagatgc caggctgatc
 2581 acccgagggg aatggcagtc ggaggcgag gacaccaga agacagggtc atcgaccaac
 2641 aacaacgagg aggagaagtc ccgctgttg gagaaggaga accgtgaat ggaanaatc
 2701 atgtgaga angaggagc tgtctctga ctgcctatc aactccagtc tcggcagcag
 2761 ctccgtccc ggcgccacc accgacacc ccagaaacct ctggggcct gccaggggga
 2821 cccctgagc ccccgaccg gcttagctgt gatggagtc gattgcatc gttataag
 2881 tgagggtagg gtgaggagg acaggccagt agggggagg aaaggagag ggaaggga
 2941 ggggactcag gaagcagggg gtcccatcc ccagctggga agaactatc atccatctc
 3001 atctctga aatacatg cccctgtgag ttctgggctg atttgggtc ctcatctc
 3061 tgggaacag acctttct ctctactg ttatgtaat ttgtatcac ctctcaca

FIGURE 19B

3121 tttagtgcgt acctggcttg aagctgctca ctgctcacac gctgcctcct cagcagccctc
3181 actgcatctt tctcttccca tgcacacccc tctctagtt accacggcaa cccctgcagc
3241 tctctgcctt ttgtgctctg ttctgtcca gcaggggctct cccaacaagt gctctttcca
3301 ccccaagggt gcctctcctt ttctccactg tcataatctc ttccaatctt acttgccctt
3361 ctatacttc tcacatgttg ctccccctga amtgcttc cttagggagc tcaatcttt
3421 cgccaaggct cacaatctcc ttgctctgc tctgtgact cagctcagc acacatgcat
3481 cctccccctt cctgcgtgtg cccactgaac atgtctcagt gtacacacgc ttctccgta
3541 tgctttctc atgttcagtc acatgtgctc tcgggtgccc tgcancaca gctacgtgtg
3601 cccctctcat ggtcattgggt ctgcccctga gcgtgtttgg gtaggcagt gcaattgtc
3661 tagcatgctg agtcagtct ttctattg cacacgtcca tgmatacca tgtacttcc
3721 ctgtgtacc tccatgtacc ttgtgtact tcttcccta aatcatggtt ttctctgac
3781 agagccatat gtacctacc ctgcacatg ttatgcactt ttccccaatt catgtttgt
3841 ggggccatcc acacctctc ctgtcacag aatctccatt tctgtcaga tccccccat
3901 ctccattga ttcatgtact acctcagtc tacactcaca atcatctct cccaagactg
3961 ctccctttg ttgtgttt tttaggggg aattaaggaa aaataagtgg gggcagggt
4021 ggagagctgc ttccagtga tagtgatga gaacctgac caaaggaagg caccctgac
4081 ttgtgggata gacagaigga cctatggggg gggaggtgtt gtcccttca cactgtgtg
4141 tctctgggg aaggatctc ccgaatctca ataacctgt gaacagtgtg actcggaaaa
4201 aaaaaaaaa aaaaaaaaa

FIGURE 20

| proximal to HSN-1, FCMD, DYS loci on chromosome 9




FIGURE 21




FIGURE 22




FIGURE 23

Coiled-coil domain in C-terminus of gb1a and HG20 mediating
heterodimerization

94ACSEAQDTHKIGSTNNREK...SRLEK...ESRELEKILAKKELVSELR...IQSRQQLASRRHP
100 QRRFCTQNGKKEQKTSV...FNOASTSRLEGLQSEHRLRRTLEDEQLKLVTHIQDTPENTTIDQ



FIGURE 25




FIGURE 26A

[illegible]

FIGURE 26B





FIGURE 27



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/02361

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :C07K 14/705; C12N 5/10, 15/09, 15/11, 15/12, 15/62; G01N 33/566 US CL :Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/23.1, 23.5; 530/350; 435/6, 7.1, 7.2, 69.1, 320.1, 325, 252.3, 254.11 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) GenBank, APS, Medline, Biosis, Caplus search terms: HG20, gaba? receptor, t mcdonald, t bonnert, gaba?, gamma?		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GenBank Database, National Library of Medicine, Bethesda, Maryland USA, HILLIER et al., Accession Number H14151, ym62d04.rl Homo sapiens cDNA clone 163495 5', 10 July 1995.	3
X	GenBank Database, Bethesda, National Library of Medicine, Maryland USA, GENEXPRESS, Accession Number Z43654, H. Sapiens partial cDNA sequence; clone c-1hh04, 21 September 1995.	3
X	GenBank Database, National Library of Medicine, Bethesda, Maryland USA, ADAMS et al., Accession Number T07621, EST05511 Homo sapiens cDNA clone HFBEL81, 30 June 1993.	3
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *Z* document member of the same patent family		
Date of the actual completion of the international search 01 JUNE 1999		Date of mailing of the international search report 02 JUL 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer CLAIRE KAUFMAN Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/02361

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P ----- A,P	WO 97/46675 A1 (NOVARTIS) 11 December 1997, especially claims 1 and 3.	3 ----- 1, 2, 4, 5, 7-9, 14, 16, 18, 19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/02361

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 6
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

THERE IS NO RECITATION OF WHAT IS INCLUDED IN THE GROUP FROM WHICH THE ENCODED PROTEIN IS SELECTED.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-5, 7-9, 14, 16, 18, 19

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/02361

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

536/23.1, 23.5; 530/350; 435/6, 7.1, 7.2, 69.1, 320.1, 325, 252.3, 254.11

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-5, 7-9, 14, 16, 18, 19, drawn to HG20 DNA, vector, host cell, protein, heterodimer comprising the protein, method of detecting binding to GABAB receptors, method of producing functional GABAB receptors, and method of expression an amino-terminal truncated HG20.

Group II, claim(s) 10-11, drawn to a polypeptide consisting of a coiled-coil domain.

Group III, claim(s) 12-13, drawn to DNA encoding a GABABR1a polypeptide and GABABR1a protein.

Group IV, claim(s) 15, drawn to method of identifying agonists and antagonists of HG20.

Group V, claim(s) 17, drawn to antibody that binds HG20.

The inventions listed as Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Pursuant to 37 C.F.R. 1.475(d), this Authority considers that the main invention in the instant application comprises the first-recited product, DNA encoding HG20, and the first-recited method of using that product, namely the method of detecting binding to GABAB receptors. Note that there is no method of making the polynucleotide. Also included in the first group is the encoded protein and the process of producing the encoded protein, in addition to a heterodimer, vector and host cell. Further, pursuant to 37 C.F.R. 1.475(b)-(d), the ISA/US considers that the materially and functionally dissimilar product of groups II and V and the additional methods of groups III-IV do not correspond to the main invention. This Authority therefore considers that the several inventions do not share a special technical feature within the meaning of PCT Rule 13.2 and thus do not relate to a single general inventive concept within the meaning of PCT Rule 13.1.